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Abstract 
 
Circulating influenza viruses have the potential to cause pandemics, as seen in 2009 with 
the emergence of a novel H1N1 virus that rapidly disseminated worldwide. In such an 
event, huge reliance is placed upon antiviral drugs for the prophylaxis and treatment of 
influenza infections. To date, only two different classes of antiviral drug are licensed for the 
treatment of influenza and only one of these, oseltamivir, has been stockpiled by major 
world governments in preparation for an influenza pandemic. However, widespread 
resistance to this drug has been documented in seasonal circulating strains, which emerged 
in the absence of intense drug use and predominated over drug-sensitive phenotypes. 
Furthermore, examples of oseltamivir resistant viruses have been found sporadically in 
pandemic A/H1N1 2009 influenza strains. The need for novel antivirals is therefore 
essential for effective infection control of influenza viruses in future years. A potential 
source of novel therapies are licensed compound libraries. We begin with the screening of 
two compound libraries, resulting in the identification of several compounds which 
inhibited influenza virus replication in vitro. After completing a traditional library screen, a 
novel approach to high-throughput compound screening using reporter plasmids expressed 
in a stable cell line was attempted. Although these cell-lines did not prove maintainable in 
the long-term, this work resulted in the generation of a reporter plasmid that is directly 
initiated by influenza infection in vitro and is thus a useful tool for assaying polymerase 
fitness of different influenza strains. The investigation then focused on one of the newly 
discovered hits and attempted to identify the spectrum of activity of this compound, a 
glycosylation inhibiting molecule, which was shown to be efficacious against influenza A 
strains only. The drug was shown to have low toxicity and proved active against the 
recently emerged pandemic influenza virus. The thesis then documents the effects of a 
common oseltamivir-resistant mutation, H275Y, on the neuraminidase protein of a 
representative 2009 pandemic influenza virus. This mutation was well tolerated in vitro by 
the virus and did not handicap replication in a human airway epithelial model. However, 
subtle impediments to the neuraminidase activity of the mutant were observed 
biochemically which may suggest why this mutation has not emerged more readily in the 
field.  
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1. Introduction 
 
The influenza virus is an important pathogen of humans and animals across the globe. As 
the etiological agent of influenza, these viruses are associated with significant morbidity 
amongst the general population and mortality amid risk groups, such as the elderly, 
immunocompromised and the very young. Influenza is a highly contagious, acutely febrile 
respiratory ailment which is often diagnosed on the following symptomatology: sudden 
onset fever, cough, headaches, debility, muscle pain and anorexia (Eccles, 2005). Influenza 
viruses are enveloped RNA viruses belonging to the Orthomyxoviridae family, more 
specifically, the Influenzavirus A, B and C genera (Palase & Shaw, 2007). Types A and B  
present a major clinical burden worldwide in the form of seasonal outbreaks, resulting in 3-
5 million cases and up to 500,000 deaths during any given influenza season (WHO, 2003). 
Influenza A viruses are comprised of a single-stranded RNA genome fragmented into eight 
segments that encode eleven or twelve separate proteins (Lamb & Krug, 2001; Wise et al., 
2009). The Influenza A viruses are further subtyped based on the haemagglutinin (HA) and 
neuraminidase (NA) glycoproteins present on the outer membrane of the virus particle, of 
which there are currently 16 recognised HA subtypes (1-16) and 9 different NA variations 
(1-9) (Alexander, 2007; Fouchier et al., 2005). Each virus particle adopts one HA and one NA 
antigen in potentially any combination. It is by virtue of this segmented genome that 
influenza viruses pose a constant pandemic threat, as reassortant viruses can emerge 
which introduce novel surface antigens into a naive population. If these viruses are able to 
transmit readily between humans, then a pandemic is likely to occur. The pandemics of 
1918, 1957, 1968 and most recently 2009, were all associated with significant illness, due in 
part to the absence of pre-existing immunity against the novel influenza strain, and in the 
case of the 20th century pandemics, this contributed to vastly increased mortality (Table 
1.1). 
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Year Subtype Estimated deaths Case fatality rate 
1918-1919 H1N1 40-100 million >2.5% 
1956-1958 H2N2 2 million <0.1% 
1968-1969 H3N2 1 million <0.1% 
1997-Present H5N1 300 >59% 
2009-Present H1N1 ~20,000 lab 
confirmed 
<0.03% 
Seasonal Influenza H1N1, H3N2 & B ~500,000 <0.1% 
Table 1. 1 Significant influenza epidemics and pandemics of the last one hundred years. 
Extrapolated from (Johnson & Mueller, 2002; Taubenberger & Morens, 2006; WHO, 2005; 
2010a; b) 
Given the toll influenza viruses continue to exact on the human population, control of both 
seasonal and pandemic infections is a challenge of significant clinical importance. There are 
currently two established infection control methods employed to reduce and prevent the 
spread of the influenza viruses: seasonal influenza vaccines and antiviral drugs.  
 
1.1. Inhibiting influenza virus spread: Vaccination 
The principle prophylactic method is immunisation using an annually updated, trivalent 
influenza vaccine. This vaccine contains antigens from two different type A influenza strains 
(H3 and H1) and one type B strain, which are chosen according to circulating viruses 
detected by the World Health Organisation’s global influenza surveillance network. 
Although the influenza vaccine is well tolerated in the general population, sole reliance on 
a vaccine to control the spread of the virus is unfeasible given the antigenic drifting and 
shifting potential of the influenza genome. Due to the high mutation rate of the virus, the 
annual vaccine remains effective for approximately one year, providing a constant need for 
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vaccine reformulation and readministration to at-risk groups. This provides a unique 
challenge to public health officials as enthusiasm for the immunisation programme and 
public attitudes towards vaccination change over time. The influenza vaccine is unlikely to 
ever eradicate influenza due to the broad host-range utilised by Influenza A viruses – able 
to infect humans, pigs, sheep, felids, equines and birds (Amonsin et al., 2006; Keawcharoen 
et al., 2004).  – and the fact that the complete virus reservoir exists entirely in free-flying 
avian populations, ensuring the risk of zoonotic infection is ever present (Capua & 
Alexander, 2002). Furthermore, there is a risk that the World Health Organisation’s 
recommended vaccine strains result in a poor match to the drift variants which eventually 
circulate during the ensuing influenza season. Such a mismatch occurred in 1997 when the 
H3N2 variant A/Sydney05/97 emerged and caused severe disease outbreaks in Europe and 
the US. Of the collected H3N2 samples analysed by the WHO during this season, only 23% 
of the isolates matched the selected H3N2 vaccine strains of A/Nanchang/933/95 or 
A/Wuhan/359/95, with the remaining 77% matching the Sydney strain. This vaccine failure 
is thought to have resulted in a drop in vaccine effectiveness from 65% to 31% at 
preventing all-cause mortality in the elderly that season (Nordin et al., 2001). Finally, the 
current vaccine manufacturing technique utilises growth of the candidate viruses in chicken 
eggs, thus precluding those with egg-related allergies from receiving the vaccine. Seasonal 
influenza vaccines are also unlikely to protect against novel, pandemic influenza isolates, as 
witnessed with the pandemic A/H1N1 2009 outbreak to which the seasonal vaccine was 
not seen to offer cross-protection (Iuliano et al., 2009; Kelly & Grant, 2009). This pandemic 
outbreak required a new vaccine to be generated, tested and marketed de novo after the 
pandemic was declared.  
1.2. Inhibiting influenza virus spread: Antiviral Drugs 
Antiviral drugs constitute the second branch of influenza infection control. Antiviral drugs, 
which target ongoing viral replication, are employed for both treatment purposes and as 
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emergency prophylactics, and their efficacy is not determined by the antigenic constitution 
of circulating viruses. Antiviral drugs were used extensively following the outbreak of 
pandemic A/H1N1 2009 and represented the only clinical option in the interim time period 
between the initial declaration of a global pandemic, and the marketing of an effective 
vaccine against this virus five months later.  Before the outbreak of pandemic H1N1 
influenza in 2009, the scientific community had anticipated the emergence of a new 
influenza pandemic, with the highly pathogenic avian influenza H5N1 virus being 
considered the most likely outbreak candidate for over a decade. Since the emergence of 
H5N1 in 1997, research has intensified in the field of influenza antivirals given their 
essential role in the management of pandemic and seasonal influenza outbreaks. However, 
to date only a limited number of authorised anti-influenza compounds exist.  
Presently, there are two classes of antiviral drug licensed for the treatment of influenza; 
the M2 inhibitors - amantadine and rimantadine and the neuraminidase inhibitors - 
zanamivir and oseltamivir. The M2 inhibitors (‘adamantanes’) represent the oldest class of 
influenza antiviral, with amantadine being discovered during the early 1960s. The drug was 
first officially approved for use against all influenza A infections in 1976, whilst its 
congener, rimantadine, was licensed in 1993 in the United States (Hayden & Aoki, 2005). 
M2 inhibitors are effective against influenza A viruses only, due to the absence of the M2 
protein from the influenza B genome. By blocking the M2 protein, adamantane drugs 
prevent proton flux across the ion channel and inhibit viral uncoating in the endosome 
(reviewed below). The clinical effectiveness of M2 inhibitors has substantially diminished in 
recent years due to the rapid emergence of resistant influenza isolates that remain 
genetically stable and fully transmissible in reservoir populations, including man. Seasonal 
influenza viruses now boast widespread resistance to this drug class and the 2009 A/H1N1 
pandemic virus is also resistant. In the early years, the adamantane drugs were widely used 
due to their low cost and long-term stability, with early studies suggesting that only 0.8% of 
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isolates emerged with drug resistance between 1992-1995 (Ziegler et al., 1999). However, 
ongoing surveillance reported that by 2004, 12.3% of worldwide H3N2 seasonal isolates 
had acquired drug resistance, with individual countries such as China and South Korea 
reporting that 96% and 72% of all H3N2 isolates were adamantane resistant respectively 
(Bright et al., 2005). Although resistance appeared to proliferate primarily and most rapidly 
in South East Asia, the United States also saw the emergence of a predominant drug 
resistant H3N2 phenotype, as surveillance reported <2% of viruses bearing drug resistance 
in 2004, 14.5% in 2004-2005 and 92.3% in 2005-2006 (Bright et al., 2006). Between 2001 
and 2007, H1N1 isolates represented the minority of circulating strains worldwide; 
however, by 2006 15.5% of all isolates were resistant to the adamantane drugs (Deyde et 
al., 2007). Meanwhile, individual regions such as Japan reported >62% of H1N1 isolates as 
conferring resistance during the 2006-2007 season (Saito et al., 2008). Resistance is almost 
ubiquitously conferred by a mutation in the M2 ion channel protein, S31N, although five 
mutations in total are known to each confer resistance to the adamantanes; at positions 
26, 27, 30, 31 and 34.  By the 2006-2007 season, the unprecedented emergence of drug 
resistance across both H1 and H3 seasonal subtypes effectively ruled out the entire drug 
class as a therapeutic option for influenza. Unsurprisingly, since 2006 it has been 
recommended that adamantane drugs no longer be considered as a treatment for 
influenza A infections in the United States (CDC, 2006).  
As well as the emergence of viral resistance towards this drug class, use of the 
adamantanes has also been linked to a number of adverse side-effects. The most 
commonly reported of these include gastrointestinal complaints such as nausea, vomiting, 
and dyspepsia, and central nervous system disturbances, including anxiety, insomnia, 
depression and confusion (Dolin et al., 1982). Long term use of amantadine therapy has 
also been linked to vision loss, hypotension, urinary retention, peripheral oedema and 
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congestive heart failure, which could greatly undermine the effectiveness of using the drug 
as a long term prophylactic measure against susceptible influenza strains (Prober, 2002).  
The neuraminidase inhibitors (NAI) are the only drug class licensed for use against both 
type A and type B influenza viruses and represent the most reliable anti-influenza drug 
available for treatment today.  NAIs inhibit the neuraminidase enzyme and thus prevent 
the final step of the virus replication cycle by prohibiting viral release from an infected cell 
after budding. This enzyme is responsible for cleaving sialic acid residues which otherwise 
remain omnipresent on both the cell surface and on the surface of adjacent budding 
virions. Deprived of neuraminidase activity, nascent virions reattach to these sialic acid 
residues via the more abundant surface glycoprotein, haemagglutinin, causing viral 
aggregation and preventing progeny virus dissemination.  
Both licensed NAI drugs are structurally similar (Figure 1.1), though zanamivir (trade name 
Relenza) is administered as an inhalant, whilst oseltamivir (Tamiflu) is administered as an 
oral dose. Relenza was marketed as the first major breakthrough in influenza treatment in 
over thirty years. The U.S Food and Drugs Administration (FDA) approved Relenza for use in 
1999, and in doing so, the first anti-influenza drug was licensed since rimantadine in 1993 
(Miller, 1999). Administration via an inhaler is necessary due to the poor absorbance of the 
drug from the gastrointestinal tract. Due to a negatively charged group on the zanamivir 
molecule, only 1-5% of an oral dose is efficiently absorbed. This necessitates topical 
delivery as a dry powder via an inhaler, which directs the drug directly to the oropharynx, 
the primary site of influenza infection. Although this advantageously directs the antiviral 
rapidly to the site of infection, it may result in bronchospasm, making treatment of 
asthmatics a risk and of those with pulmonary destructive diseases altogether unfeasible.   
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Figure 1.1. The molecular structure of sialic acid and the neuraminidase inhibitors, 
oseltamivir and zanamivir. 
 
Oseltamivir is administered as an inactive prodrug, oseltamivir phosphate, which is 
metabolised into its active form, oseltamivir carboxylate in the liver. Although both drugs 
are administered in different ways, their clinical effectiveness is equally comparable and 
both treatments alleviate influenza symptoms by approximately 0.5-1 day (Burch et al., 
2009). The development of the first orally administered neuraminidase inhibitor allowed 
for the treatment of younger children, and provided a more convenient drug delivery 
method for those with respiratory complications. In anticipation of an influenza pandemic, 
oseltamivir has become the focus of stockpiling strategies due to its low toxicity and 
convenient oral formulation (Meijer et al., 2007). Between 2004 and the outbreak of 
pandemic H1N1 influenza in 2009 it has been suggested that 350 million treatment 
regimens were stockpiled by governments worldwide, which equates to approximately 
enough doses to treat 5% of the global population (Reddy, 2010). Compared to the 
adamantane drugs, NAIs are less inclined to generate resistant viruses and until 2007, only 
0.2% of all human epidemic influenza viruses monitored possessed natural resistance to 
oseltamivir (Sheu et al., 2008). However, the effectiveness of oseltamivir as a therapeutic 
drug was significantly reduced during the 2007/2008 influenza season, which saw the 
unexpected emergence of H1N1 viruses containing the mutation H275Y (N1 numbering) in 
the N1 neuraminidase protein. The H275Y mutation is well characterised in H1N1 viruses 
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and confers resistance to both oseltamivir, and the experimental neuraminidase inhibitor 
peramivir, but not to zanamivir (Abed et al., 2006). The detection of NAI-resistant viruses 
by surveillance networks occurred simultaneously across several countries and did not 
correlate with drug use (Eshaghi et al., 2009; Hurt et al., 2009; Meijer et al., 2009; Njouom 
et al., 2010). The following 2008/2009 season saw this trend continue as drug resistant 
viruses predominated over susceptible seasonal H1N1 strains, with some countries 
reporting up to 100% of isolates possessing resistance to oseltamivir via H275Y (Baranovich 
et al., 2010; Correia et al., 2010; Kawai et al., 2009a; Kawai et al., 2009b). Pandemic 
nvH1N1 viruses remain largely susceptible to the NAI class of drug, even with oseltamivir 
being prescribed on a wide scale as a pandemic control measure, though resistant isolates 
containing H275Y have been detected (Chen et al., 2009; Harvala et al., 2010; Memoli et 
al., 2010; Valinotto et al., 2010). Had pandemic nvH1N1 emerged with the same 
invulnerability to oseltamivir as seasonal H1N1 viruses, then stockpiles of this drug would 
have been rendered redundant, leaving only limited supplied of zanamivir available for 
infection control measures. Reliance on a single drug, against which substantial resistance 
presides in circulating viral strains, is dangerous and could prove costly in terms of human 
health and finance. Thus, the need for novel inhibitors of influenza viral replication is an 
urgent priority in preparation for future epidemics and pandemics. 
Subtype Oseltamivir Zanamivir Adamantanes 
Seasonal H1N1 Resistant Susceptible Mostly Susceptible 
Seasonal H3N2 Susceptible Susceptible Resistant 
Influenza B Susceptible Susceptible Resistant 
HP H5N1 Mostly Susceptible Susceptible Mostly Resistant 
Pandemic H1N1 Susceptible Susceptible Resistant 
Table 1. 2. Susceptibility of currently circulating influenza isolates to antiviral drugs. 
(Correct as of June 2010. Adapted from (WHO, 2010c)) 
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Thankfully, this observation has not gone unnoticed and research into antiviral compounds 
against influenza has generated many previously undescribed molecules with novel 
mechanisms of action. This review seeks to give a broad overview of the numerous 
compounds presented in the literature and draw attention to the potential for each of 
these drugs to complement our current clinical armamentarium.   
1.3. Drugs which target the influenza virion 
Both of the currently licensed classes of antiviral drug target components of the influenza 
virion in order to inhibit replication of the virus. By specifically targeting the influenza 
virion, antiviral drugs should ideally succeed in having low toxicities in humans and avoid 
causing adverse side effects. Novel drugs which interact with and inhibit the proper 
function of influenza proteins have thus remained popular in the area of antiviral research. 
In order to understand where and how potential new drugs can interfere with the virus 
replication cycle, a knowledge of virion structure and the mechanism by which it 
reproduces itself is required. The following section seeks to introduce the influenza virion 
and then elaborate on the well-characterised methods by which the influenza virus infects 
host cells, replicates its genome, and then passes progeny virus on to other cells. Potential 
targets for therapeutic intervention by novel compounds will be reviewed at each step of 
the replication cycle.  
 
1.3.1. The influenza virion 
The influenza viral envelope consists of a lipid bilayer contributed by the host cell, 
containing three transmembrane proteins on the outside and matrix protein (M1) on the 
inside (Figure 1.2.). The three transmembrane proteins: haemagglutinin (HA), 
neuraminidase (NA) and M2 (ion channel) are anchored in the lipid bilayer, with 
haemagglutinin the dominant presence covering approximately 80% of the virion surface. 
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Underlying the lipid bilayer is the M1 protein, a major structural component of the virion. 
The M1 shell surrounds the viral core, consisting of helical ribonucleocapsids (RNP) which 
contain the negative stranded RNA genome of the virus, coiled to nucleoprotein (NP) and 
three polymerase proteins (3P proteins: PB1, PB2 and PA) (Portela & Digard, 2002). Minor 
quantities of NEP (Nuclear Export Protein, formerly known as NS2) are also present in the 
virion complex. Other proteins encoded by the influenza genome include NS1, which is 
expressed intracellularly and absent from the final virion and in some strains, PB1-F2, 
which is also excluded from the virion and is not essential for virus replication (Chen et al., 
2001). 
 
Figure 1.2. The influenza A virion.  
(Image credit: (Kaiser, 2006)) 
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1.3.2. Attachment 
The first step of the replication cycle is attachment of the virus to the host cell, a process 
mediated by the haemagglutinin glycoprotein. Haemagglutinin is a homotrimer which binds 
to sialic acid residues, which are found ubiquitously on the surface glycoproteins of cells, 
via a shallow receptor binding site at the distal end of the protein. The conformation of 
sialic acid present on the cell surface (α2,3-linked or α2,6-linked) is an important 
determinant of species-specific restriction of certain influenza viruses, with the viral 
haemagglutinin of human influenza viruses traditionally preferring the α2,6-linkage of sialic 
acid, compared to the α2,3-linkage preferred by avian strains (Gambaryan et al., 2005; 
Rogers & Paulson, 1983). This observation likely explains the tendency of human influenza 
viruses to infect tracheal epithelial cells abundant in α2,6-linked sialic acid and cause a 
localised respiratory infection, compared to avian influenza viruses which replicate in the 
α2,3-linked rich area of the avian gut and remain enteric (Ito & Kawaoka, 2000). It should 
be noted that this observed viral specificity is not absolute, however, and that certain cells 
in the human lower airway have been shown to present α2,3-linked sialic acid moieties 
(Shinya et al., 2006). Moreover, ciliated cells in human airway cultures also display α2,3-
linked sialic acid and are vulnerable to infection with avian influenza viruses (Matrosovich 
et al., 2004; Thompson et al., 2006). The interaction between the distal tip of a 
haemagglutinin spike and the sialic acid receptor is one of low-affinity, and the high avidity 
of the influenza virion for cell surfaces is achieved through multiple low-affinity 
interactions. Influenza attachment, and in particular the haemagglutinin protein, 
represents an attractive target for drug design due to its highly conserved active site and its 
tendency to be maintained even through antigenic drift events. Futhermore, neutralising 
antibodies generated by the host immune system are effective by targeting the 
haemagglutinin protein, and the ability to inhibit viral replication and provide therapeutic 
intervention before pathogen proliferation is an obvious incentive. 
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1.3.2.1. Inhibiting viral attachment 
The innate immune system of humans pre-dates clinical science in attempting to inhibit 
viral replication through the prevention of initial attachment. Components of the host sera 
and mucosal secretions are capable of binding the surface glycoproteins of influenza 
viruses. Such components include collagenous lectins (collectins) which bind glycosylated 
regions of influenza glycoproteins and can inhibit haemagglutination, as well as virus 
replication in vitro and in vivo. Collectins are inhibitory via both steric hindrance of the HA 
protein and by enhancing immune cell opsonisation (Benne et al., 1995; Hartshorn et al., 
1994; LeVine et al., 2001). Furthermore host proteins present in the saliva, such as mucins, 
are highly sialated and restrict the spread of influenza viruses by providing false receptors 
to which viral haemagglutinin will bind instead of susceptible cells (White et al., 2009). Our 
increasing understanding of the pulmonary secretory system has led some to speculate 
that the individual peptides utilised by our innate immune response, refined and selected 
over many evolutionary generations, may represent therapeutic potential (Doss et al., 
2009). If such a drug was developed that utilised non-specific host proteins as its active 
element, then it is likely that the therapy would have a very broad-spectrum of activity 
across multiple microorganisms and theoretically, few toxicity issues. An early attempt to 
create a compound that utilises collectins resulted in the generation of a trimeric molecule 
that contains the truncated neck, and carbohydrate recognition domain (CRD) of surfactant 
protein-D (SP-D); an innate defence collectin found in the BAL of humans. This compound 
was initially shown to be less effective at neutralising haemagglutination and in vitro 
infectivity of MDCK cells by influenza A viruses when compared with the natural multimeric 
form of SP-D (Hartshorn et al., 2007). However, the neutralisation ability of this molecule 
could be restored by replacing the neck and carbohydrate recognition domain with that of 
bovine SP-D rather than the human form (Hartshorn et al., 2010). These compounds were 
shown to be antiviral via several mechanisms including inhibition of the viral neuraminidase 
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protein, by enhancing uptake by neutrophils and causing enhanced virus aggregation. 
These early studies highlight the potential of using trimeric collectins as a therapy, however 
the advantageous effects have only been measured in vitro to date and it remains to be 
seen whether they can be recapitulated in a relevant animal model.  
A similar high molecular weight protein, pentraxin 3 (PTX3), has also been shown to exhibit 
antiviral activity and plays a role in recognising and binding a range of pathogens. PTX3 is 
an innate, long-chain protein that is rapidly upregulated in response to primary 
inflammatory signals by several cell types, including endothelial and dendritic cells, as well 
as mononuclear phagocytes (Bottazzi et al., 2006). Human PTX3 was shown to inhibit 
haemagglutination by an H3N2 virus in vitro and also improved the survival of mice from 40 
to 100% when administered daily as a treatment. It was also shown that infection of mice 
lacking the PTX3 gene generated higher viral titres in the BAL than wild type mice that 
retained PTX3 function (Reading et al., 2008). Interestingly, PTX3 only inhibited older 
subtypes of virus, with H3N2 viruses isolated after 1975 being resistant to the antiviral 
effects of the protein. This observation reflects the change in sialic acid binding preferences 
of H3N2 viruses which over time have evolved to bind preferentially to α2,6-linked sialic 
acid, whereas PTX3 is antiviral due to its abundance of α2,3-linked glycoconjugates, which 
operate as false receptors for the virus. Indeed, most recent evidence suggests that both 
the pentraxin and collectin families are ineffective against the A/H1N1 pandemic influenza 
virus (Job et al., 2010). These observations probably precludes PTX3 as an effective 
antiviral, though it again highlights the potential of innate molecules as therapeutic 
interventions.  
Another mechanism for preventing viral attachment is via steric inhibition. Cyanovirin-N 
(CVN) is an example of a drug which inhibits in this manner, and was initially discovered as 
an anti-HIV drug, before showing activity against several other enveloped viruses including 
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Ebola and influenza (Barrientos et al., 2003; Boyd et al., 1997; O'Keefe et al., 2003). CVN is 
a mannose-binding protein and binds to glycosylation sites on the haemagglutinin. 
Treatment with CVN resulted in a 1000-fold reduction in viral titre in the mouse model 
when treatment began 4 hours pre-infection. This was superior to ribavirin, which only 
reduced viral titres 30-fold. In ferrets, the drug also succeeded in reducing nasal viral titres 
and in doing so showed greater efficacy than oseltamivir (Smee et al., 2008). Although the 
drug showed efficacy in the mouse and ferret models, the compound suffers from a similar 
disadvantage to PTX3 in that only certain viral strains are susceptible. Mutants that 
abrogate glycosylation sites in the haemagglutinin protein can restrict drug binding and 
allow the virus to withstand the inhibitory effects of CVN. In general, mouse-adapted 
influenza viruses are resistant to CVN due to the occlusion of glycosylation sites in the 
haemagglutinin protein as part of the adaptation process. Resistance to the drug has also 
been demonstrated in cell culture, suggesting that the selective pressure of the drug could 
select for isolates that are naturally resistant to CVN (Smee et al., 2007).  
Since the structure of viral haemagglutinin in complex with sialic acid receptors was 
resolved in the late 1980s (Weis et al., 1988), there have been numerous attempts to 
generate synthetic inhibitors which target the active site of this protein. Initial research 
attempted to generate low-molecular weight, monovalent, sialic-acid-containing receptor 
mimics that it was hoped would have sufficient affinity to the receptor binding site to 
competitively inhibit the haemagglutinin protein. Such molecules were found to inhibit the 
ability of an H3 haemagglutinin to adsorb human erythrocytes in a dose-dependent 
fashion. However, large concentrations of compound in the millimolar range (15mM) were 
required to guarantee complete inhibition (Pritchett et al., 1987). Conversely, utilisation of 
the high molecular weight ‘glycoprotein 2’ from bovine erythrocytes, artificially modified to 
present approximately 200 sialic acid residues on its surface was shown to inhibit 
haemagglutination by influenza viruses at micromolar concentrations (1-4µM) (Suzuki et 
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al., 1987). These experiments reveal that influenza haemagglutinins bind preferentially to 
multivalent substrates and suggest that any attempt to inhibit binding should be made with 
larger compounds which present multiple sialic acid residues. Multivalent substrates are 
much more representative of the receptors that viruses have evolved to bind during the 
course of an infection, and given the low affinity individual haemagglutinin proteins display 
for single receptors, it is unlikely that monovalent molecules will compete effectively with 
the multivalent interactions which occur between the virus and cell surface. Polyvalent 
inhibitory molecules have undergone continued development since the late 1980s and as a 
result, multiple structural variations of sialic-acid-containing polymers have been reported. 
To date, polymeric inhibitors have appeared as sialic-acid containing dendritic polymers 
(Reuter et al., 1999), sialyllactose covered polystyrene molecules (Tsuchida et al., 1998) 
and glutamic-acid-bound sialyloligosaccharides (Totani et al., 2003), each with the 
capability to bind potently to influenza surface glycoproteins and prevent 
haemagglutination in vitro. However to date the effect of these compounds on the 
influenza replication cycle, and indeed use of these compounds in vivo, has not been 
reported and thus this therapy remains at an early stage of development. It should also be 
mentioned that this class of drug has typically exhibited subtype specific inhibition 
depending on which sialic acid residues (α2,6- or α2,3-linked) were presented by the 
inhibitory polymer. Furthermore it is prudent to assume that these compounds may face 
the problem of irreversible destruction by the influenza neuraminidase enzyme and thus 
their success may depend on the neuraminidase activity of the target virus. 
Alternative mechanisms for inhibiting influenza virus entry have been proposed which do 
not involve inhibiting the haemagglutinin protein at all. Instead of mimicking the sialic acid 
receptor, the novel antiviral drug Fludase (also DAS181) purports to prevent attachment by 
completely removing sialic acid receptors from the cell surface. Of all the attachment 
inhibiting compounds mentioned so far, Fludase is the closest to clinical use. Billed as a 
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‘broad spectrum therapeutic agent for all annual and pandemic variations of influenza’, 
Fludase emerged as a result of Biodefense funding from the National Institute of Allergy 
and Infectious Diseases (NIAID). The drug is further unique compared to the 
aforementioned compounds in that it targets the host cell, rather than viral components in 
order to prevent influenza infection. More specifically, Fludase is a sialidase fusion protein 
which removes the sialic acid receptors used by influenza to bind to the host cell and thus 
prevents attachment and endocytosis of the virion into the host cell. The sialidase 
component of Fludase is acquired from Actinomyces viscosus, a commensal microorganism 
of humans, linked to an epithelial anchoring domain to ensure drug concentrations remain 
localised to the trachea. The compound is mass produced in Escherichia coli, leaving the 
potential for easy up-scaling should increased demand arise (Malakhov et al., 2006). The 
bacterial sialidase functions analogously to influenza neuraminidase and actively cleaves 
both α2,3-sialic acid-linked receptors, traditionally utilised by avian influenza viruses and 
α2,6-sialic acid-linked receptors, preferred by human influenza viruses (Teufel et al., 1989). 
The mechanism of action of Fludase has led to concerns against its potential use in the 
clinic (Zhang, 2008); namely that the removal of sialic acid receptors has been shown to 
increase susceptibility to secondary infection by pneumonia-causing bacteria in a number 
of different animal models (Braun et al., 2007; McCullers & Bartmess, 2003; van der Sluijs 
et al., 2004). Bacterial pneumonia has long been associated with influenza virus infection 
and it is believed that secondary bacterial pneumonia was responsible for more deaths 
during the influenza pandemics of the 20th century than acute influenza infection itself. 
However, a recent study has moved to alleviate this concern by suggesting that Fludase 
treatment did not exacerbate secondary bacterial infection in mice by S. Pneumoniae and 
in fact those mice receiving the drug were protected from other opportunistic bacterial 
pathogens compared to those receiving vehicle formulations (Hedlund et al., 2010). It has 
been suggested that removing sialic acid receptors is not enough to completely block 
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influenza virus infection and that while sialic-acid enhances the efficiency of viral entry, it 
was ultimately ‘dispensable’ as sialidase treatment did not abolish replication of influenza 
in vitro (Stray et al., 2000). However, a recent study has highlighted the importance of sialic 
acid on the cell surface in the role of successful viral replication. It was revealed that by 
suppressing sialic acid production in cells using siRNA against key sialyltransferases involved 
in the biosynthesis of α2,3-linked sugar moieties, subsequent attempts to infect these cells 
with an H5N1 virus resulted in attenuation of virus replication by approximately 2 logs 
(Monteerarat et al., 2010). Furthermore, Fludase has been shown effective at reducing viral 
titres of a number of recent seasonal oseltamivir-sensitive and -resistant H1N1 viruses in 
vitro and was efficacious as a prophylactic and therapeutic measure in mice challenged 
with highly pathogenic avian influenza A/Vietnam/1203/2004 (H5N1) (Belser et al., 2007; 
Triana-Baltzer et al., 2009). An isomeric precursor molecule of Fludase (DAS178) was well 
tolerated in ferrets when administered twice daily for seven days over the course of the 
experiment, and improved the outcome of an H1N1 challenge infection, protecting 25% of 
the animals from any detectable influenza infection at all (Malakhov et al., 2006). Having a 
therapeutic drug that targets the host cell should ensure less frequent emergence of viral 
resistance and thus gives Fludase a potential benefit over other novel anti-virals. The 
results of an ongoing phase one clinical trial are now highly anticipated. 
Finally, a broad-spectrum antiviral compound was recently described with potency against 
several enveloped viruses, including Ebola, HIV, West Nile, Yellow Fever, HCV and influenza 
(Wolf et al., 2010). It is known that, unlike the host cell, viruses lack the ability to repair or 
recycle plasma membranes and are entirely reliant on the lipids accumulated from the host 
during the budding process. This therefore leaves the viral membrane susceptible to 
specific disruption by antiviral drugs. The compound described, LJ001, exploits the virion’s 
inability to restore lipid membrane function and irreversibly binds to the virion envelope. It 
is hypothesised that after intercalating into the lipid bi-layer, the polar pharmacophore 
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group of the compound remains free to disrupt lipid membranes and subsequently disturb 
fusion of the viral and cell membranes during viral entry. Although this drug is capable of 
chelating with host-cell membranes, it remains largely nontoxic to the cell, though the 
presence of inhibitors of fatty-acid biosynthesis markedly enhance the toxicity of the drug, 
suggesting that the host cell’s membrane reparation ability is only sufficiently able to cope 
with the potentially toxic mechanism of the drug under normal conditions. Although this 
compound has exhibited a broad-spectrum activity against several enveloped viruses in 
vitro, it has thus far only exhibited prophylactic activity and must interact with the virus 
before it contacts the cell to be effective.  
1.3.3. Entry and fusion 
Influenza virions bound to cell surface sialic receptors are then internalized via receptor-
mediated endocytosis (Matlin et al., 1981). Following endocytosis, the virion must escape 
from the endosome before it can deposit its genetic material in the nucleus. Once inside an 
endosome, the virus is exposed to a low pH environment thus facilitating the next step of 
the replication cycle; fusion. Fusion of the virion with the endosome is initiated by an 
irreversible conformational change in haemagglutinin glycoproteins on the surface of the 
internalised virion, provided that the HA0 precursor molecule has been cleaved into two 
subunits, HA1 and HA2 (Lazarowitz & Choppin, 1975). This fusion event results in the 
exposure of the hydrophobic HA2 N-terminal fusion peptide core of the haemagglutinin 
protein, while the HA1 receptor binding domain remains structurally intact (reviewed in 
(Stegmann, 2000)). The exposed domain can now interact with the endosomal membrane, 
resulting in the HA2 component having contact with both the endosomal membrane via its 
N-terminus and the virus membrane via its C-terminus. Once several HA molecules have 
undergone this structural change, the opposing membranes are essentially pulled together 
and then fused with each other, creating a fusion pore (Figure 1.3.). Cleavage of HA is thus 
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an absolute requirement for infectivity. Without proper HA cleavage, virions may bind to 
and enter the cell, but will remain in the endosome and are essentially non-infectious.  
 
Figure 1.3. Fusion of the viral and endosomal membranes. 
(A) HA spike undergoes a conformational change due to the low pH in the endosome, 
resulting in exposure of the hydrophobic core which then interacts with the membrane of 
the endosome. (B) The force of several HA spikes undergoing the same changes pulls the 
membranes apart, resulting in a fusion pore, via which the viral RNP can exit the 
endosome. 
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The acidic conditions of the endosome also facilitate conformational changes in the M2 ion 
channel protein, which opens and allows the influx of H+ ions that result in the acidification 
of the virion core. This shift in pH disrupts protein-protein interactions and results in the 
release of vRNPs from the M1 structural protein, enabling them to exit through the fusion 
pore (Bui et al., 1996). The dissociation of genome from particle is essential for the 
successful replication of influenza A viruses and has unsurprisingly been targeted by 
antiviral drugs in the past.  
 
1.3.3.1 Inhibiting viral entry and fusion 
The ion channel blockers amantadine and rimantadine specifically target the M2 protein of 
influenza A viruses and inhibit the acidification of the virion core (Hay et al., 1979; Skehel et 
al., 1978). Interestingly, the M2 protein also plays a role in the latter part of the virus 
lifecycle, particularly of viruses with readily cleaved HA0, such as H5, H7 and HPAIV. Here 
M2 regulates the pH in the Golgi apparatus during protein translation, preventing 
premature cleavage of the newly folded haemagglutinin protein. This theoretically presents 
two phases of the virus lifecycle that could be targeted by inhibitors of the ion channel 
protein. Despite many years as first-choice antiviral drugs, the mechanisms by which 
amantadine and rimantadine block the ion channel have only recently been elucidated. 
Structural data published in 2008 suggested amantadine bound inside the ion channel pore 
and prevented the flow of ions via simple physical obstruction (Figure 1.4. Right) (Stouffer 
et al., 2008).  
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Figure 1.4. Proposed mechanisms of ion channel inhibition. 
Left: A transverse view of the C-terminus of the M2 ion channel is shown with Rimantadine 
molecules binding on the outward facing exterior of the protein (shown in red), modelled 
by Schnell et al. Right: Amantadine (shown in sky blue and white) modelled to the interior 
of the ion channel by Stouffer et al, 2008. 
 
This proposed mechanism is supported by the fact that amantadine was shown to attach in 
close proximity to residues 27, 30, 31 and 34 in the ion channel, which have all been shown 
confer resistance to this class of drug when mutated in clinical influenza isolates. A 
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simultaneous publication proposed an alternative inhibitory mechanism for the 
adamantane drugs. The surprising structural findings suggested that multiple rimantadine 
molecules bound to the ion channel at the outward facing intermembrane portion of the 
ion channel. It was proposed that rimantadine could ‘block’ the ion channel allosterically by 
keeping the homotetramer locked in its closed conformation (Figure 1. 4., Left (Schnell & 
Chou, 2008)). Supporting evidence for this binding mechanism comes from the fact that 
amantadine binds much more easily to the ion channel in its closed conformation than its 
open conformation, which does not make intuitive sense for a channel blocking molecule 
(Wang et al., 1993). Furthermore, several of the drug resistance mutations that line the ion 
channel pore have actually been shown to retain drug binding, which would not correlate 
with a loss of susceptibility to the drug if binding was all that is required for drug affectivity 
(Astrahan et al., 2004). Further studies on the M2 protein revealed that amantadine does 
indeed bind to both the lumen of the ion channel, and on the outward facing surface of the 
protein, though is more likely to bind in the former confirmation due to an increased 
affinity of the drug for this region of the protein. Indeed, drug binding to the outside of the 
protein was seen to be an interaction of low-affinity and was only observed when high 
doses of amantadine were recorded inside the lipid bilayer (Cady et al., 2010). This last 
study also observed that binding of the drug to the outer face of M2 did not affect binding 
of other amantadine molecules to the lumen.  
Due to the pervading problem of drug resistance, the association of these drugs with 
adverse side effects, and the subtype specific restriction of adamantane use, the ion 
channel inhibitors might not seem like an obvious candidate for further development. 
However, these structural studies have inspired the development of novel and next 
generation M2 protein inhibitors that may be of some therapeutic use. The search for 
effective ion channel inhibitors has since branched into two arms; (i) the refinement of 
amantadine-based molecules and (ii) the development of unrelated inhibitory compounds. 
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It is known that amantadine binding to the lumen of the ion channel is sub-optimal and 
thus there is room for the development of rationally-derived amantadine analogues which 
may bind more efficiently to the protein. Modification of both amantadine and rimantadine 
molecules has resulted in a multitude of drugs which potently inhibit influenza viruses at 
micromolar concentrations in vitro, with most of these compounds displaying favourable 
cytotoxicity and more potent IC50 values than their parent drugs (Kolocouris et al., 1994; 
Kolocouris et al., 1996; Stamatiou et al., 2003; Zoidis et al., 2006; Zoidis et al., 2003). The 
subtle changes introduced to the precursor adamantanes are represented in Figure 1.5.  
 
- 43 - 
 
 
Figure 1.5. Chemical structure of Amantadine and Rimantadine, and derivative 
compounds which inhibit influenza replication in vitro. 
Amantadine and rimantadine share structural similarities which enable both to exact an 
antiviral effect against the viral M2 ion channel protein. By maintaining these common 
structural features, the adamantane backbone can be modified to incorporate novel side-
groups which alter the targeting and binding properties of the drug. With this approach it is 
hoped that novel antiviral drugs will be identified which supersede the established 
adamantane drugs in terms of clinical efficiency and resistance profiles (Reviewed in (De 
Clercq, 2006)). 
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Although it seems that these drugs are abundant and diverse, to date they have only been 
screened against H3N2 and H2N2 isolates in vitro and have not yet been assayed in animal 
models, nor against recent clinically relevant strains of influenza. It thus remains to be seen 
whether these drugs could evolve into effective anti-influenza therapies. Another group 
has proposed that modification of the amantadine molecule to contain more than one 
active pharmacophore group could result in more efficient inhibition of the ion channel, 
when taking into account the proposed exterior facing binding site on the M2 protein (Du 
et al., 2010). As M2 is a homotetramer, four amantadine molecules are required to bind 
each constituent helix of the protein; however, a multivalent amantadine could be 
engineered to bind multiple neighbouring helices at once, thus requiring fewer drug 
molecules to inhibit the protein and increasing avidity. At present this potential drug type 
remains a hypothetical concept and no experiments using multi-valent adamantanes have 
yet been described.  
This drug class continues to evolve via the discovery of novel inhibitors of the ion channel 
which are not based on the adamantane scaffold. In 1995, a novel inhibitor of M2 function 
was identified using a screen in Saccharomyces cerevisiae cells (Kurtz et al., 1995). Briefly, it 
was observed that transient expression of the M2 ion channel in these cells impaired 
growth, but that this impairment could be alleviated with amantadine. This led to the 
development of a high-throughput screen which assayed for compounds which also 
restored growth to S. cerevisiae cultures and presumably negated the toxic effects of the 
ion channel in a similar manner to amantadine. This screen identified BL-1743, a spirene-
containing lipophilic molecule which was then shown to inhibit growth of a H3N2 influenza 
virus in a plaque reduction assay, albeit at higher concentrations than amantadine. 
Regrettably, BL-1743 did not inhibit a virus containing the S31N amantadine resistance 
mutation now prevalent in many circulating influenza strains. Further characterisation of 
this compound revealed that whereas amantadine binding results in irreversible inhibition, 
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the effects of BL-1743 could be reversed; and that other amantadine resistance mutations 
at positions 27, 30 and 34 in the M2 protein also conferred resistance to BL-1743 (Tu et al., 
1996). Since its identification, BL-1743 has undergone derivative changes at the hands of 
structural chemists, much like the adamantane drugs mentioned previously, in the hope of 
finding superior inhibitory compounds. A more recent study identified a derivative of BL-
1743 from a family of newly synthesised analogues, which exhibited the promising ability 
to potently inhibit H3N2 viruses containing the known L26F and V27A amantadine 
resistance mutations in plaque reduction assays. However, once again known resistance 
mutations built into the M2 protein at positions 31, 30 and 34 diminished the ability of 
these drugs to inhibit the ion channel (Balannik et al., 2009). This study moves to both 
highlight the potential of developing analogous molecules that improve upon their parent 
drugs, and also the difficulties faced in inhibiting a protein that can seemingly mutate 
multiple residues to escape drug inhibition without incurring an overwhelming fitness 
costs. The ease at which influenza viruses can acquire and maintain resistance to ion 
channel inhibiting drugs is clearly a cause for valid concern, and coupled with the fact that 
drugs of this class are typically specific to treating only influenza A subtypes, may make 
future development of these drugs less appealing. It is worth remembering, however, that 
the M2 inhibitors enjoyed over thirty years of active service as an only option influenza 
therapy during a period of time that saw only sporadic emergence of resistant variants, and 
that the influenza A subtypes are arguably the most important influenza viruses and indeed 
the strains with pandemic potential. One may even argue that a novel M2 inhibitor, that 
lacked the ability to inhibit influenza B subtypes and therefore precluded itself as a reliable 
seasonal influenza therapy, might actually represent an ideal stockpiling candidate in 
preparation for future pandemic emergencies.  
Finally, an anti-influenza therapy currently licensed in Russia is known to inhibit fusion of 
the viral membrane with the host cell early on during infection. Arbidol has been shown to 
- 46 - 
 
inhibit the replication of multiple influenza A and influenza B subtypes in vitro as well as 
reducing the duration of illness in infected patients by 1.7-2.6 days in clinical studies 
(Boriskin et al., 2008). The drug is reported to be well tolerated and exhibit no severe side 
effects in the general population, however, details regarding the size and experimental 
design of these clinical trials are scant and thus all published results must be treated with a 
degree of caution. Although Arbidol was first approved for the treatment and prophylaxis 
of seasonal influenza viruses in 1990, use of the drug outside of Russia and China is rare 
and it is likely that the non-rigorous nature of published clinical data has restricted the 
acceptance of this drug in other parts of the world. Indeed, the WHO concluded that there 
was insufficient data on either the efficacy or safety of arbidol and thus the drug could not 
be adopted as a recommended treatment for the A/H1N1 pandemic influenza virus (WHO, 
2010c). Recent studies have suggested that arbidol is active against the HA2 portion of the 
viral haemagglutinin and by binding to this region, stabilises the HA in a manner that 
reduces its ability to undergo the necessary conformational change usually induced by low 
pH in the endosome (Leneva et al., 2009). By generating arbidol-resistant viruses, the 
researchers observed that mutations in the haemagglutinin that conferred resistance were 
successful at de-stabilising the HA protein in a manner that made it re-susceptible to 
conformational change at a low pH. Furthermore, arbidol has been accredited with 
immunomodulatory activity, in particular the ability to stimulate interferon and activate 
phagocytes, as well as possessing antioxidant activity (Silin et al., 2009). These findings 
have led to the assumption that arbidol could function as a broad spectrum antiviral and 
indeed evidence has shown that the drug inhibits acute and chronic HCV infection in vitro  
(Boriskin et al., 2006; Pecheur et al., 2007). Other human respiratory viruses such as RSV, 
rhinovirus 14 and parainfluenza virus type 3 have also been shown to be inhibited by 
arbidol in vitro, suggesting the therapeutic potential of arbidol is at least sufficient enough 
to warrant a stringent clinical trial in the near future (Brooks et al., 2004). 
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1.3.4. Nuclear import and RNA synthesis 
All viral RNA synthesis of the influenza segments occurs in the cell nucleus and no nascent 
viral RNA is ever exposed in the cytoplasm due to the complex it forms with the 3P 
polymerase proteins and NP. The vRNP complexes, once released from the virion, are too 
large to rely on passive diffusion in order to reach the nucleus and instead contain nuclear 
localisation signals which facilitate their interaction with nuclear import machinery (Jones 
et al., 1986; Mukaigawa & Nayak, 1991; Nath & Nayak, 1990; Nieto et al., 1994). Once 
inside the nucleus, transcription of the negative sense viral RNA (vRNA) into messenger 
RNA (mRNA) occurs. A 5’ methylated mRNA cap is cleaved off of host-cell pre-mRNAs and 
then used to ‘prime’ transcription of the vRNA into mRNA (Plotch et al., 1981). It is the PB2 
component of the vRNP which binds the 5’ cap of host mRNAs, and the PA component 
which provides endonuclease activity to cleave caps of 10-13 nucleotides (Dias et al., 2009). 
Each viral segment contains a string of 5-7 uracil residues located approximately 17 
nucleotides from the 5’ end, and the PB1 protein responsible for chain elongation (Braam 
et al., 1983) will continue synthesizing complementary mRNA in the direction of the 
terminal 5’ end until it reaches this tract. The RdRp then generates a poly-A tail for the 
mRNA transcript thanks to the process of ‘reiterative slipping’ in which the polymerase will 
stutter on this poly-U sequence and generate a string of A residues in the mRNA strand 
(Poon et al., 1999). This results in mRNA transcripts which are not full length when 
compared to their vRNA template. The newly transcribed mRNA thus comprises a proper 
methylated 5’ cap and a poly-adenylated tail and is treated as a regular host-cell transcript. 
 This primary round of transcription is followed by production of full length copies of the 
original vRNA as cRNA. cRNAs differ from mRNAs in that they are full length transcripts that 
do not have poly-A tails nor methylated 5’ caps structures. The cRNAs are then used as 
templates to produce more vRNA transcripts which are subsequently used as the genomic 
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constituents of new virions, or used as templates for more mRNA (reviewed in (Portela & 
Digard, 2002)).  
 
 
 
Figure 1.6. Viral RNP complex 
Each segment of the influenza genome forms its own RNP. Here, the 3P complex can be 
seen, comprised of PB1, PB2 and PA. The bold black line indicates vRNA coiled around a 
series of polymeric NP proteins (blue spheres) (Adapted from Portela & Digard, 2002).  
 
1.3.4.1. Inhibiting replication of the viral genome 
The vRNP complex is a highly specialised polymerase system and its function is essential for 
virus propagation. It therefore represents an attractive target for inhibition by antiviral 
drugs. Several compounds which target the replicative machinery of the virus are known 
and these will be described here beginning with the most recently discovered nucleodise 
analogues. Favipiravir (also T-705), is currently under development by Toyama Chemicals 
and has exhibited inhibitory effects against a wide array of influenza viruses both in vitro 
and in vivo. Favipiravir has potent inhibitory activity against all three types of Influenza, A, B 
and C (Furuta et al., 2002) and has shown efficacy against seasonal oseltamivir-resistant 
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and -sensitive H1N1 isolates, pandemic H1N1/09 isolates and highly pathogenic H5N1 
viruses in vitro, as well as mouse-adapted H5N1 isolates in the murine model (Kiso et al., 
2009; Sleeman et al., 2010). The mechanism of action for this drug is reasonably well 
understood; in the host cell, Favipiravir undergoes ribosylation and consequent 
phosphorylation and subsequently functions as a nucleoside analogue. The favipiravir anti-
metabolite then specifically inhibits the formation of viral RNA and not cellular DNA or 
RNA. This specificity accounts for a much lower toxicity than another known nucleoside 
analogue, ribavirin (reviewed later), a drug which is also less effective at inhibiting RNA 
synthesis than favipiravir (Furuta et al., 2005). By virtue of its mechanism of action, 
favipiravir has also shown efficacy against other RNA viruses, such as bunyavirus, 
arenavirus and west Nile virus, making it an attractive target for further development given 
its obvious potential as a broad-spectrum, non-toxic drug (Furuta et al., 2009).  
Ribavirin functions as a nucleoside analogue, much like T-705, and can incorporate into a 
replicating viral genome causing lethal mutations in any virus which utilises RNA-dependant 
replication machinery. Ribavirin has been licensed for the treatment of severe RSV 
infection in children (Rodriguez, 1999), and since 1998 has been used in combination with 
interferon-α as a therapy for HCV infection (Lerebours et al., 2002). Although the anti-
influenza effect of ribavirin has been known since the early 1970’s (Sidwell et al., 1972) it 
has never been widely marketed as an influenza treatment and the exact mechanism of 
action remains controversial. The drug is thought to inhibit influenza viral replication in 
several ways; firstly in the host cell, ribavirin is metabolised into ribavirin triphosphate 
(RTP), a nucleotide-resembling molecule capable of selectively inhibiting influenza 
polymerase (Eriksson et al., 1977). Secondly, in its monophosphate form (RMP), ribavirin 
inhibits the intracellular enzyme Inosine Monophosphate Dehydrogenase (IMPDH), 
preventing the conversion of inosine monophosphate (IMP) into xanthosine 
monophosphate (XMP) which under normal conditions is then metabolised into guanine 
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metabolites such as GTP – an essential precursor of RNA synthesis (Streeter et al., 1973). 
Thirdly, during polio infection, RTP has been shown to incorporate into viral genomes 
during replication causing ambiguous base-pairing (Crotty et al., 2000). These multiple 
mechanisms of action have resulted in very few examples of viral resistance across the 
panel of RNA viruses susceptible to this drug; to date, ribavirin-resistant isolates of HCV and 
poliovirus have been detected with resistance being conferred by mutations in the RdRp 
proteins of each virus (Pfeiffer & Kirkegaard, 2003; Young et al., 2003). To date, no 
ribavirin-resistant influenza isolates have been reported in the literature. However, given 
the indiscriminate activity of the drug, use of ribavirin has been associated with significant 
toxicities and teratogenicity, and common side effects of prolonged treatment include 
haemolytic anaemia (Kowdley, 2005). An obvious fact that has so far precluded ribavirin 
from receiving widespread authorisation for the treatment of influenza viruses is that 
clinical trial data regarding its use has been inconsistent and insignificant. An early trial in 
1988 noted no significant benefit between ribavirin treated or placebo treated patients 
suffering from influenza B infections (Bernstein et al., 1988), however this was preceded by 
a trial in which inhaled ribavirin was associated with improved outcome (reduction in 
duration of fever, more rapid clearance of influenza virus from respiratory secretions) in 
students suffering from H1N1 and H3N2 seasonal isolates in 1981 (Knight et al., 1981). In 
one of the largest clinical trials of ribavirin to date (n=67), the aerosolised form of the drug 
was shown to reduce fever duration in children by approximately 14 hours, though no 
other improvements were observed between the drug- and placebo- treated groups 
(Rodriguez et al., 1994). Clinical trials for ribavirin repeatedly feature unsubstantial sample 
sizes (rarely more than 50 patients), which make statistical conclusions about the efficacy 
of the drug difficult to obtain. It is also often administered as a last-line treatment option 
for the chronically ill and thus it may not be surprising that ribavirin is unable to improve 
outcomes in those suffering from particularly severe infections. 
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In an attempt to circumvent the known toxicity issues associated with ribavirin use, 
analogous compounds have been devised which are significantly less toxic than the parent 
drug. Taribavirin (viramidine) is a prodrug of ribavirin and is currently under development 
as a ribavirin-alternative for the treatment of HCV. Viramidine resembles adenosine, and is 
rapidly converted into ribavirin by the hepatic enzyme adenosine deaminase. Compared to 
ribavirin, viramidine remains concentrated to the liver after adsorption, which although 
desirable for HCV treatment, is unlikely to prove beneficial in the treatment of influenza. 
However, phase II clinical trials have identified a definite advantage of viramidine 
treatment over ribavirin from the fact that viramidine is less likely to cause haemolytic 
anaemia, due to a lower efficiency of the compound to uptake into red blood cells (Gish et 
al., 2004; Lin et al., 2003). This observation may allow for increased dosages of viramidine 
to be administered in the clinic, which may translate to a more potent antiviral effect. 
Viramidine has been shown in vitro to inhibit replication of influenza viruses of H1N1, 
H3N2, H5N1 and influenza B subtypes, as well as protecting mice from a H1N1 challenge in 
vivo, with viramidine exhibiting three-fold less toxicity than ribavirin (LD50 of 610mg/kg/day 
and 220mg/kg/day respectively)(Sidwell et al., 2005). Viramidine was shown to be effective 
even when administered 48 hours post-infection, as well as when administered at high-
doses in drinking water. Although no human clinical trials have been undertaken to date to 
assess the efficacy of viramidine against influenza, the revelation from other clinical trials 
that the drug is well tolerated in patients trials is reassuring. 
Recently, a novel molecule with inhibitory mechanisms not related to nucleoside mimicry 
was published by Wunderlich and colleagues (Wunderlich et al., 2009). Building on the 
knowledge that PB1 and PA interaction is necessary for functional polymerase activity 
(Fodor et al., 2002; Perales & Ortin, 1997), they attempted to prevent it by synthesizing a 
short peptide based on the PA-binding domain of the PB1 protein. By synthesising a short 
25 amino acid peptide synonymous with the highly conserved PA binding domain of the 
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PB1 protein of influenza A viruses, and introducing a single influenza B specific amino acid 
change, they identified a molecule which could recognise and bind to the PA protein of 
both types. In binding the PA protein and blocking the interface between PA and PB1, the 
drug was shown to have dose-dependent antiviral activityl against influenza A and B viruses 
in vitro, demonstrating that inhibiting protein-protein interactions necessary for viral 
replication has potential as an antiviral mechanism.  
Finally, the nucleoprotein of influenza A has recently been described as a target for novel 
inhibitory compounds. The nucleoprotein represents the most abundant protein 
transcribed by influenza viruses during infection and serves to stabilise the RNA genome as 
the major protein component of vRNPs, and potentially plays an important role in export of 
the polymerases complexes from the nucleus of infected cells (reviewed by (Portela & 
Digard, 2002)). Kao and colleagues observed that the treatment with the commercially 
sourced compound nucleozin dose-dependently inhibited the infection of MDCK cells by 
H3N2 and H5N1 test viruses, and was also effective when administered 6 hours post-
infection (Kao et al., 2010). The antiviral mechanism of this compound was shown to be via 
potent inhibition of NP accumulation in the nucleus. During the course of investigation, a 
resistant viral phenotype emerged carrying an amino acid change in the NP protein 
(Y289H). This virus was still replication competent, though replication activity of the viral 
genome was approximately 20% less in the mutant than in the wild type virus. Nucleozin 
did not disrupt the binding of RNA to NP, nor disrupt or block the nuclear import signal. 
Instead it is thought that nucleozin treatment results in the formation of large NP 
aggregate complexes that are functionally useless and too large to enter the nucleus. The 
compound also demonstrated efficacy in vivo by protecting 50% of mice infected with a 
highly virulent avian influenza strain and lead to a ten-fold reduction in lung titres when 
compared to the infected but untreated group. However, although the Y289H mutation 
was found to be rare in circulating human isolates prior to 2009, the pandemic A/H1N1 
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virus was found to naturally contain this mutation and demonstrated a natural resistance 
to the drug.  
1.3.5. Virus assembly  
Influenza viruses are known to assemble and bud from the apical membrane of polarized 
cells and consequently, no complete influenza virus particles are found inside an infected 
cell. The M1 protein, as well as binding to the nuclear RNP complex, can also associate with 
lipid membranes, suggesting that M1 plays a key role in assembly by recruiting newly 
synthesised genomes to the assembly site at the plasma membrane (Schmitt & Lamb, 
2005). Following synthesis on membrane-bound ribosomes, the integral membrane 
proteins of influenza enter the ER. Here, NA and HA are glycosylated, HA is trimerised and 
NA and M2 form tetramers. The proteins are then transferred to the Golgi apparatus and 
eventually directed to the virus assembly site via their apical membrane sorting signals 
(Barman et al., 2001). These same sorting signals also promote the association of HA and 
NA with lipid rafts. Lipid microdomains are located in the plasma membrane and are rich in 
sphingolipids and cholesterol (reviewed by (Ono & Freed, 2005)). Completed influenza 
virions selectively bud from these lipid raft domains – which is evident from the lipid 
content of purified virus particles (Scheiffele et al., 1999).  
The HA molecule is particularly vulnerable to changes in pH at this point in the replication 
cycle. Once synthesised, the HA protein is transported to the trans-Golgi network and 
accompanied by the M2 protein. The role of M2 is to prevent acidification of the Golgi 
lumen and transportation vesicles, thus preventing premature conformational changes in 
the HA protein. A low pH will cause a conformational change in the HA molecule, similar to 
that which occurs during endosome fusion with the virion membrane during viral entry. 
Because of the involvement of M2 as an ion channel in this part of the replication cycle, this 
step is susceptible to inhibition via adamantine drugs (Hay, 1992). 
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1.3.6. Viral budding and release 
Haemagglutinin and neuraminidase have been recently suggested as critical proteins in the 
budding process (Chen et al., 2007) as opposed to the M1 protein, which was previously 
thought to be the driving force behind bud formation (Gomez-Puertas et al., 2000). The 
importance of M2 in bud morphogenesis has also been alluded to, suggesting this process 
likely requires multiple interactions between several structural proteins (Iwatsuki-Horimoto 
et al., 2006). Influenza viruses face the problem of grouping all eight vRNP segments 
together in the correct location before successful budding can take place and because the 
structural proteins alone can initiate virus-like particle (VLP) budding, it is not uncommon 
to have incomplete or non-infectious particles budding out from the infected cell. This can 
lead to the generation of ‘defective interfering (DI)’ viruses, which are generally defined as 
particles that exist without critical genomic material necessary for functionality. Such 
viruses are generally non-functional without co-infection with other viruses to provide the 
missing genomic material (Dimmock, 1985).  
Fusion of the host cell membrane at the base of the bud completes the budding process, 
though the new virion cannot escape the cell immediately because of the interaction of its 
own HA proteins with sialic acid receptors still abundant on the infected cell surface. 
Neuraminidase, as a receptor destroying enzyme, is required for the release of the virion 
from the infected cell and without the hydrolysing activity of NA, influenza viruses ‘clump’ 
together on the cell surface, unable to depart the cell, resulting in a loss of infectivity 
(Colman, 1994). 
1.3.6.1 Inhibiting the release of progeny viruses 
The neuraminidase glycoprotein is the target for oseltamivir and zanamivir. Neuraminidase 
consists of four identical monomers anchored into the viral membrane and each monomer 
possesses a deep cleft which houses a binding site for the sialic acid substrate (Figure 1.7). 
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This cleft is highly conserved throughout various strains of influenza which makes it an 
obvious choice for drug targeting (Colman, 1994). 
 
Figure 1.7. Structure of N1 Neuraminidase 
A top-down schematic of the viral neuraminidase tetramer. Each of the monomers is 
shown complexed with a zanamivir molecule (highlighted on the left-most monomer with a 
red ring). Image adapted from (Russell et al., 2006). 
 
 It was long-since known that synthetic analogues of sialic acid such as 2-deoxy-2,3-
didehydro-N-acetylneuraminic acid (DANA) could inhibit neuraminidases of a wide range of 
species (Meindl & Tuppy, 1969). However, the non-specific inhibition of human, bacterial 
and viral neuraminidases exhibited by DANA and early derivatives of this analogue was 
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regarded as undesirable for a therapeutic against influenza (Meindl et al., 1974). 
Furthermore, animal studies involving the most potent neuraminidase inhibiting DANA 
derivative (2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid) found no beneficial 
effect of the drug against influenza infection (Palese & Schulman, 1977). Utilising the 
crystal structure of N2 group influenza neuraminidases and the computer-aided design 
software, ‘GRID’, researchers then synthesised novel compounds which were predicted to 
inhibit viral neuraminidase with a higher affinity and specificity than DANA (von Itzstein et 
al., 1993). It was observed that when docked in the neuraminidase binding site, the 
hydroxyl group at position 4 of the C-ring of DANA directly aligned with a negatively 
charged Glutamic Acid at position 119, thus it was suggested that replacing the hydroxyl 
group with a positively charged amino group would lead to an increased affinity of the 
inhibitor for the active site. Indeed, this substitution lead to the formation of a stable salt 
bridge between Glu119 and the 4-amino substituted group of DANA, resulting in an 
inhibitory effect approximately 100-fold greater than the parent analogue. GRID then 
suggested that position 4 could be further altered to contain a guanidinyl group instead of 
a hydroxyl or amino group to further enhance the affinity between drug and active site. In 
this conformation, the drug bound even more tightly due to interactions of the guanidinyl 
group with both positions Glu119 and Glu227 of the active site (von Itzstein et al., 1993). 4-
guanidino-Neu5Ac2en showed significant inhibition of viral neuraminidase activity and 
plaque formation, as well as dose-dependent inhibition of influenza virus replication in 
mice (Woods et al., 1993).  This compound came to be called zanamivir, and represented a 
successful example of rational, computer-assisted drug development. Zanamivir’s 
positively-charged guanidinyl group ensures a high-affinity binding directly into the 
neuraminidase cleft (Figure 1.7.) and results in binding without any induced conformational 
change in the enzyme. The alterations to the initial DANA template resulted in a molecule 
which binds with specificity to influenza neuraminidases and although analogous sialidases 
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are utilised by other species, zanamivir has been shown to exhibit a one million times 
greater affinity to influenza NA than other types of non-viral neuraminidase (Gubareva et 
al., 2000).  
The discovery of zanamivir was followed rapidly by the marketing of a second 
neuraminidase inhibitor, oseltamivir. Following the example of structure-led drug design, 
researchers set out to generate another neuraminidase inhibiting compound. A 
neuraminidase inhibitor which could be taken orally was still commercially desirable and 
thus the ultimate aim was to create a more stable compound which could be administered 
as a pill. As seen in figure 1.1., both sialic acid and zanamivir contain a dihydropan ring as 
their core structure. Oseltamivir differs from these compounds by containing a carbocyclic 
template at its core, deliberately chosen for its enhanced stability and structural 
malleability. Using X-ray crystallographic analysis it was observed that a hydrophobic 
pocket inside the neuraminidase binding site could potentially accommodate lipophilic 
groups, absent from both zanamivir and sialic acid, but which would be desirable for 
enhancing the bioavailability of a novel drug and allow greater absorption through the 
intestinal tract (Kim et al., 1997).  Although this novel compound was found to be more 
lipophilic than zanamivir, it exhibited poor oral bioavailability in the animal model. In order 
to remediate the problem of low bioavailability, further modifications to the lead 
compound were made in order to deliver it as an esterised prodrug. This modification led 
to higher and more sustained concentrations of the drug in multiple animal models 
following oral administration (Li et al., 1998). Today, oseltamivir is administered orally as 
oseltamivir phosphate and rapidly metabolised to the active form oseltamivir carboxylate 
by esterases in the liver, with >75% of the dose entering systemic circulation (Gubareva et 
al., 2000).  
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The discovery of neuraminidase inhibitors which so closely mimicked the natural substrate 
of influenza sialidase led to the hope that significant resistance mutations would not readily 
arise in circulating isolates. However, as mentioned previously, resistance to the 
neuraminidase inhibiting class of antiviral has been reported.  
One of the principle mechanisms of drug resistance is a mutation in the neuraminidase 
protein of N1 subtypes at position 275, where histidine is replaced by tyrosine. This 
mutation confers resistance against oseltamivir and peramivir in vivo (Weinstock et al., 
2003), however, other mutations at position 119 and 292 are also known confer resistance 
to neuraminidase inhibitors in N2 and N9 neuraminidase subtypes (Gubareva, 2004). This 
observation suggests that there are numerous mechanisms of resistance to NI drugs that 
are not yet well characterised. 
Although nine different neuraminidase proteins are utilised by influenza viruses, and amino 
acid sequences vary substantially between these different subtypes, the active site of the 
neuraminidase protein is highly conserved and oseltamivir has been shown to inhibit all 
nine known neuraminidases (Thomas et al., 1994). The fact that neuraminidase inhibition 
can successfully lead to broad cross-protection against potential pandemic subtypes has 
ensured that the active site of neuraminidase has therefore remained an attractive drug 
target, and has led to the continued development of neuraminidase inhibiting compounds 
such as the experimental drugs peramivir and CS-8958.  
Peramivir, like oseltamivir and zanamivir, is a potent inhibitor of the neuraminidase enzyme 
at nanomolar concentrations in vitro (Gubareva et al., 2001). Furthermore, peramivir has 
demonstrated inhibitory efficacy in the animal model, contributing to improved outcomes 
in both mice (44% increase in survival rates) and ferrets (40-63% increase in survival rates) 
when challenged with a robust H5N1 infection (Yun et al., 2008). Importantly, peramivir is 
administered either intramuscularly or intravenously, and thus represents a novel 
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mechanism of drug delivery for seriously ill patients who are unable to commit to oral or 
inhaled dosing regimens. Following the outbreak of nvH1N1 pandemic influenza in 2009, 
peramivir was granted an Emergency Use Authorisation (EUA) by the FDA for ‘last-line’ 
treatment of pandemic influenza, making it the first unapproved drug to be recommended 
for use in patients in this fashion (Birnkrant & Cox, 2009). Unfortunately, despite still being 
an unlicensed drug, resistance to peramivir already exists in the community with the 
common H275Y mutation in H1N1 viruses conferring resistance to this inhibitor in the same 
manner as oseltamivir (Abed et al., 2006). Furthermore, both R292K, R152K and 
E119V/D/G/A have been shown to grant resistance to Influenza B viruses against peramivir 
in vitro, suggesting that even once licensed, the drug may already have diminished efficacy 
(Jackson et al., 2005). 
A second novel neuraminidase inhibiting drug, laninamivir (also known as CS-8958 & R-
118958), is also under development, which like zanamivir is an inhaled NAI, but is long-
acting and remains in the host for many hours after administration. Laninamivir has shown 
efficacy against neuraminidase subtypes 1-9 in vitro and in a mouse model has prolonged 
the survival of animals challenged with lethal doses of A/Puerto Rico/8/34 (H1N1). When 
laninamivir and zanamivir were administered singly, seven days pre-infection, 100% of mice 
were dead in the zanamivir group by day 8, compared to a 90% survival rate seen in the 
laninamivir group on this day, confirming the long-acting properties of the drug (Yamashita 
et al., 2009).  This study also highlighted the efficacy of laninamivir against oseltamivir-
resistant seasonal influenza viruses, including H1N1 isolates carrying H275Y mutation, 
suggesting that the widespread prevalence of this mutation will not impact on the drug’s 
effectiveness in the clinic. This finding has been reinforced in vivo in a study which accredits 
laninamivir with reducing the duration of shedding of oseltamivir-resistant influenza viruses 
by 30 hours compared to oseltamivir in humans (Sugaya & Ohashi, 2010). Laninamivir has 
also demonstrated efficacy against the pandemic H1N1 virus, and H5N1 isolates in the 
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mouse model (Itoh et al., 2009; Kiso et al., 2010a). Pharmacokinetic analysis of laninamivir 
suggests that the drug is eliminated slowly from the body, still being present in the urine of 
patients after 144 hours, and that even with repeat  and high concentration dosing 
regimens, no adverse effects are recorded in healthy human males (Ishizuka et al., 2010). 
The benefits of a long-acting drug are obvious. Presently, both oseltamivir and zanamivir 
are administered twice daily for five days as a treatment, or once daily for ten+ days as a 
prophylaxis, for influenza infection in uncomplicated patients. If such laborious treatment 
regimens can be replaced by a single-dose therapy, then far fewer stockpiled doses would 
be needed for pandemic protection, and there will be a reduced risk of patient non-
compliance with long-term prophylaxis.  
 
1.4. Inhibiting influenza spread by targeting the innate immune response 
The innate immune system of the host is capable of mounting a powerful and complex 
antiviral response to a myriad of viral infections. Influenza viruses have had to evolve 
mechanisms to circumvent the full complement of secreted chemokines and cytokines 
utilised by the host to limit viral replication and spread. The NS1 protein of influenza in 
particular is crucial in constraining the interferon response of the host in an attempt to 
maintain optimal replication conditions in the cell (reviewed in (Hale et al., 2008)) and thus 
represents a potential target for antiviral intervention. The NS1 protein is anti-
inflammatory via several mechanisms, including via the sequestering of viral double-
stranded RNA (a pathogen associated molecular pattern (PAMP)), thus preventing 
intracellular detection and degradation of viral genomic material by the host cell and by 
blocking the nuclear export of cellular proteins involved in the interferon response. Basu 
and colleagues recently described several novel antimicrobials that dose-dependently 
reduced viral titres of lab-adapted isolates in MDCK cells (Basu et al., 2009). Treatment with 
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one compound in particular resulted in a reduction in viral protein synthesis, as observed 
by the absence of viral NP in infected cells 24 hour post-infection, and the restoration of 
the interferon-β signal in virally infected cells, which was otherwise inhibited by the 
presence of untreated virus. 
 
1.4.1 Modulating the host immune response as an influenza therapy. 
With the host cell capable of mounting such an effective antiviral response to influenza 
infection, it may seem intuitive to suggest that both artificial stimulation and/or 
upregulation of the system may prove beneficial in treating viral infection. Indeed, a recent 
study by Dudek and colleagues reported that in vitro treatment of cells with the known 
proteosome inhibitor PS-341 (also known as Bortezomib and Velcade) resulted in a 
reduction of viral titres (Dudek et al., 2010). Ironically, the researchers were attempting to 
inhibit the pro-inflammatory effects of the well characterised transcription factor, nuclear 
factor κB (NF-κB), due to their previous observation that activation of the NF-κB pathway 
was essential for efficient influenza replication (Wurzer et al., 2004). However, rather than 
resulting in the inhibition of NF-κB signalling, the drug instead was shown to activate this 
transcription factor and lead to low-level induction of the interferon response early in the 
course of infection. It is likely that the drug gave cells a head start on interferon induction 
which caused the reduction of progeny viral titres. This drug also benefits from current 
clinical use as an anti-cancer therapy, so may be somewhat tolerated in humans, and has 
displayed no cytotoxic effect in human cells in vitro. 
Early work intending to explain the high pathogenicity of human H5N1 infections observed 
that infection with this virus resulted in rapid accumulation of proinflammatory cytokines 
and chemokines and that this hyperactivity of the immune system actually correlated with 
higher viral loads in pharyngeal secretions (Cheung et al., 2002; de Jong et al., 2006). This 
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observation was also true of another highly pathogenic virus, the 1918 pandemic strain, 
and is likely a major determinate of viral pathogenesis (Kash et al., 2006). The discovery 
that certain viruses could not only induce high levels of cytokines, but also replicate 
extensively in their presence (Seo et al., 2002) led to the suggestion that clinical 
management of such patients should focus on managing the intense ‘cytokine storm’ 
induced by viral replication. The host proinflammatory response can potentially be 
mediated by immunomodulatory compounds which are both relatively well characterised 
and tested in humans and also hugely abundant across the globe. Many 
immunomodulators exist in generic forms and are especially cheap to acquire with long 
shelf-lives, making them an appealing alternative to specific and heavily patented antiviral 
drugs which are currently stockpiled in insufficient quantities to benefit the majority of the 
global population (Fedson, 2008).   
 
1.4.2. The case against using immunomodulatory compounds 
 Early mouse studies suggested that hypercytokinemia alone was not sufficient to explain 
the high pathogenicity and fatal outcome of H5N1 infection. TNF-α, IL-6 and CC Chemokine 
ligand 2 (CCLR2) are three proinflammatory cytokines known to be elevated in humans and 
mice during H5N1 infection. Salomon and colleagues observed that knockout mice 
genetically deficient in either TNF-α (or its receptors TNFR1 or TNFR2), IL-6 or CCLR2, all 
succumbed to H5N1 infection in a similar manner to wild-type mice with functional 
cytokine responses (Salomon et al., 2007). Furthermore, treatment of wild-type mice with 
anti-inflammatory glucocorticoids did not reduce lethality of H5N1 challenge, suggesting 
that suppression of inflammatory cytokines does not result in improved outcomes in mice. 
A similar study by Szretter and colleagues also found that mice lacking individual cytokine 
responses were just as likely to succumb to highly pathogenic H5N1 infection as wild-type 
- 63 - 
 
mice. This study also highlighted that mice lacking Interleukin 1 receptor (IL-1R) exhibited 
heightened mortality and morbidity to a low pathogenic H5N1 challenge (Szretter et al., 
2007). Another obvious criticism of relying solely on immunomodulatory molecules to 
control influenza infection is that not every influenza isolate induces cytokine storms, 
indeed the A/H1N1 2009 pandemic isolate was not associated with significant cytokine 
dysregulation in the majority of cases and thus reliance on immunomodulatory treatments 
that do not impact on viral replication might be unhelpful.  
 
1.4.3. The case for using immunomodulatory compounds 
The principal focus on anti-inflammatory therapies that might be beneficial in controlling 
pandemic infection has been the statins. These agents are currently widely used as 
cholesterol-lowering drugs, though laboratory studies have identified their pleiotropic and 
anti-inflammatory effects (Terblanche et al., 2007). Statins may hypothetically exhibit 
direct antiviral effects through their cholesterol depletion properties. Influenza viruses are 
known to require cholesterol for efficient viral replication, as they bud from cholesterol-
rich lipid microdomains at the apical plasma membrane of infected cells (Nayak & Barman, 
2002). Indeed, approximately 44% of the lipid content of influenza virions is comprised of 
cholesterol (Lenard & Compans, 1974). Statins generally inhibit the enzyme HMG-CoA 
reductase, which is the first dedicated enzyme of the cholesterol biosynthesis pathway, 
resulting in a reduction of cellular cholesterol concentrations and all upstream 
intermediates of this pathway (Figure 1.8.). Many of these upstream intermediates are 
involved in protein prenylation and serve as post-translational modification molecules for 
various membrane-bound proteins involved in inflammatory signalling. By slowing the rate 
of prenylation, statins interfere with the proper intracellular trafficking of signalling 
proteins involved in inflammation and thus exhibit an immunomodulatory effect. 
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Figure 1.8. Intermediates of the cholesterol biosynthesis pathway 
Image credit: (Menge et al., 2005) 
Statins are effective as cholesterol lowering drugs because they force the host to 
upregulate low density lipoprotein (LDL) receptors and subsequently attract cholesterol 
back into the cell from circulation (Ma et al., 1986). It is unclear whether this would result 
in any hindrance to viral replication as the cell attempts to source more cholesterol or 
whether it is sufficient to inhibit virus propagation. Laboratory studies documenting the 
direct effect of statins on influenza replication are rare, however one such study observed 
the effect of a combination of caffeine and statin against influenza challenges of H1N1, 
H3N2 and H5N1 subtypes in mice. The combination of 200μg caffeine and 50µg of statin 
- 65 - 
 
inhibited viral replication and ameliorated lung damage by all isolates with a similar 
potency to oseltamivir (Liu et al., 2009). However, several retrospective cohort studies have 
been performed to assess the effect of statin prescription with morbidity: Over ten 
influenza seasons in Canada, statin use was associated with small protective effects against 
pneumonia hospitalisation and mortality, as well as all-cause mortality. The researchers 
concluded that although the minimal protective effect against influenza morbidity was 
statistically significant, ‘clinicians should focus on other measures to reduce morbidity and 
mortality from the next influenza pandemic’ (Kwong et al., 2009).  Two further studies also 
noted that statin use did not correlate with positive respiratory infection outcomes and 
suggested that the beneficial effects of statin use are limited to their established area of 
action; vascular disease (Fleming et al., 2010; Smeeth et al., 2009).   
Other classes of immunomodulators include PPAR agonists. An animal study on mice 
identified a significant mortality reduction from H2N2 challenge virus when animals 
received gemfibrozil (a fibrate that acts as a PPAR-α agonist) as late as four days post-
infection (Budd et al., 2007). Gemfibrozil is also a long-established lipid-lowering compound 
with noted pleiotropic effects, including the reduction of TNF-α and Interferon-γ in serum 
(Madej et al., 1998). Although no direct antiviral effect of this drug is known, the 
observation that mice survival was enhanced by an anti-inflammatory compound may 
provide a proof of principle for future research into immunomodulators as a 
complementary arm of influenza treatment.  
Research has also shown that a combination of a neuraminidase inhibitor (zanamivir) with 
two anti-inflammatory drugs, calecoxib (an inhibitor of cyclooxygenase-2 (COX-2)) and 
mesalazine, increased survival rates of mice infected with extremely high doses (1000 LD50) 
of H5N1 virus (Zheng et al., 2008). Following triple combination therapy administered 48 
hours post-infection, mice survival was increased from 0 to 53% after 20 days. The triple 
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combination was more effective than zanamivir with a single anti-inflammatory, though the 
effects of either calecoxib or mesalazine alone after 48 hours were not examined. When 
treatment was administered 4 hours post-infection, only zanamivir alone was sufficient to 
prevent mouse mortality, with neither calecoxib, mesalazine or a combination of the two 
improving the outcome in mice, suggesting the timing of treatment with such regimes may 
be critical. 
 
1.5. Utilising combination therapies to treat influenza 
As previously described, drug resistant strains of influenza exist against both of the licensed 
classes of antiviral therapy. The ability of influenza viruses to acquire and propagate drug-
resistance mechanisms can often preclude the use of entire classes of drug against 
particular subtypes of virus, particularly when no fitness cost is associated with the 
resistance mutation (Table 1.2.). The standard course of treatment for uncomplicated 
influenza infections has always centred on the prescription of a single drug. With the 
adamantanes now largely ineffective, and oseltamivir resistance emerging amongst 
seasonal H1N1s, it is obvious that the monotherapy strategy will continue to breed 
resistant variants and force clinicians to move onto alternative drugs, which are in very 
short supply. It is likely that the future of influenza treatment strategies lies in combination 
therapies. Although there is an obvious financial burden associated with prescribing and 
stockpiling multiple drugs, the probability of higher treatment success rates and a much 
slower accumulation of resistant variants should ensure a long-term cost-efficiency of this 
strategy. As antiviral research into novel compounds continues, we will invariably discover 
compounds which target alternative areas of the viral replication cycle, or indeed the host 
cell, which may then have the potential to act synergistically if prescribed together. It then 
stands to reason that the virus will be unable to generate resistance if several of its 
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proteins are blockaded at the same time. Combination therapy has proven effective in the 
treatment of retroviral infections, with highly active antiretroviral therapy (HAART) being 
particularly effective against HIV infection (Palella et al., 1998). However, the complexity of 
such treatment regimens has also highlighted the problems of serious side-effects borne 
from taking multiple drugs, the potential that two drugs will have negative synergies, and 
the possibility that patient non-adherence to the regimen may lead to the generation of 
resistant viruses. It may be likely that combination therapy against influenza virus infection 
would not be so complex given the self-limiting nature of the infection, with one assuming 
that patients would be medicated over the course of several days rather than years.  
Currently, the most obvious choice for influenza combination therapy would be to 
administer an M2 inhibitor simultaneously with a neuraminidase inhibitor. The 
combination of these two drugs has been shown to synergistically and additively inhibit the 
replication of several influenza A isolates in MDCK cells (Govorkova et al., 2004). The 
presence of a neuraminidase inhibitor was also shown to delay the emergence of 
amantadine-resistant influenza variants when viruses were grown in the presence of both 
drugs, whereas viruses in the presence of amantadine alone rapidly generated resistance 
after five passages (Ilyushina et al., 2006). This result was recapitulated in vivo using a 
mouse model, where it was shown that whereas oseltamivir or amantadine alone would 
provide 50-60% survival against H3N2 and H1N1 challenge infections, a combination of 
both drugs would confer 100% survival (Masihi et al., 2007). This study also noticed that 15-
fold less oseltamivir was required to confer complete protection. Given that drug resistance 
emerges rapidly to M2 inhibitors and that most circulating and recently emerged viruses 
are already resistant to the adamantanes, as well as the fact that influenza B viruses are 
immune to the effects of ion channel blockers, it is unlikely that this combination would be 
clinically useful. This has led researchers to consider other combinations of drugs, such as a 
neuraminidase inhibitor with ribavirin. In one study using a recent mouse-adapted H1N1 
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(A/New Caledonia/20/99) isolate, oseltamivir failed to protect mice unless administered 4 
hours before infection. Intriguingly, when administered 1-4 days post infection, oseltamivir 
granted no protection to mice, whereas ribavirin treatment prevented mortality by 50-80%. 
However, when an influenza B challenge was used, both ribavirin and oseltamivir afforded 
50-80% and 30-40% survival respectively when administered 2-4 days post infection, and in 
combination survival rates were superior to either compound alone (Smee et al., 2006). 
Similar results were obtained when oseltamivir was issued in combination with the 
experimental polymerase inhibitor favipiravir. When administered alone, oseltamivir and 
favipiravir protected 41% and 8% of mice from H1N1 challenge respectively. When these 
two combinations were administered in combination however, survival was increased to 
100%. When tasked with protecting against an H5N1 challenge, oseltamivir and favipiravir 
protected 0% and 40% respectively, but when combined protected 90% of mice (Smee et 
al., 2010).  Further studies have highlighted the success of using a triple combination 
therapy of amantadine, ribavirin and oseltamivir to successfully treat a panel of influenza A 
viruses in vitro. The triple combination of all three drugs were significantly more potent at 
inhibiting viral replication than either combination used singularly or in a double 
combination (Nguyen et al., 2009). This triple combination regimen was then shown to 
inhibit drug-resistant isolates of influenza, including A/H1N1 09 pandemic virus, with 
amantadine contributing to the overall synergy of the triple therapy even if the virus isolate 
was resistant to drug (Nguyen et al., 2010). These experiments highlight the potential for 
combination therapy to inhibit influenza replication with greater potency, and diminish the 
effect and emergence rate of drug-resistance mutations. Interestingly, this study also 
utilised combinations of zanamivir/oseltamivir and zanamivir/peramivir to treat A/H1N1 09 
pandemic influenza isolates, but found no synergism as a result. This is likely because all 
three drugs target the identical substrate binding pocket of neuraminidase and essentially 
compete with one another. However, the question of whether a combination of two 
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neuraminidase inhibitors would actively prevent the emergence of drug resistant 
mutations remains unanswered.  
 
1.6. Other compounds that exhibit anti-influenza activity. 
Finally, as interest in the field of influenza antivirals continues to grow, it becomes 
increasingly common to read of established drugs and familiar molecules having newly 
discovered activity against the virus. The macrolide antibiotic clarithromycin, used 
traditionally to treat bacterial infections of the respiratory tract, was found to inhibit 
influenza A virus replication in vitro (Miyamoto et al., 2008). The antibiotic did not inhibit 
any stage of viral attachment or entry but was shown to prevent virus-induced apoptosis of 
infected cells, suggesting that the viral replication cycle is directly inhibited by the drug. 
Clarithromycin is an effective antimicrobial via its ability to inhibit bacterial protein 
synthesis, and with the observation that the drug is effective between the 4th-7th hours of 
influenza infection, it is suggested that the mechanism of action against influenza is also 
through the prevention of protein synthesis.  
A separate study found that polyphenolic catechin compounds, abundantly found in green 
tea, were able to inhibit influenza virus replication in MDCKs of H1N1, H3N2 and Influenza 
B viruses (Song et al., 2005). The compounds inhibited haemagglutination and viral RNA 
synthesis in cell culture. Catechin compounds were also shown to inhibit viral 
neuraminidase activity at high concentrations, further enhancing their potency against the 
virus.  
Another polyphenolic compound, Resveratrol, which is synthesised by many plant species 
including grapes, was found to strongly inhibit influenza replication in MDCK cells 
(Palamara et al., 2005). The mechanism by which Resveratrol inhibits replication is via the 
prevention of ribonucleoprotein translocation out of the nucleus into the cytoplasm, and 
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the reduction of late protein expression by the virus. The compound is nontoxic and found 
in clinically relevant concentrations in red wine. This drug also improved the survival of 
mice infected with H1N1 PR8 challenge. 
Of these compounds, resveratrol is the only one to be assayed in vivo and thus it remains 
to be seen whether they represent genuine potential as future antiviral compounds or not. 
Whether in vivo experiments with the other compounds have been performed with 
ineffectual results, or whether any further work has simply not been undertaken after the 
initial publication is not clear.  
Finally, it has also been suggested that defective-interfering influenza particles could play a 
role in the treatment of influenza viruses. DI particles exist as partially-intact virions which 
can competently enter cells, but whose genomes contain internal deletions of sequences 
required for the transcription of necessary viral proteins. This usually results in the 
presence of genetic material that contains the usual terminal promoter regions, meaning 
they are recognised by viral polymerases from another replicating virion in the same cell. 
The suggestion that DIs may have a therapeutic benefit stems from the observation that 
they act as competitive inhibitors of ‘genuine’ virus replication, as their usually miniature 
genomes can be replicated rapidly and preferentially by influenza polymerases at the 
expense of longer, whole influenza segments. Early studies showed that mice could be 
protected from a lethal WSN challenge if they were treated with DI particles of WSN 
(Morgan et al., 1993). But since then, literature on the subject has been sparse, which is 
surprising given the advances in reverse genetics technology which would allow for a much 
more convenient and regulated method for generating DI particles. 
1.7. Lessons learned from the 2009 pandemic outbreak 
The 2009 A/H1N1 pandemic outbreak offered insights into how we prepared and then 
tackled the outbreak, and with retrospect, suggests how we can better prepare ourselves 
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for future pandemics. We witnessed the alarming rate at which the pandemic spread from 
its source in Mexico to the rest of the world. After emerging in March 2009, the virus has 
spread to North America and Europe by April and by June had been declared a global 
pandemic. This is despite widespread attempts by the Mexican government to close down 
public and private facilities across the country. Thus, it is likely that should a new pandemic 
virus emerge, it would be extremely difficult to contain and quarantine the pathogen 
before it rapidly spread worldwide, a problem exacerbated by the popularity of air travel 
across the globe. This knowledge, coupled with the fact that influenza vaccines can take 
months to assemble and license, suggests that antiviral drugs will certainly be required to 
treat a future pandemic virus and that stockpiles should be maintained.  
We know that the attack rate of the pandemic virus was higher in children than in adults, 
and that the virus was predominantly transmitted by children (Ghani et al., 2009). It would 
therefore be beneficial to target children with a drug that is effective and convenient for 
younger people to take, particularly given the unpopularity of closing schools and the fact 
that school closure does not prevent children socially interacting with one another. Of the 
list of drugs reviewed in this introduction, perhaps the most convenient drug on the list is 
the long-acting neuraminidase inhibitor, laninamivir, which if licensed would only require a 
single dose administered at the beginning of each week to guarantee long-term 
prophylaxis, which is an obvious advantage when treating any patients, particularly young 
children.  
We were also fortuitous in that our sole stockpiled drug was mostly effective against the 
pandemic strain. Stockpiles of anti-influenza drugs should be augmented to contain 
multiple drugs, preferably with different mechanisms of action in the event of virus 
acquiring resistance to one particular compound. In an ideal world, multiple therapies 
would be stockpiled and administered in combination to patients in order to enhance the 
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potency of our treatment regimes. Such combination therapies should also be restricted to 
those who are more severely at risk from influenza infection, such as the 
immunocompromised, pregnant and at risk age groups. More stringent control of the drug 
stockpile should clearly be implemented and administration strategy should be based on 
the severity of the pandemic isolate. Thankfully, the 2009 pandemic virus resulted in 
mostly uncomplicated and largely asymptomatic infections, which throws into doubt why 
so much oseltamivir was administered throughout the outbreak.  
Another key feature for any stockpiled drug would be its shelf-life. According to Roche, the 
shelf-life of oseltamivir is five years, which following the outbreak of the pandemic was 
extended to seven years (Reddy, 2010). Thus, if oseltamivir was available following the last 
influenza pandemic in 1969 and we maintained a stockpile ever since, we would have had 
to have completely replaced the entire stockpile five times before the 2009 outbreak. This 
obviously represents a huge financial burden for any government, and one wonders 
whether the stockpile would have been maintained as a precautionary measure, or 
whether continued investment in the drug would be regarded as unfeasible. A drug set that 
was therefore stable, cheap and conveniently administered would therefore be the ideal 
therapeutic answer to pandemic influenza outbreaks. 
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1.8 Aims of thesis 
This work will focus on the discovery and characterisation of novel antiviral compounds 
against influenza isolates, and asses the suitability of relying on oseltamivir as the sole 
stockpiled drug for pandemic influenza emergencies. 
 A novel compound library was screened for antiviral activity against influenza 
viruses. 
 A selection of hits from this screen were then further categorised for their ability to 
inhibit a range of influenza viruses. 
 Compound library hits from a previous library screen were also probed as to 
discover their efficacy as potential future therapies. 
 A novel cell screening tool was generated with the potential to improve on the 
current high throughput screening techniques used to identify the aforementioned 
compounds. 
 A pandemic representative virus was generated using reverse genetics and a 
mutation conferring drug resistance to NAIs was artificially mutated into this virus. 
 The effect of harbouring this mutation on viral fitness was then investigated in 
these pandemic isolate viruses. 
 A Human Airway Epithelial cell line was assessed in its ability to provide a more 
human-like and challenging growth strata on which to assay for differences in viral 
growth kinetics. 
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2. Materials and Methods 
 
2.1. Materials 
2.1.1. Cell lines and primary cultures 
Cell Line Comments Source 
A549 Human lung epithelial cell line derived from 
carcinoma. 
ATCC 
   
HAE Fully differentiated human airway epithelial 
model comprised of primary cells cultured 
from the bronchus, trachea and nasal cavity 
of humans. 
Epithelix-Sàrl 
   
MDCK Madin Darby Canine Kidney cells ATCC 
   
MDCK-SIAT1 MDCK cells which express enhanced levels 
of α-2,6-linked sialic acid (Matrosovich et 
al., 2003). 
Mikhail Matrosovich, Phillips 
University, Marburg, 
Germany 
 
293T Human kidney cells expressing large T-
antigen of SV40 
ATCC 
   
Table 2. 1 Cell lines used in this study. 
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2.1.2. Virus strains 
Virus Type Comments Source 
A/Victoria/3/75 H3N2 Reverse genetics derived. This project 
    
A/Puerto Rico/8/34 H1N1 Reverse genetics derived. This project 
    
A/England/195/2009 H1N1 Reverse genetics derived. This project 
    
A/England/195/2009H275Y H1N1 Reverse genetics derived, 
containing H275Y mutation 
in the NA gene. 
This project 
    
A/England/195/2009 H1N1 Pandemic human isolate. HPA Colindale 
    
B/Beijing/1/87 B Wild type virus. Professor Wendy 
Barclay, Imperial 
College London 
 
A/Duck/England/1/62 H4N6 Avian wild type virus Dr. Anna Hayman, 
Reading University 
    
PR8 
(Victoria NA) 
H1N2 Recombinant virus 
generated using reverse 
genetics. Seven segments of 
PR8 were rescued with 
segment 6 of Victoria. 
This project 
    
PR8 
(Victoria HA) 
H3N1 Recombinant virus. Seven 
segments from PR8 with 
segment 4 of Victoria. 
This project 
    
PR8 
(Victoria HA & NA) 
H3N2 Recombinant virus. Six 
segments from PR8 and 
segments 4 and 6 of Victoria. 
This project 
    
RG14 
 
H5N1 Recombinant virus. Six 
segments of PR8 and 
segments 4 and 6 of 
A/Vietnam/1194/04 (minus 
multi-basic site in segment 
4). 
NIBSC 
    
RD3 H7N1 Recombinant virus. Six 
segments of PR8 and 
segments 4 and 6 of 
A/Chicken/Italy/4789/1999 
Professor Wendy 
Barclay, Imperial 
College London 
    
    
Table 2. 2 Viruses used in this study. 
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2.1.3. Plasmid vectors 
 
All plasmids used in this study contain genetic antibiotic resistance to Ampicillin unless 
otherwise stated. 
 
Plasmid Comments Source 
pCMV-VictoriaPB2 Helper plasmid for rescuing 
reverse genetics viruses, 
containing segment 1 of 
A/Victoria/3/75 
Dr. T. Zurcher, 
GlaxoSmithKline 
   
pCMV-VictoriaPB1 Helper plasmid for rescuing 
reverse genetics viruses, 
containing segment 2 of 
A/Victoria/3/75 
Dr. T. Zurcher, 
GlaxoSmithKline 
   
pCMV-VictoriaPA Helper plasmid for rescuing 
reverse genetics viruses, 
containing segment 3 of 
A/Victoria/3/75 
Dr. T. Zurcher, 
GlaxoSmithKline 
   
pCMV-VictoriaNP Helper plasmid for rescuing 
reverse genetics viruses, 
containing segment 5 of 
A/Victoria/3/75 
Dr. T. Zurcher, 
GlaxoSmithKline 
   
pPol.I-VictoriaPB2 pPol.I vector containing segment 
1 of A/Victoria/3/75 
Dr. T. Zurcher, 
GlaxoSmithKline 
   
pPol.I-VictoriaPB1 pPol.I vector containing segment 
2 of A/Victoria/3/75. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
   
pPol.I-VictoriaPA pPol.I vector containing segment 
3 of A/Victoria/3/75.. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
   
pPol.I-VictoriaHA pPol.I vector containing segment 
4 of A/Victoria/3/75. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
   
pPol.I-VictoriaNP pPol.I vector containing segment 
5 of A/Victoria/3/75. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
   
pPol.I-VictoriaNA pPol.I vector containing segment 
6 of A/Victoria/3/75. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
   
pPol.I-VictoriaM pPol.I vector containing segment 
7 of A/Victoria/3/75. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
   
pPol.I-VictoriaNS pPol.I vector containing segment 
8 of A/Victoria/3/75.. 
Dr. T. Zurcher, 
GlaxoSmithKline. 
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pPol.I-PR8PB2 pPol.I vector containing segment 
1 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-PR8PB1 pPol.I vector containing segment 
2 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-PR8PA pPol.I vector containing segment 
3 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-PR8HA pPol.I vector containing segment 
4 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-PR8NP pPol.I vector containing segment 
5 of PR8. 
Dr. Alison Whiteley, 
Reading  
University. 
   
pPol.I-PR8NA pPol.I vector containing segment 
6 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-PR8M pPol.I vector containing segment 
7 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-PR8NS pPol.I vector containing segment 
8 of PR8. 
Dr. Alison Whiteley, 
Reading University. 
   
pPol.I-England195PB2 pPol.I vector containing segment 
1 of A/England/195/09. 
GeneArt AG. 
   
pPol.I-England195PB1 pPol.I vector containing segment 
2 of A/England/195/09. 
GeneArt AG. 
   
pPol.I-England195PA pPol.I vector containing segment 
3 of A/England/195/09. 
GeneArt AG. 
   
pPol.I-England195HA pPol.I vector containing segment 
4 of A/England/195/09. 
GeneArt AG. 
 
   
pPol.I-England195NP pPol.I vector containing segment 
5 of A/England/195/09. 
GeneArt AG. 
   
pPol.I-England195NA pPol.I vector containing segment 
6 of A/England/195/09 
(Kanamycin resistance). 
GeneArt AG. 
 
   
pPol.I-
England195NAH275Y 
pPol.I vector containing segment 
6 of A/England/195/09 
(Kanamycin resistance). 
This project. 
   
pPol.I-England195M pPol.I vector containing segment 
7 of A/England/195/09. 
GeneArt AG. 
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pPol.I-England195NS pPol.I vector containing segment 
8 of A/England/195/09. 
GeneArt AG. 
   
p-β-galactosidase β-galactosidase reporter plasmid. Steve Goodbourn, St. 
George’s, London. 
   
   
pPol.I-Luc Luciferase reporter plasmid 
flanked by non-coding regions of 
influenza A segment 8. 
Steve Goodbourn, St. 
George’s, London. 
   
pPol.I-358Luc Luciferase reporter plasmid 
flanked by non-coding regions of 
influenza A segment 8, containing 
triple up-promoter mutations in 
the 3’end. 
This project 
   
pPol.I-mGFP GFP reporter plasmid flanked by 
non-coding regions of influenza A 
segment 7. 
Dr. Manuela Mura, 
Imperial College London. 
   
pPol.I-358mGFP GFP reporter plasmid flanked by 
non-coding regions of influenza A 
segment 7, containing triple up-
promoter mutations in the 3’end. 
This project 
   
PCDNA3-358mGFP GFP reporter plasmid flanked by 
non-coding regions of influenza A 
segment 7, containing triple up-
promoter mutations in the 3’end. 
Provides eukaryotic antibiotic 
resistance to zeocin. 
Dr. Manuela Mura, 
Imperial College London. 
   
pCMV-mCherryRed Expression plasmid encoding 
Cherry Red signal under a CMV 
promoter. Provides eukaryotic 
antibiotic resistance to geneticin.  
Dr. Manuela Mura, 
Imperial College London. 
   
pCAG-E195NA Expression plasmid encoding 
FLAG-tagged neuraminidase 
protein from A/England/195/09. 
Deena Blumenkrantz, 
Imperial College London. 
   
   
   
Table 2. 3. List of plasmid vectors used in this study. 
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2.1.4. Antibodies 
 
 
Antibody Comments Source 
Mouse α-NP Primary monoclonal antibody 
raised against an H7N1 avian 
isolate and reactive with 
influenza A nucleoprotein.  
(Diluted 1:300 for blue cell assay) 
HPA, Colindale. 
   
Goat α-mouse IgG- β-
galactosidase 
Secondary antibody conjugated 
to β-galactosidase for use in blue 
cell assay. 
(Diluted 1:400 for blue cell assay) 
Immunologicals Direct, 
Oxford, UK 
   
Mouse αFLAG Primary M2 monoclonal antibody 
used to probe for FLAG tag. 
(Diluted 1:300 for FACS analysis) 
Sigma (F3165) 
   
Goat αMouse IgG-FITC Secondary antibody FITC tagged. 
(Diluted 1:1000 for FACS analysis) 
Oxford Biotechnology 
   
Table 2. 4. List of antibodies used in this study. 
 
 
2.1.5. Oligonucleotides 
 
Name of Primer Sequence Use 
NA Fwd 1 CCC CGG GCG CTC CGT GTG 
TGG CTG CGA T 
Sequencing primer of 
A/England/195/2009 NA 
   
NA Rev 1 GGT GTT TGG ATA GGG AGA 
ACT AAA AGC 
Sequencing primer of 
A/England/195/2009 NA 
   
NA Fwd 2 CTC CCT ATC CAA ACA CCA 
TTG CCG 
Sequencing primer of 
A/England/195/2009 NA 
   
NA Rev 2 GGA ATT TCT GGC CCA GAC 
AAT GGG GCA GTG G 
Sequencing primer of 
A/England/195/2009 NA 
   
NA Fwd 3 CCA CTG CCC CAT TGT CTG 
GGC CAG AAA TTC C 
Sequencing primer of 
A/England/195/2009 NA 
   
NA Rev 3 GGA TTA GCC ACT CAA TTC 
AAC TTG GG 
Sequencing primer of 
A/England/195/2009 NA 
   
NA Fwd 4 CCC AAG TTG AAT TGA GTG 
GCT AAT CC 
Sequencing primer of 
A/England/195/2009 NA 
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NA Rev 4 CTC GAT CCG GAT ATA GTT 
CCT CCT TTC 
Sequencing primer of 
A/England/195/2009 NA 
   
H275Y MexNA Fwd GAA TGC CCC TAA TTA TTA 
CTA TGA GGA ATG CTC C 
Mutagenic Primer to 
introduce H275Y mutation 
into A/England/195/2009 
   
H275Y MexNA Rev GGA GCA TTC CTC ATA GTA 
ATA ATT AGG GGC ATT C 
Mutagenic Primer to 
introduce H275Y mutation 
into A/England/195/2009 
   
NSLuc 35 F GAC CAT GCC GGC CAG TAG 
AAG CAG GGT GAC AAA G 
Mutagenic Primer to 
introduce up-promoter 
mutations at positions 3 and 
5 in the 3’ end of pPol.I-Luc 
vector. 
   
NSLuc 35 R CTT TGT CAC CCT GCT TCT 
ACT GGC CGG CAT GGT C 
Mutagenic Primer to 
introduce up-promoter 
mutations at positions 3 and 
5 in the 3’ end of pPol.I-Luc 
vector. 
   
NSLuc 8 F CCG GCC AGT AGA AAC AGG 
GT 
Mutagenic Primer to 
introduce up-promoter 
mutation at position 8 in the 
3’ end of pPol.I-Luc vector. 
   
NSLuc 8 R ACC CTG TTT CTA CTG GCC 
GG 
Mutagenic Primer to 
introduce up-promoter 
mutation at position 8 in the 
3’ end of pPol.I-Luc vector. 
Table 2. 5. List of oligonucleotides used in this report. 
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2.1.6. Buffers, diluents and culture media. 
 
Solution Recipe Uses 
TAE Buffer 
 
40mM Tris-acetate pH 8 
1mM EDTA 
DNA gel electrophoresis 
 
   
6x DNA loading buffer  0.25% Bromophenol blue 
40% (w/v) sucrose. Used at 1x. 
Loading of DNA samples 
   
Phosphate Buffered 
Saline (PBS) 
8% Sodium chloride 
0.2% Potassium chloride 
1.15% Na2HPO4 
0.2% Na2HPO4 pH 7.4 
 
Used for washes, dilutions 
and short-term storage of 
cellular monolayers at 4°C 
LacZ Buffer 60mM Na2HPO4.7H2O 
40mM NaH2PO4.H2O 
10mM KCl 
1mM MgSO4 
Developing β-galactosidase 
assays 
   
Methylene Blue 2% Formaldehyde (36.5%) 
10% Methanol 
0.175% Methylene Blue (1.4%) 
PBS to 100ml 
Methylene Blue 
cytotoxicity and cell 
viability assay 
   
Virus Diluent 0.35% BSA  
1% Penicillin-Streptomycin  
PBS 
Collecting virus for 
timepoint sampling 
   
Antibody Diluent 0.35% BSA 
0.2% Sodium Azide 
PBS 
Antibody dilutions (Blue 
cell assay) 
   
2x MuNANA Assay 
Buffer 
13g 2-(N-
morpholino)ethanesulfonic acid 
(MES) 
8mL 1M Ca Cl2 
Distilled Water 
(Filter sterilise) 
MuNANA assays 
   
10x CN Buffer 30mM Ferricyanide 
30mM Ferrocyanide 
10mM MgCl2 
Blue cell assays 
   
5-bromo-4-chloro-3-
indolyl- beta-D-
galactopyranoside (X-
gal) Substrate 
Prepared to 2% in 
Dimethylformamide (DMF). 
Blue cell assays 
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Lysogeny Broth (LB)   
 
 
1% Oxoid tryptone  
0.5% Oxoid yeast extract  
0.5% NaCl  
0.1% glucose  
 
Culturing transformed 
bacterial cells 
   
L Agar (LA) 
 
LB + 1.5% (w/v) Difco Agar 
Supplemented with 1% Ampicilin 
or 2% Kanamycin 
Culturing transformed 
bacterial cells 
   
SOC Medium 2%  Oxoid tryptone  
0.5% Oxoid yeast extract  
10mM NaCl  
2.5mM KCl 
10mM MgCl2 
10mM MgSO4 
20mM glucose 
 
Recovery medium used 
during transformation of 
Escherichia coli TOP10 
cells. 
NZY+ Broth 
 
1% NZ Amine 
0.5% Yeast extract 
0.5% NaCl 
15mM MgCl2 
15mM MgSO4 
10mM glucose 
Recovery medium used 
during transformation of 
Escherichia coli XL-10 Gold. 
   
Serum Free DMEM Dulbecco’s modified Eagles 
medium (DMEM) (Invitrogen) 
1% glutamine (200mM) 
2% non-essential amino acids 
1% penicillin-streptomycin 
(5000IU/ml) 
(no pen-strep in media used for 
cells undergoing transfection) 
Mammalian cell culture 
and virus propagation 
   
10% DMEM Serum Free DMEM  
10% Fetal calf serum (FCS) 
Mammalian cell culture 
   
Plaque assay overlay  100ml 10 x Earle’s minimal 
essential medium (EMEM) 
28ml  7.5% BSA 
1 % glutamine (200mM) 
20ml 7.5% NaHCO3 
10ml 1M HEPES 
5ml 1% DEAE Dextran (Sigma) 
1% penicillin-streptomycin 
(5000IU/ml) 
0.6% Agarose (Oxoid) 
 
 
 
Plaque assays 
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Avicel overlay (Used in place of 0.6% agarose 
above) 
2.6% avicel in 186ml distilled H2O, 
sterilised by autoclave. 
 
Plaque assays 
 
Epithelix Culture 
Medium 
Ready-to-use MucilAir Culture 
Medium (EP04MM) 
Culturing Human Airway 
Epithelieal cells. 
   
   
Trypsinising solution 8ml 10x 2.5% Trypsin 
2mM EDTA 
PBS 
Detaching cells from 
plasticware 
   
Saponin 
permeablisation buffer 
0.05% Saponin 
1% BSA 
0.2% Na Azide 
PBS 
Permeablising cells, 
antibody dilutions. 
   
Table 2. 6. List of reagents used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 84 - 
 
2.2. Methods 
 
2.2.1. Cell and virus culturing techniques 
2.2.1.1. Cell culture 
Madin – Darby canine kidney cells (MDCKs), 293T and A549 cells were passaged in 
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) containing 1% non-essential 
amino acids plus 1% penicillin and streptomycin and supplemented with 10% fetal calf 
serum (FCS) (v/v) (Gibco BRL). All cells were grown at 37°C with 5% atmospheric CO2. 
 
HAE cells (Epithelix-Sàrl MucilAir™) were maintained at an air-liquid interface with Epithelix 
culture medium being replenished underneath the wells every 4-5 days. At the same time a 
single wash of the apical surface was performed with Phosphate Buffered Saline (PBS) to 
remove mucus secretions. 
 
To create frozen stocks of immortalised cell lines, all cells from a T75 flask were detached 
from plasticware using Trypsin and centrifuged at 80xg for 5 minutes. The cells were then 
resuspended in 5ml PBS and centrifuged again at the same speed. The cells were then 
slowly resuspended in 1ml of medium containing 10% DMSO to 90% FCS and 0.5ml aliquots 
were prepared into cryovials. These cryovials were kept in a container carrying room-
temperature isopropanol and placed at -80°C overnight, before being transferred to liquid 
nitrogen for long-term storage. 
 
To thaw immortalised cells from liquid nitrogen storage, frozen cryovials were warmed in a 
37°C water bath until the ice pellet melted, and then all 0.5ml of cells were transferred into 
a T75 tissue culture flask. Slowly, 10ml of DMEM supplemented with 10% FCS was added to 
the cells, and the flask was cultured overnight at 37°C/5% CO2. 
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2.2.1.2. Virus propagation  
Wildtype viruses were propagated in MDCK cells at 37°C/5% CO2. Cells were infected at an 
MOI of 0.01 in serum free DMEM (SF DMEM) containing 1 g/ml of Trypsin (Worthington). 
To harvest viruses, supernatant fluid was collected 3 days post infection. Collected 
supernatant was clarified by centrifugation at 1000xg for 10 minutes, distributed into 
aliquots, and stored at -80°C. 
 
2.2.1.3. Virus infections 
MDCK cells were infected with influenza virus at the relevant multiplicity of infection (MOI) 
in SF DMEM. After 1 hour incubation at 37°C, medium was removed and cells washed twice 
with PBS. Where appropriate, cells were acid-washed with PBS pH3.3 for 1 minute followed 
by a further wash with PBS to inactivate extracellular virus. Serum free DMEM containing 
1μg/ml Trypsin was added, and cells incubated at 37°C. In experiments involving drug 
treatment, the overlaying SF DMEM was supplemented with drug at the appropriate 
concentration.  
 
For HAE cells, the apical surface was washed once with PBS directly prior to infection. Virus 
was then added to the apical cell surface of the well in volumes of 50µl (viral titre 
permitting) for 1 hour. Following infection, the virus inoculum was removed and the cells 
washed 3 times with PBS, leaving an air-liquid interface with no fluid at the apical surface. 
To collect time points from these wells, 200µl virus diluent (PBS containing 0.35% BSA and 
1% Penicillin-Streptomycin) was added to the well for 2 minutes, before being recovered 
and stored for future use in viral titre assays. These cells were then incubated at 37°C/5% 
CO2. 
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2.2.1.4. Determining virus yields  
Viral yields were determined by haemagglutination and plaque assays. Haemagglutination 
assays were performed by mixing serial two-fold dilutions of virus-containing supernatant 
with equal volumes of 1% chicken or turkey red blood cell suspensions, in PBS in 96 well V-
bottom plates (Greiner bio-one). These were incubated for 1 hour on ice. The HA titre of 
the virus was determined as the well prior to the first concentration displaying a red blood 
cell pellet. 
 
Plaque assays were performed by incubating 200μl of 10-fold serial dilutions of samples 
onto MDCK monolayers for 1 hour at  37°C/5% CO2. Medium was then removed and 2.6% 
avicel overlay medium containing 1 g/ml Trypsin was added to the wells. For plaque 
reduction assays, this overlay medium was supplemented with antiviral drugs at 
appropriate concentrations. These were incubated at 37°C/5% CO2 for 3 to 4 days and then 
visualised by either crystal violet staining or in the case of A/England/195/2009 virus, 
immunostaining (‘blue cell assays’). The number of plaques were then counted and used to 
determine virus titres. 
 
Blue cell assays were performed by removing the overlaying supernatant from plaque 
assays and fixing the monolayer with 1:1 methanol:acetone for 5 minutes. The 
methanol:acetone was then aspirated from the cells and the cells washed three times with 
PBS. A primary mouse α-NP antibody was diluted 1:300 in antibody diluent (PBS containing 
0.35% BSA and 0.2% sodium azide) 
and 200µl added to individual wells of a 12-well plate. The plates were incubated at room 
temperature with shaking for 1 hour. Primary antibody was then removed from the plates 
and the plates washed twice with PBS. A secondary Goat-αMouse antibody, conjugated to 
β-galactosidase, was then used to probe the cells at a 1:400 dilution for 1 hour, with 
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shaking, at room temperature. The secondary antibody was then removed from the cells by 
flick of the wrist, and the plates washed twice with PBS. A developing solution was then 
prepared containing 0.25ml 2% 5-bromo-4-chloro-3-indolyl- beta-D-galactopyranoside (X-
gal) in Dimethylformamide (DMF), 1ml 10x cyanide buffer (30mM Ferricyanide, 30mM 
Ferrocyanide and 10mM MgCl2 in water) and 9.75ml PBS. This developing solution was 
added to cells in 400µl volumes overnight at 37°C. Plaques were then counted to calculate 
viral titre per millilitre.    
 
2.2.1.5. Assaying viral neuraminidase activity 
Viral desialylation ability was detected by establishing a haemagglutination assay, but 
following 1 hour on ice, the plate was transferred to 37°C for 1-2 hours until 
haemagglutination reversal could be observed. 
 
The neuraminidase activity of viral isolates was assessed biochemically using the 2-(4-
methylumbelliferyl)-a-D-N-acetylneuraminic acid (MuNANA) substrate (Potier et al., 1979). 
Black 96-well plates (Greiner bio-one) were used for the assay. Influenza virus NA activity 
was initially assessed by incubating viruses 2-fold serially diluted in 1x MuNANA assay 
buffer (MES buffer containing 8mM CaCl2, mixed 1:1 with distilled water), in the presence 
of 0.15mM working stock of MuNANA substrate at 37°C for 1 hour. The plate was then read 
for fluorescence using the UV optic of the BMG Fluoscan plate reader (Excitation 360, 
Emission 450). A set dilution of virus was then chosen for Km and drug IC50 assays. To assess 
Km values, a single concentration of virus was added to the plate in the presence of 
increasing 2-fold concentrations of MuNANA substrate (highest concentration 0.15mM). 
The plate was then transported to the Fluoscan plate reader and measurements of 
fluorescence were taken every five minutes for sixty minutes. Km and Vmax calculations 
were then calculated using Michaelis-Menten enzyme kinetic calculations. To assess NAI 
- 88 - 
 
IC50 values, a single virus dilution was incubated in the presence of increasing 
concentrations of either oseltamivir of zanamivir, serially diluted in 1x Munana assay 
buffer, for 1 hour at 37°C with shaking. 0.15mM MuNANA substrate was then added to 
each well and the plate re-incubated at 37°C for 1 hour. The plate was then read as 
described above.  
 
2.2.1.6. Cytotoxicity assays 
Cytotoxicity of Phytopure compounds was measured on MDCK cells using the ToxiLight® 
Non-Destructive Cytotoxicity BioAssay Kit (Lonza) according to manufacturer’s protocol. 
Briefly, cells were seeded onto 96-well plates (Greiner bio-one) and incubated in the 
presence of Phytopure compound for 3 days. At 24 hour time points, AK detection reagent 
was added to cells, incubated for 5 minutes and then 20µl of supernatant was measured 
for luminescence. Drugs were assayed in triplicate with each time point being conducted 
on individual plates. This kit measured the release of the enzyme adenylate kinase from 
dead cells. This enzyme actively phosphorylates ADP into ATP, which was then measured 
using a bioluminescent firefly luciferase reaction. Luminescence readings were compared 
to those obtained from a control group that underwent full lysis, and expressed as a 
percentage of this value. 
 
Cytotoxicity of Summit Plc. compounds was determined using a Methylene Blue assay. 
Confluent MDCK cells were grown on 96 well plates in the presence of serially diluted 
compound and at 24 hour time points, supernatant was removed and replaced with 40µl 
working stock methylene blue solution. Following a 2 hour room temperature incubation, 
methylene blue was removed by a flick of the wrist and cells were washed 3 times in PBS 
before being incubated for a further 30 minutes in PBS at room temperature. Then, 100µl 
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of 1% SDS was added to cells and plates were incubated with shaking for 1 hour at room 
temperature before being read for absorbance at 660nm using a spectrophotometer. 
 
 2.2.2. Molecular biology  
 
2.2.2.1. vRNA extraction 
Total vRNA was extracted from virus-containing supernatants using the QIAamp viral RNA 
mini kit (QIAGEN) following manufacturer’s instructions. Briefly, 280μl of virus stock were 
lysed using the AVL buffer containing RNAsin. This was bound to silica membrane, washed 
and eluted in 30μl of AVE elution buffer. The vRNA was stored at -20 C. 
 
2.2.2.2. RT-PCR and first-chain amplification 
First-strand synthesis using reverse transcription PCR (RT-PCR) of vRNA was performed 
using the following reaction procedure. A total of 2µg of isolated RNA was added to the 
forward segment-specific primer (3.2pmol) in a volume of 11µl, and heated to 70°C for 5 
minutes. The solution was then added to ice for 5 minutes to cool, before being added to a 
reaction mixture (AMV Reverse Transcriptase kit, Promega) containing the following: 5µl 
AMV Reverse Transcriptase 5x Reaction buffer, 2.5µl 10mM dNTP mix, 1µl (30 units) of 
AMV Reverse transcriptase, and nuclease free water to a final volume of 25µl. 
 
The mix was incubated at 37°C for 1 hour. The RT PCR products were amplified as follows: 
5μl 10x Platinum Pfx DNA polymerase reaction buffer (Invitrogen), 1.5μl 10mM dNTPs 
(ABI), 1 μl 50mM MgSO4 (Invitrogen), 5μl cDNA from RT PCR, 50pmoles of segment specific 
forward and reverse primers, made up to 50μl with sterile water (Sigma), were amplified 
using an initial denaturation step of 95 C for 2 minutes followed by 35 cycles of 
denaturation at 95 C for 30 seconds, annealing at 51 C for 1 minute and elongation for 
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1:45 minutes. An elongation time of 10 minutes was used on the final cycle. The PCR 
products were purified using a QIAquick gel extraction kit (QIAGEN), following 
manufacturers’ instructions. Products were eluted in 30μl sterile water and stored at -20 C. 
 
2.2.2.3. Site directed mutagenesis 
Site-directed mutagenesis was performed using the Quikchange XL site directed 
mutagenesis kit (Stratagene), following the manufacturers protocol. The mutagenic PCR 
reaction mixtures comprised of 10ng of DNA template, 125ng of each of forward and 
reverse primers, 1μl 10 M dNTPs, 1x reaction buffer, 3 L Quikchange solution, 2.5 units of 
Pfu turbo DNA polymerase and made up to 50μl with sterile water. The PCR was carried out 
using an initial denaturation stage of 2 minutes at 94 C, followed by 18 cycles of 
denaturation at 94 C for 50 seconds, annealing at 78 C for 50 seconds and elongation at 
68 C for 5 minutes. The final elongation step occurred at 68 C for 7 minutes. The PCR 
products were digested with 10 U (1µl) of DpnI restriction enzyme to remove the 
methylated parental (non-mutated) DNA prior to transformation. Plasmids were 
transformed into XL10-Gold Ultracompetent cells (Stratagene) following manufacturers’ 
instructions, and plated out onto L Agar + 100 g/mL ampicillin or 200 g/ml kanamycin 
plates. 
 
2.2.2.4. Small scale plasmid purification 
A single bacterial colony was picked from agar plates containing a selection antibiotic 
(ampicillin or kanamycin) and grown overnight in 10ml Lysogeny Broth (LB) containing the 
same antibiotic at 37 C, with shaking. Bacteria were pelleted from 1.5 ml of the bacterial 
suspension in a 1.5ml Eppendorf using a microcentrifuge at 14000xg for 3 minutes. The 
supernatant was discarded, 1.5mls fresh bacterial suspension added and the process 
repeated. Plasmid DNA was purified using the QIAprep spin miniprep kit (QIAGEN) 
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following the manufacturers protocol. This involves alkaline lysis of bacterial cells followed 
by neutralisation and binding of plasmid DNA to a silica membrane. The membrane was 
washed and plasmids eluted in 30 L of sterile water. Plasmids were stored at -20 C to 
prevent DNA degradation. In some cases, 300 l of the original suspension was mixed with 
300 l of sterile glycerol and stored at -80 C as a glycerol stock. 
 
2.2.2.5. Large scale plasmid purification 
A 100 l sample from either an overnight culture or a glycerol stock was inoculated into 
100ml of LB containing selection antibiotic at the appropriate concentration, and grown 
overnight at 37 C with shaking. Plasmids were recovered using the high-speed plasmid 
purification maxi kit (QIAGEN) according to the manufacturer’s instructions. Briefly, 
bacterial cells weight-adjusted to match using LB broth and then pelleted by centrifugation 
at 2300xg for 15 minutes at 4 C. The supernatant was discarded and cells resuspended in 
10mls of resuspension buffer containing RNaseA. Alkaline lysis buffer containing SDS was 
added to lyse the cells and denature the chromosomal DNA. The suspension was 
neutralised, precipitating contaminants, and passed through a resin containing column that 
binds plasmid DNA. The columns were washed and plasmid DNA eluted. Isopropanol was 
added to desalt and precipitate plasmid DNA, which was then ethanol washed and eluted 
in 500μl of TE (elution) buffer (QIAGEN). Plasmid preparations were stored at -20 C. 
 
2.2.2.6. Agarose gel electrophoresis and product purification 
DNA fragments were separated on 2% agarose gels diluted with 1x TAE buffer (0.04M Tris-
acetate buffer + 0.001M EDTA) and supplemented with 1μg/ml Gel Red (Sigma). Gels were 
submerged in TAE buffer. Samples were run simultaneously with a commercially available 
DNA size marker at 80-100V until the bands had separated. DNA was visualised using a UV 
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transilluminator. Slices containing the required DNA fragments were excised, and DNA 
extracted using QIAquick gel extraction kit (QIAGEN) following manufacturer’s instructions. 
 
2.2.2.7. DNA Sequencing 
Constructs were sequenced using the ‘in-house’ sequencing service by Ivan Andrew (MRC 
Clinical Sciences Centre, Hammersmith Campus, Du Cane Road, London, W12 0NN). 
Samples are subjected to automated fluorescent DNA sequencing using the ABI3730xl 
instrument. The reaction mixture was dispatched as a 10µl solution containing 3.2pmol 
primer, 200ng DNA and nucleotide-free water. 
 
2.2.3. Transfection of immortalised cell lines. 
2.2.3.1. A549 cell transfections 
The A549 cell-line was seeded to achieve ~80% confluence the next day. Cells were 
transfected using Polyfect as described in the product manual. Briefly, 1.75μg of total 
plasmid DNA was mixed with 100μl serum-free DMEM, 14μl Polyfect and 0.6ml 10% FCS 
DMEM and added drop-wise to monolayer containing fresh 10% FCS medium. For stable 
cell line experiments, an initial killing curve was performed to determine antibiotic 
selection sensitivity. These A549 cells were plated into 6-well plates and allowed to reach 
50% confluency overnight. The supernatant was then removed and replaced with fresh 
DMEM containing zeocin or geneticin at varying concentrations ranging from 0 to 
1000µg/ml. The selection medium was replaced every 3-4 days with fresh DMEM 
containing the desired concentration of antibiotic. The concentration of antibiotic which 
killed approximately 90% of cells within 14 days was chosen as the concentration to use in 
stable cell line generation experiments. Fresh A549 cells were then plated onto 6 well 
plates and allowed to reach a confluency of ~80% before being co-transfected with 
mCherry Red and m358GFP plasmids. Twenty four hours later, the medium was removed 
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and the cells detached from the plate using Trypsinising solution. Cells were seeded onto 
fresh 100mm dishes at varying densities and grown in 10% DMEM containing both 
selection antibiotics. Monolayers were analysed daily for surviving foci over the course of 
several weeks. 
 
2.2.3.2. Transfection of 293T cells. 
All transfections involving 293T cells were performed on Poly-L-Lysine treated plasticware. 
Poly-L-Lysine was diluted to 0.0001% in PBS and added to tissue culture plates for five 
minutes before being removed and the plates washed once with PBS. 293T cells were then 
seeded to achieve 95% confluency the next day. For 24-well plate transfections, the 
medium was changed to 0.25ml/well 2% DMEM (without antibiotics) prior to transfection. 
The ratio of Lipofectamine:DNA used throughout this study was 3µl:1µg and a master mix 
containing lipofectamine in 125µl OptiMem per well was incubated for 5 minutes at room 
temperature. Simultaneously, 0.125μg plasmid DNA was diluted into 125μl OptiMEM per 
well and incubated in the same manner, before both solutions were mixed and incubated 
for a further 20 minutes at room temperature. The Lipofectamine:DNA mix was then added 
dropwise to 293T cells. The quantity of DNA used to transfect per well was scaled up or 
down depending on the size of the plate. For experiments involving fluorescent signal read-
outs, cells were seeded onto black 96-well plates with translucent bottoms (Costar).  
 
2.2.3.3. Rescuing recombinant influenza virus using a 12-plasmid transfection.  
Sub-confluent 293T cells (70-80% confluency) were transfected in 12-well plates using 
Fugene6 (Roche Biochemicals, cat. No. 1815091). Two hours prior to transfection, medium 
was replaced to 0.5ml DMEM with 2% FCS. The 12 reverse genetics plasmids were 
aliquotted into Eppendorf tubes, each at 0.5μg apart from pCMV-NP, which was added at 
1μg. Then, 130μl of serum-free DMEM was added to 20μl Fugene6 and incubated for 5 
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minutes. DNA was added to the medium/Fugene, mixed, incubated for 15 minutes and 
added dropwise to the 293T cells. Transfected 293T cells were incubated overnight at 37°C. 
The following day, confluent MDCK cells were treated with Trypsin and resuspended in 
20ml DMEM with 10% FCS. Four drops of 1mg/ml Trypsin solution was added to each well 
of 293T cells, together with 1 ml of MDCK cell suspension. This was transferred to a 25cm2 
flask together with a further 4ml of MDCK suspension. This co-culture was incubated for 3-
4 hours at 37°C until the cells attached, then washed in 5ml of SF DMEM and incubated 
with 5ml of fresh serum-free DMEM containing 2.5μg/ml of porcine Trypsin. After 3-4 days, 
successful rescues resulted in cytopathic destruction of the monolayer and this was used as 
an indicator to harvest the virus and seed a new flask of MDCKs to propagate this virus 
stock. In all rescue procedures, a PR8 virus was rescued alongside as a control measure to 
determine whether any rescue failures were caused by a faulty procedure, or rather 
incompatible virus gene segments. 
 
2.2.4. Analysis of protein expression 
2.2.4.1. Luciferase and β-galactosidase 
The supernatants of transfected or infected wells were removed by aspiration and the 
monolayers lysed with 1x Cell Culture Lysis Reagent (CCLR, Perkin Elmer). For 24-well 
plates, 150µl/lysis reagent per well was used. Cell lysates were left on the plate and frozen 
at -80°C to aid in the lysis process, before being thawed and spun at 14000xg in a 
centrifuge. Whilst avoiding the cell pellet, 20µl of supernatant fluid was removed and 
added to a Starstedt tube which was automatically mixed with 100µl  of luciferase assay 
reagent (LAR; Promega cat. No. E1500), and the luminescence measured with a 10-second 
read using a Luciferase Reader. Transfection efficiency was controlled with the co-
transfection of a β-galactosidase plasmid, and the signal was measured by adding 20µl of 
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sample to 100µl LacZ Buffer and 20µl ONPG at 37°C until a yellow colour developed. 
Absorbance was then read at 420nm in a spectrophotometer.  
 
2.2.4.2. GFP and Cherry Red 
Transfections involving these proteins were carried out in black 96-well plates with 
translucent bottoms (Greiner bio-one). This allowed for fluorescent readouts to occur 
without terminating the experiment. Cells were simultaneously read through the bottom or 
top optic using two different filter sets. Cherry Red was assayed using the excitation: 570, 
emission: 610 filter set, whilst GFP was assayed using excitation: 485, emission: 520. 
Background readings of untransfected cells were automatically subtracted from positive 
signals using BMG Mars Data Analysis software.  
 
2.2.4.3. FACS analysis 
Confluent 293T cells in 12-well plates were transfected with 0.25µg of pCAG-E195NA FLAG 
tagged plasmid and left to transfect using lipofectamine for 3 hours. Medium was then 
removed and replaced with 2% DMEM containing 100µM of drug or drug vehicle and 
incubated overnight at 37°C/5% CO2. The following day, the medium was removed and cells 
detatched from the plastic ware using PBS/EDTA. Triplicate wells were then centrifuged at 
2500xg for 5 minutes in Eppendorf tubes, before being resuspended in PBS, pooled and 
centrifuged again. Supernatant was discarded and cells were resuspended in 2% 
paraformaldehyde in PBS and fixed for 15 minutes at room temperature. Cells were 
centrifuged again and resuspended in PBS containing 0.05% Saponin, 1%BSA, 0.2% Na 
Azide and permeablised for 10 minutes at room temperature. Cells were then centrifuged 
and resuspended in the above buffer (either with or without Saponin, depending on 
whether permeablised or non-permeablised cells were being treated) containing primary 
antibody. Cells were left for 1 hour at room temperature, and washed once, before the 
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secondary antibody was added for 45 minutes at room temperature. Cells were washed 3 
times and then analysed by FACS.    
 
2.2.5. Drug maintenance and screening assays 
 
2.2.5.1. Compound library reconstitution 
Phytopure and Summit Plc compound libraries were supplied as lyophilised powders and 
were reconstituted using Dimethyl sulfoxide (DMSO) to a concentration of 10mM (100% 
DMSO for Phytopure compounds, 70% DMSO for Summit Plc compounds). Compounds 
were then kept at -20°C in 20µl aliquots to prevent repeated freeze-thawing. Compounds 
were diluted in SF-DMEM to a concentration of 40μM for each experiment. 
 
2.2.5.2. Compound library screen 
Fully confluent MDCK cells were infected with one of three viruses: A/Victoria/3/75, 
B/Beijing/1/87 or RG14 for 1 hour at 37°C or 33°C at TCID50 concentrations which had been 
shown previously to destroy the cell monolayer over three days in a TCID50 assay. Virus 
inoculum was removed and replenished with SF DMEM containing an individual Summit 
compound at 40µM and 1µg/ml of Trypsin. Each of the triplicate plates contained one 
untreated and one uninfected column as negative controls. Plates were incubated at either 
37°C or 33°C, depending on virus, for 3 days. The supernatant was then removed and the 
cells stained with crystal violet solution. 
 
2.2.5.3. Drug treatment of transfected cells 
293T cells were transfected with appropriate plasmids overnight and then infected with 
A/Victoria/3/75 for 1 hour at 37°C. Virus was then removed and medium replaced with 
fresh SF DMEM containing drug at the concentrations specified. For multicycle infections 
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on 293T cells, overlaying medium was supplemented with 0.1µg/ml of exogenous Trypsin. 
In all experiments, mock-treated conditions were included by incubating an equivalent 
concentration of diluted DMSO to control cells. 
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Chapter 3: Development of screening methods suitable for screening a compound library 
for novel inhibitors of influenza viruses. 
 
3.1. Introduction 
Novel antiviral drugs which effectively inhibit influenza viruses are a potentially lucrative 
investment opportunity. Influenza epidemics are a guaranteed annual global occurrence 
and with such a high seasonal morbidity rate, there will always be a market for therapeutic 
interventions. Moreover, most governments have a ‘pandemic plan’ that includes the 
stockpiling of anti-influenza drugs. Even before the recent 2009 pandemic outbreak, 350 
million treatment courses of oseltamivir had been supplied as stockpiles to worldwide 
governments, and the drug’s manufacturer, Roche, reported profits of £1.9 billion at the 
end of 2009 following increased demand during the ‘swine flu’ outbreak. Both oseltamivir 
and zanamivir were generated using a targeted approach which relied on the modification 
of existing compounds to inhibit a pre-determined viral component (von Itzstein & 
Thomson, 2009). An alternative method used to identify novel antiviral compounds is high 
throughput screening. Compound libraries of structurally related molecules may be 
commercially available or owned privately by industrial companies and are a potential 
source of new drugs. The financial incentive for a private company to screen compounds, 
to which it owns the patents, against influenza is obvious. High throughput screens may be 
an advantageous method for screening large libraries thanks to their ability to unearth 
inhibitory compounds with novel mechanisms of action against the virus.  
There are numerous examples in the scientific literature of high throughput screens being 
utilised to hunt for novel molecules which inhibit the replication of influenza and/or other 
viruses (Hoffmann et al., 2008; Patkar et al., 2009; Yao et al., 2010; Yu et al., 2009). 
Two privately owned compound libraries were provided to the laboratory by small 
companies who wished them screened for antiviral activity against a human influenza virus. 
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The first was a library of 1600 Phytopure compounds provided by MNL pharma, and the 
second was a library of 196 iminosugar molecules acquired from Summit plc. Both libraries 
were screened for ability to inhibit the replication of an H3N2 challenge virus 
(A/Victoria/3/75). The method used for the initial screen involved infecting MDCK cells with 
a concentration of virus that was guaranteed to destroy the entire monolayer over three 
days, and testing whether this still occurred in the presence of test compounds. Seven of 
the test compounds from the Phytopure library inhibited the cytopathic effect of the virus 
and maintained monolayer integrity. From the iminosugar library, three molecules which 
protected the monolayer from virus cytopathic effect were discovered. To begin with, the 
seven hits from the Phytopure compound library were taken forward in an attempt to 
discover mechanisms of action and select compounds for further development.  
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3.2 Results 
 
3.2.1. High throughput screen of iminosugar library against A/Victoria/3/75 (H3N2) 
influenza virus. 
Prior to the library screen, A/Victoria/3/75 virus was titrated in MDCK cells using a TCID50 
assay to determine viral titre. A challenge dose of 31.6TCID50 was chosen for the screen to 
assure a concentration of virus that would yield a microtitre plate well devoid of cell 
staining through cytopathic destruction under normal viral growth conditions, and would 
represent a viral challenge for the drugs that was not too stringent. The Phytopure library 
was screened with the drugs reconstituted in 100% DMSO at 40µM. This work was 
performed by a previous lab member, Chris Bull. The iminosugar library obtained from 
Summit Plc. was reconstituted in 70% DMSO on the company’s instruction and tested 
against Victoria virus at a final concentration of 40µM as part of this project. Virus was left 
to propagate for three days before the supernatant was removed and the viable cells that 
remained in each well stained with crystal violet solution. Each drug was assayed in 
triplicate and positive samples – ‘hits’ – were scored only if the monolayer had been 
protected by the cytopathic effect of the virus in all three replicates (Figure 3.1.). From a 
screen of 196 compounds, three hits which protected the monolayer in triplicate were 
identified. These hits were described by their Summit catalogue number as compounds: 
SMT014275, SMT014350, SMT014453. The Phytopure library had yielded 7 hits (Table 3.1.) 
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Figure 3. 1. High throughput screening hit from iminosugar library. 
(Figure legend overleaf) 
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Figure 3.1. 
MDCK cells at full confluency were infected with 31.6TCID50 of challenge strain 
A/Victoria/3/75 for one hour, before being incubated at 37°C for three days in the presence 
of drug. After three days the supernatant was removed and all wells were stained with 
crystal violet for one hour. The left hand column corresponds to column 12 of the 96-well 
plate and represents MDCK cells which were not infected with virus. Column 1 of the plate 
(right hand column) contained untreated wells in which the challenge virus replicated in 
the absence of any drug. Wells without drug treatment were also supplemented with an 
equivalent amount of DMSO as a control measure. These controls were repeated on each 
plate to ensure cell and virus viability. The drug at position D7 (SMT014453) successfully 
protected the monolayer from viral cytopathic effect in triplicate, and was scored as a hit. 
This image represents eighty compounds assayed in triplicate on three separate plates. 
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Following the initial screen of the Phytopure library, MNLpharma resupplied the seven 
identified compounds so that further characterisation experiments could be performed. 
The next step was to identify the most potent compound to take forward for further drug 
development. The Summit Plc. compounds were not resupplied until much later and form 
the basis of experiments in the next chapter. 
3.2.2. Cytotoxic effect of Phytopure compounds on MDCK cells. 
Initial screens of the Phytopure compound library suggested that the compounds chosen 
for further screening were non-cytotoxic because MDCK cell monolayers were not 
compromised when incubated in their presence. To elucidate the cytotoxicity profile of 
each compound more stringently, 40µM concentrations of each drug were assayed for 
cytotoxicity using a Toxilight Bioassay kit (Lonza). The Toxilight bioassay quantitatively 
measures the release of Adenylate Kinase (indicative of membrane damage in mammalian 
cells) in a bioluminescent format. Control monolayers were lysed, using Lonza lysis reagent, 
to provide a value that represented 100% lysis at each time point. Raw data was then 
expressed as a percentage of the 100% lysis control to determine the cytotoxicity of 
Phytopure compounds (Figure 3.2.). After 24 hours of drug exposure, six of the seven 
compounds did not appear cytotoxic. However at 72 hours, only four candidates shared 
cytotoxicity equal to or less than untreated cells. Compounds 48, 230 and 994 were 
dismissed from further study due to their apparent toxicity. This same pattern of results 
was also observed when using 80µM of drug (data not shown). 
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Table 3. 1. Positive hits identified from MNLpharma and Summit Plc. screens. 
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Figure 3. 2. Results of Toxilight Bioassay cytotoxicity assay. 
 
The Toxilight Bioassay kit was used to assess cytotoxicity of Phytopure compounds. 
Compounds were tested at 40μM concentrations over a 72 hour period on MDCK cells. 
Samples of supernatant were collected after 24, 48 and 72 hours and bioluminescence was 
quantified using a luminometer. Control wells were lysed completely at each time point 
using a lysis reagent and then read using a luminometer. This value was taken as 100% lysis 
and results are expressed as a percentage cytotoxicity of this value. Error bars correspond 
to standard deviation between triplicate experiments. 
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In order to assess the commercial potential of these compounds, and attempt to narrow 
down the potential mechanism of action, the remaining four Phytopure compounds were 
screened against the H3N2 influenza A virus (A/Victoria/3/75), an Influenza B virus 
(B/Beijing/87) and an avian influenza virus (A/Duck/England/1/62) of H4N6 subtype, to see 
if they were active against different viral types or subtypes (Figure 3.3.). Cells were 
incubated for 16 hours in the presence of virus and individual Phytopure compounds at 
40μM and then the supernatants were subjected to plaque assay on MDCKs. Compound 80 
was shown to be the least potent of the four experimental drugs and only inhibited the 
avian influenza strain under these conditions, it was subsequently expelled from further 
experiments. Compounds 397, 453 and 1243 were potent across all three virus subtypes, 
with 1243 being the most potent molecule of the three. These results suggested that the 
remaining three drugs had a generic mechanism of action that worked across multiple virus 
types. By exhibiting activity against avian and human influenza A and B viruses, these 
compounds demonstrated commercially desirable broad-spectrum activity. Furthermore, it 
ruled out the possibility of the drugs targeting individual proteins that are influenza A or B 
type specific (for example, M2). 
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Figure 3. 3. Effect of Phytopure compounds on the replication of influenza A and B 
viruses. 
 
Four Phytopure compounds were assayed for their ability to inhibit the replication of three 
distinct viruses: An influenza A virus (A/Victoria/3/75), an influenza B virus (B/Beijing/87) 
and an avian virus (A/Duck/England/62). These viruses were used to infect MDCK cells at an 
MOI of 1 in the presence of 40μM compound and the viral titre released at 16 hours post 
infection calculated by plaque assay and expressed as a percentage of the untreated 
control titre. Data shown represents the mean of duplicate wells.  
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3.2.3. Assessing the effect of Phytopure compounds on influenza and host-cell 
polymerase activity 
The influenza polymerase proteins represent an ideal target for novel antiviral drugs given 
the importance of these proteins in successful viral replication. The effect of Phytopure 
compounds on influenza polymerase activity was then assessed using reconstituted 
polymerases to drive in situ amplification and expression of a viral-like minigenome 
encoding a luciferase reporter. The viral polymerase proteins PA, PB1, PB2 and NP were 
transfected into 293T cells in a pPol.II plasmid backbone. Inside the cell, these plasmids are 
transcribed by host cell machinery before assembling into the influenza polymerase 
complex, the minimum required proteins necessary for viral transcription and replication. 
An initial experiment to assess the effect of Phytopure compounds on influenza polymerase 
activity revealed that viral expression of a luciferase reporter gene was reduced in the 
presence of all three compounds (Figure 3.4). Compound 397 was the least potent drug of 
the three. As a transfection control, β–galactosidase was transfected into cells to report on 
host-cell polymerase activity and gene expression. The results indicated that the Phytopure 
compounds also inhibited the β–galactosidase signal and subsequently host-cell 
polymerase activity. This result stresses the importance of including a reporter gene that 
can assay host cell function as well as viral replication. The fact that these compounds 
inhibited host-polymerases was deemed an undesirable trait from a commercial 
perspective and subsequently MNLpharma withdrew interest in the drugs. 
 
- 109 - 
 
 
Figure 3. 4. Effect of Phytopure compounds on influenza polymerase activity and host-cell 
gene expression. 
 
a) Plasmids encoding the three Influenza A virus polymerase genes and NP (with a human, 
Pol.II promoter) were transfected into 293T cells alongside a plasmid encoding luciferase 
(with a Pol.I promoter, to make viral-like RNA) and left for 30 minutes at 37°C. Phytopure 
compounds were then added at 40µM concentration to the monolayer and incubated for 
24 hours at 37°C. Cells were lysed using CCLR buffer and luciferase activity measured with a 
luminometer. b) β–galactosidase was also co-transfected into the same cells as above 
under the control of a cellular promoter (Pol.II). The extracts from the above experiment 
were also used to assay for β–galactosidase activity using a photospectrometer. The error 
bars correspond to the Standard Deviation between triplicate samples. A two-tailed 
unpaired t-test was used to calculate P values (** = p <0.01, *** = p < 0.005).  
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3.2.4.Using reporter plasmids as indicators of viral replication 
In an attempt to provide a more efficient screening assay, we attempted to engineer a 
reporter system which could be used simultaneously to assess the cytotoxicity and 
influenza inhibiting potential of novel compounds using fluorescent reporter constructs at 
the stage of the initial screening step. It has previously been published that influenza virus 
superinfection can be used to transcribe intracellular reporter plasmids that are flanked by 
the non-coding regions of influenza segments. Work conducted by Lutz and colleagues 
showed that GFP and Luciferase reporter genes flanked by the non-coding regions of 
segment 5 (NP), could be driven by both intracellularly reconstituted vRNP complexes, and 
by subsequent superinfection with a range of influenza A viruses (Lutz et al., 2005). Our 
laboratory possesses three similar reporter constructs (CAT, Luciferase and GFP flanked by 
NS, NS and M segment non-coding regions, respectively), but in conflict with the Lutz 
published results, we found that reporter gene expression from these constructs could only 
be driven by reconstituted viral polymerases and not by whole virus infection. This is 
demonstrated with the luciferase reporter construct in Figure 3.5. 
In order to determine the suitability of our ‘wild type’ pPol.I reporter plasmids as screening 
tools, we assessed the ability of A/Victoria/3/75 infection to drive expression of the 
reporter gene in cell culture. The data in Figure 3.5. shows that the wild type reporter does 
not express a measurable amount of luciferase in cells infected with influenza virus as the 
source of viral polymerase, and the signal at 24 hours was lower than that at 9 hours. 
Furthermore, the signal-to-noise ratio obtained at each time point with each MOI was 
extremely low (Table 3.2.) and the luciferase signal did not depend on virus input. 
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Figure 3. 5. Expression of pPol.I wild type luciferase by A/Victoria/3/75 virus infection in 
293T cells. 
 
A/Victoria/3/75 influenza virus was used to drive expression of a luciferase reporter 
construct at three different MOIs. Each condition was tested in triplicate and the mean of 
three uninfected wells containing a transfected luciferase plasmid was subtracted as the 
background reading from the raw data obtained. Each well was then normalised to its 
individual β-galactosidase value, and the mean of this normalised data is represented. The 
error bars represent the Standard Error of the Mean (SEM). This graph is representative of 
data that has been obtained on three separate occasions using luciferase as the reporter 
gene. The 24 hour time point has also been repeated using wild type GFP and CAT reporter 
genes and shows similarly low and MOI-independent signals when driven by 
A/Victoria/3/75 virus infection (data not shown). 
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3.2.5. Generating the 3-5-8 triple mutation GFP and Luciferase reporter plasmids. 
The data obtained from the previous experiment suggested that our reporter plasmids 
were poorly and unpredictably expressed by influenza virus superinfection and would not 
be effective as components of a screening cell line. In an attempt to improve the signal 
generated during virus driven mini-genome replication, we engineered a triple mutation 
into the 3’ non-coding region of the viral promoters that flank the reporter gene (Figure 
3.6.). Work by Neumann and Hobom identified that this triple mutation resulted in 
increased expression when driven by a mouse-adapted influenza strain in a murine cell line 
(Neumann & Hobom, 1995). Using a two-step mutagenesis PCR, the triple mutation was 
engineered into reporter plasmids encoding both the luciferase reporter and the GFP 
reporter. The first mutagenesis successfully introduced the double nucleotide changes at 
positions 3 and 5, and this product then underwent a further mutagenic PCR to introduce 
the final mutation at position 8. Several attempts were made to introduce all three 
nucleotide changes in a single mutagenic PCR, however this proved unsuccessful. The 
luciferase reporter gene is flanked by the non-coding regions of influenza segment 8, 
whereas our GFP reporter gene is flanked by non-coding regions of segment 7. Due to the 
segment specific nucleotides which follow the conserved regions at the 5’ and 3’ ends of 
each influenza segment, a separate set of mutagenic primers was required for each 
reporter plasmid. 
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Figure 3. 6. Three point mutations introduced to 3’ end of luciferase reporter mini-
genome construct. 
 
Three point mutations were introduced to the 3’ end of a luciferase reporter mini-genome 
construct using site-directed mutagenesis. Nucleotide 112 in the sequence chromatogram 
corresponds to the beginning of the 3’ non-coding region. Position 3 (nucleotide 114) is 
mutated from C → T, position 5 from A → G and position 8 from G → A. The primers used 
for reporter gene mutagenesis are listed in the methods section. 
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3.2.6. Effect of the 3-5-8 triple mutation on luciferase gene expression 
The ability of either virus infection or reconstituted viral polymerase proteins to drive the 
expression of the reporter gene within the mini-genome flanked by wild type noncoding 
regions or by non-coding regions containing the 3-5-8 triple mutation was assayed. The 
four plasmids to reconstitute influenza polymerase components were transfected into 293T 
cells simultaneously with either the wild type or mutated luciferase reporter gene, along 
with a β-galactosidase plasmid as a transfection control. The expression of luciferase was 
observed at 3, 6, 9, or 24 hours post-transfection. The results shown in Figure 3.7 confirm 
that both viral infection and reconstituted polymerases are capable of driving 3-5-8 
reporter gene synthesis. Although reconstituted influenza polymerases drove higher 
expression of the reporter gene flanked by the 3’ triple mutant NCR, these differences were 
not significantly different. However, when reporter gene expression was driven by virus 
infection, significantly higher signals were generated from the triple mutant reporter when 
compared with the wild type reporter at each time point (Figure 3.7., lower panel). With 
the triple mutant construct, the luciferase signal was cumulative over time and had a 
superior signal-to-noise ratio compared to the wild type reporter plasmid (Table 3.2.). 
These data suggest that the 3-5-8 triple mutant construct was detected and transcribed by 
viral polymerases during infection and would be a suitable quantitative read-out to assess 
virus replication inhibition mediated by antiviral compounds. 
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Figure 3. 7. Comparison of luciferase reporter gene expression from wild type and triple 
mutant 3-5-8 viral-like minigenomes by reconstituted viral polymerases or whole virus. 
 
a) The viral polymerase complex was reconstituted in situ following transfection of 
plasmids containing the three influenza polymerase genes and NP into 293T cells. At 3, 6, 9 
and 24 hours post-transfection, cells were lysed and luminescence detected using a 
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luminometer. A two-tailed unpaired t-test was used to assess statistical significance 
between the luciferase signal driven by wild-type and 3,5,8 luciferase reporters, however 
the difference in expression levels was not statistically significant. b) Viral infection was 
used to drive replication of the wild type or triple mutant construct, which was transfected 
into 293T cells 24 hours prior to infection. The error bars correspond to the Standard Error 
of the Mean across triplicate samples. A two-tailed unpaired t-test was used to calculate P 
values (* = p <0.05, ** = p <0.01).  
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MOI Luciferase 3-5-8 Luciferase 
0.1 1 : 1.7 1 : 185 
1.0 1 : 2.4 1 : 236 
3.0 1 : 2.4 1 : 188 
 
Table 3. 2. Noise-to-Signal ratio of wild type and triple mutant luciferase reporter gene 
driven by A/Victoria/3/75 virus infection.  
 
The ratios of signal-to-noise were calculated in triplicate at each time point by dividing the 
mean ‘background’ normalised reading of three uninfected wells, which contained a 
luciferase reporter, with the values generated by wells which contained the reporter and 
were infected. The 3-5-8 triple mutant reporter results in greater signal-to-noise readouts 
than the wild type reporter plasmid. The data presented in this table are the average of 
three calculations per MOI. 
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A follow up experiment was conducted to assess the effect of different virus MOIs on the 
expression of the 3-5-8 luciferase (3-5-8luc) reporter construct (Figure 3.8.). For its 
intended use, the reporter construct should be able to detect differences in the amount of 
replication, here driven by changing the input multiplicity of virus. 293T cells were 
transfected with the 3-5-8luc reporter and β-galactosidase plasmids overnight and then 
infected the following day with A/Victoria/3/75 at various MOIs. The luciferase signal was 
measured after twenty-four hours and normalised to the β-galactosidase reading. Figure 
3.8. shows a viral dose-dependent luciferase  signal obtained between MOIs of 0.1 down to 
0.0001. To guard against the possibility that screened library compounds are cytotoxic to 
the host cell – an observation which may result in a reduced luciferase signal due to 
cytopathic destruction of viable cells that the influenza virus would otherwise infect – we 
require the permanent presence of a reporter of host-cell polymerase viability. If the viral 
reporter signal is reduced, yet the host reporter signal remains normal, it is likely that a 
genuine hit will have been scored in the assay. Without the host cell reporter, it is possible 
that a cytotoxic compound could relay a reduction in luciferase signal and resemble a false 
positive hit in the screen.  
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Figure 3. 8. 3-5-8luc signal generated by different multiplicities of virus. 
 
293T cells were transfected with the 3-5-8luc and β-galactosidase plasmids overnight and 
subsequently infected with A/Victoria/3/75 virus for one hour at four different MOIs. 
Luciferase expression was measured 24-hours post-infection and normalised to β-
galactosidase readings. An uninfected control containing 3-5-8luc plasmid was also assayed 
and subtracted from the ‘background’ reading from each condition. Data shown represents 
the mean of triplicate wells and error bars correspond to the standard deviation between 
samples.  
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3.2.7. Assessing the effect of antiviral drugs on reporter signalling.  
In order to assess the suitability of the 3-5-8luc reporter plasmid as a drug screening tool, 
the ability of the system to detect the antiviral activity of established antiviral compounds 
was tested. Oseltamivir, Ribavirin and a hit identified in initial drug screen 3.2.1., 
SMT014350, were added to cell medium following overnight transfection of the 3-5-8luc 
plasmid into 293T cells and subsequent infection with A/Victoria/3/75 virus. The drug was 
present in the medium for 24 hours post-infection, after which time the cells were lysed 
and the luciferase signal read. The drug concentrations used were chosen either based on 
published EC50 data of the compounds, or from concentrations that were known to inhibit 
viral replication from previous experiments. The novel compound SMT014350 was included 
as a way of validating the reporter plasmid as an antiviral drug identifying tool (Figure 
3.9a.). The drug resulted in a small reduction of luciferase signal although this difference 
was not significantly different. Ribavirin, a known inhibitor of influenza polymerase, was 
effective at inhibiting influenza-driven expression of the luciferase signal in a dose-
dependent fashion. Oseltamivir did not significantly inhibit the luciferase signal, as would 
be expected since the drug is effective at a later stage of the infectious cycle and does not 
affect polymerase activity. This experiment demonstrates that drugs which are active at 
later stages of the replication cycle would not be identified by this primary screen system.  
 
In an attempt to extend the assay to find drugs that act later at stages of assembly or 
budding, we removed the supernatant from the first round of infection and used it to infect 
and drive a second round of luciferase expression (Figure 3.9b.). Now we saw a significant 
effect of oseltamivir, which completely ablated the luciferase signal in the second cell 
monolayer, as did the high doses of ribavirin.  The effect of SMT014350 was also evident 
since the drug significantly decreased luciferase signal in the second cell monolayer (p < 
0.01.) 
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Figure 3. 9. The effect of known drugs and a previously discovered screening hit on host-
cell and viral polymerase activity. 
(Figure legend overleaf) 
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Figure 3. 10.  
a) 293T cells containing the 3-5-8luc and β-galactosidase reporter plasmids were infected 
with A/Victoria/3/75 virus at an MOI of 1 and incubated overnight in the presence of 
several drugs. The luciferase signal was not significantly inhibited by either oseltamivir, or a 
low concentration of ribavirin (4.1µM). Higher concentrations of ribavirin (20.5 µM and 
above) did significantly reduce the luciferase signal generated by influenza polymerases 
supplied from infecting virus (p = <0.0001). Experimental compound SMT014350 was also 
shown to significantly reduce the expression of the 3-5-8luc reporter signal although to a 
lower level of significance. None of the drugs inhibited the expression of the host-cell 
transcribed reporter plasmid. b) The supernatant from the above experiment was then 
treated with Trypsin for two hours at 37°C in order to activate the HA proteins on progeny 
virions, and then used to infect new cells containing the 3-5-8Luc plasmid overnight. The 
oseltamivir and ribavirin treated supernatants were all significantly inhibited in their ability 
to drive expression of the reporter plasmid. The effect of compound SMT014350 was also 
statistically significant. The data shown is the result of triplicate samples expressed as a 
percentage of an untreated control and is a representative data set of two individual 
experiments. The expression of the host-driven β-galactosidase signal was not affected by 
any of the drug treatment conditions, as above (data not shown). The error bars 
correspond to the standard deviation between triplicate samples. A two-tailed, unpaired 
students t-test was used to assess statistical significance between drug treated and 
untreated samples, with **= p < 0.01 and *** = p < 0.0001. 
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3.2.8 Using fluorescent reporter mini-genomes to detect efficacy of drugs against 
influenza and simultaneously monitor host driven gene expression. 
Finally, in order to assess the potential of our constructs as high-throughput screening 
tools, we transfected 293T cells with plasmids containing the fluorescent variants of pPol.I 
(3-5-8-mGFP) and pPol.II (mCherryRed) reporter genes and challenged the cells with a low 
multiplicity of A/Victoria/3/75 virus (0.1) in the presence of several compounds. We then 
measured the fluorescence generated over time to observe the effects of these drugs on 
viral replication and host-cell survival. Figure 3.10 shows how each of the compounds 
affected the expression of virally transcribed GFP and host-driven Cherry Red. Compounds. 
Oseltamivir a), SMT014350 b), Ribavirin c) and Amantadine d) all inhibited the production 
of GFP when compared with untreated virus infection, whilst maintaining robust Cherry 
Red signal. Over time, drug treated cells generated a higher cherry-red output than the 
cells undergoing an untreated viral infection, possibly due to the protection from the 
effects of viral replication such as host cell shut off offered by these drugs. Compounds 
1243 e) and cyclohexamide f) however resulted in a knockdown of both GFP and Cherry 
Red, suggesting they were cytotoxic to global protein expression. Cyclohexamide is a 
known inhibitor of eukaryotic protein-synthesis, and was included here as a control to 
illustrate the detection of effects on host gene expression. Experimental compound 1243 
(identified in 3.2.1.) was included to confirm its activity as a drug which inhibited both viral 
and host-cell protein synthesis. The exact mechanism of this compound remains unknown, 
though its profile in this assay resembles the toxic profile of cyclohexamide which suggests 
it is unlikely to be pursued as a serious candidate for an anti-influenza drug. The data 
generated by this experiment results in a very clear visual format to illustrate compounds 
that are non-toxic inhibitors of influenza viral replication. 
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Figure 3. 11. Effect of antiviral drug treatment on the expression of host cell- and virally- 
driven fluorescent reporter plasmids. 
(Figure legend overleaf) 
 
 
 
- 125 - 
 
Figure 3.10.  
293T cells were seeded into black 96-well plates with translucent bottoms and allowed to 
proliferate overnight. mCherry Red and GFP-containing reporter plasmids were then co-
transfected into the cells for a further 24 hours. A/Victoria/3/75 virus was then infected 
onto cells at an MOI of 0.1 and removed after one hour. The medium was then replaced 
with SFDMEM containing: a) oseltamivir, b) SMT014350, c) Ribavirin, d) Amantadine, e) 
1243, f) cyclohexamide at the concentrations shown in the side bars to each figure or no 
drug, and supplemented with 0.1µg/ml of Trypsin. The plate was read at 24, 48 and 72 
hours post-infection using a FluoStar plate reader (BMG Labtech), for GFP and Cherry Red 
signal. GFP and Cherry Red signals from untransfected wells were then subtracted from all 
other well readings as a background measurement. A transfected but uninfected well was 
then further subtracted from GFP signals, whereas an untransfected well measurement 
was used to normalise mCherry Red signal, across the rest of the plate. Data shown is 
expressed as a percentage of the signal generated by the untreated A/Victoria viral 
infection and displays the average of quadruplicate wells. The error bars correspond to the 
SEM between samples.  
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3.2.9 Generating a reporter cell line containing fluorescent reporter genes. 
The previous section highlights the potential of these reporter genes to be used in a high-
throughput screening assay. We next attempted to implement this technology into a cell-
line that could be infected instantly when required, thus removing the necessary 
transfection step of the reporter plasmids each time. We also decided a change in cell-line 
from 293T cells to A549 cells would be desirable, as 293T cells are less adherent and less-
tolerant of exogenous Trypsin which is a required addition for multicycle virus infections. 
A549 cells were transfected with the mCherry Red and 3-5-8mGFP plasmids and grown in 
the presence of two antibiotics: geneticin and zeocin, at concentrations which were 
individually shown to result in cell death of approximately 90% of cells over fourteen days, 
prior to the transfection. The mCherry Red and 3-5-8mGFP backbone vectors encode for 
geneticin and zeocin resistance, respectively and thus cells containing both plasmids were 
expected to survive the co-treatment. Despite several attempts to generate a cell-line that 
constitutively contained both plasmids, we could not select for a stable colony that 
survived serial passage following initial selection. The reasons for this failure are unclear, 
though selection failure seemed to map to the inclusion of the 3-5-8mGFP plasmid, as cells 
containing mCherry Red alone could be passaged. The entire 3-5-8GFP plasmid was 
sequenced and the geneticin resistance gene found to be intact. 
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3.3. Discussion 
Using a rudimentary screening assay, several compounds were identified that prevented 
cytopathic destruction of an MDCK monolayer by A/Victoria/3/75 influenza virus during an 
in vitro experiment to assess the potential antiviral activity of 2 compound libraries. Three 
of these hits subsequently form the focus of the following chapter in which attempts are 
made to elucidate their mechanism of action. Seven other hits were investigated here and 
it was found that the most potent compounds showed adverse effects on host gene 
expression, that had not been identified using an initial simple screen that relied on them 
preserving the integrity of an MDCK cell monolayer. In light of the limitations encountered 
during initial screening by cytopathic effect, we envisaged a reporter cell line which could 
be utilised as a screening tool for high-throughput library screening assays, which would 
utilise fluorescent reporter genes to simultaneously quantify influenza replication and cell 
viability status in the presence of our compounds. 
 
The work presented in this chapter has shown that reporter genes flanked by segment-
specific non-coding regions of influenza genes are inefficiently transcribed by influenza 
virus during super-infection. Although these reporter plasmids are routinely used to gauge 
the transcriptional activity of intracellularly reconstituted influenza RNA-dependant RNA 
polymerases produced from transfected plasmids, they are transcribed poorly when those 
polymerases are delivered via whole virus infection. However, the modification of three 
nucleotides in the 3’ end of the non-coding region resulted in a significant increase in 
reporter signal generated by viral superinfection. Interestingly, the reconstituted 
polymerase complex of A/Victoria/3/75 did not express the 3-5-8luc mini-genome more 
efficiently than that of the wild type reporter (Figure 3.7. a). It has been reported that a 
similar minigenome expressing CAT as the reporter gene was poorly transcribed by 
reconstituted A/Victoria/3/75 polymerases in COS-1 cells, and indeed in that study the 3-5-
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8 triple mutation exhibited a ‘down promoter’ effect. This observation appeared to be 
specific for the origin of the viral polymerase as other human virus complexes tested also 
failed to upregulate transcription of the triple mutant, whereas avian virus polymerase 
complexes did enhance transcription of the 3-5-8 reporter (Crescenzo-Chaigne et al., 2002). 
It is thus intriguing that whole A/Victoria/3/75 virus is capable of driving a significantly 
enhanced reporter signal from the viral-RNA like segment containing the 3’ end triple-
mutation. The 3’ and 5’ ends of vRNA segments show partial complementarity in their 
conserved regions, which is essential for functional promoter activity. Evidence exists which 
suggests that the 3’ and 5’ ends do not simply fold back flat onto one another, but instead a 
secondary ‘corkscrew’ motif is formed whereby a stem-loop structure is formed in both 
ends of the promoter (Flick & Hobom, 1999). These hairpin loop structures at the 3’ and 5’ 
ends are a requirement for efficient endonuclease activity of the influenza polymerase, 
which is essential for cap-snatching and subsequent transcription of the vRNA into mRNA 
(Leahy et al., 2001a; Leahy et al., 2001b). The three nucleotide changes in the 3’ region of 
the triple-mutant reporter plasmid would hypothetically maintain a stem-loop in the 
corkscrew model at the 3’ end as complementary base-pairing is conserved between 
positions 3 – 8.  However, the triple mutations would further enhance the complementarity 
between the 3’ and 5’ ends of the vRNA segment were these ends to pair into a flat pan-
handle configuration. This complementarity essentially results in both the 3’ and 5’ ends 
having identical promoter regions. Initiation of transcription thus could occur at the same 
intensity from the 3’ end of a vRNA chain as it would from the 5’ end of a cRNA chain 
(Figure 3.11.).  
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Figure 3. 12. Predicted panhandle and corkscrew promoter regions of wild type (left) and 
triple-mutant (right) luciferase reporter genes. 
 
 
The diagram above represents the suggested ‘corkscrew’ or ‘panhandle’ structures of a 
negative-sense influenza NS segment, whereby the linear strand has been doubled back on 
itself and exhibits partial base-pairing, as suggested by Flick and colleagues (Flick et al., 
1996), for the corkscrew, or complete base-pairing for the panhandle. 
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The reason as to why reconstituted polymerase is unable, where whole virus infection is 
able, to drive transcription of the reporter plasmid is unknown, but one may speculate that 
the cellular environment during whole virus infection is markedly different than during 
plasmid transfection and polymerase gene expression. Whole influenza infection would 
likely drive expression of different host factors that may affect the function of viral 
polymerase (Geiss et al., 2002). An alternate possibility is that the binding of polymerase to 
RNA is affected and that another viral factor such as NS1, not present in the plasmid 
transfections, modulates the polymerase promoter complex. These possibilities were not 
tested here. 
The ‘up promoter’ reporter minigenome was able to detect different concentrations of 
influenza virus and generated lower signals when fewer virions were present to drive 
transcription of the reporter, providing virus MOI was ≤1. This indicates that the constructs 
could potentially be used to detect decreases in viral titres over multi-cycle infections, 
should an experimental drug result in viral inhibition.  
To eliminate the need for original transfections of reporter plasmids and transfer this 
technology to a more stable cell-type, we attempted to generate a reporter A549 cell line 
which would constitutively express an mCherry Red fluorescence signal to report on host-
cell transcription status, as well as a 3-5-8mGFP fluorescence signal which would be 
activated upon successful viral replication. Both reporter plasmids were transfected into 
A549 cells and contained individual antibiotic resistance genes to ensure their inclusion 
into cells cultured in the presence of geneticin and zeocin. Despite numerous attempts to 
culture a cell line which included both plasmids, a sustainable cell line could not be 
generated. It is unlikely that the antibiotic selection is to blame for the observed cell death 
as the concentrations of each drug used was determined individually using concentration 
killing curves. We questioned whether a faulty geneticin resistance gene was responsible 
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for failing to protect cells under the selection of this antibiotic, but found no defect in the 
resistance gene after sequencing of the plasmid. A similar cell-line containing viral like mini-
genome reporter RNAs under the expression of pPol.I promoters have been reported  in 
the literature, as described in the paper by Lutz et al though no experimental data 
generated using the cell line is presented in the manuscript (Lutz et al., 2005). A recent 
publication also utilised a reporter cell line harbouring a virus inducible reporter mini 
genome  to screen an RNAi library, using the similar technique of driving a second round of 
reporter gene replication with the supernatant of previously treated cells as we have 
described in 3.2.7. (Karlas et al., 2010).  It is not clear from this paper whether the cell lines 
constitutively expresses the viral like RNA. Furthermore, a high throughput screen using the 
358 up-promoter technology was described by Hoffmann and colleagues (Hoffmann et al., 
2008). Once again a careful read of the methodology reveals that transfections for the 
reporter minigenomes were performed de novo for each screen suggesting difficulties in 
obtaining a constitutive cell line.  The screening methodology of Hoffmann et al. resulted in 
the successful identification of several novel classes of anti-influenza compounds, though 
required two simultaneous screens: one to detect the effect of various compounds on virus 
replication using a 358 luciferase reporter plasmid, and a second to assess the cytotoxicity 
of the library. The screening tools presented here could reduce the workload given the 
ability to detect antiviral activity and cytotoxicity simultaneously. 
Although we were unsuccessful in our attempt to generate a stable reporter cell line 
capable of real-time drug screening, the generation of a triple-mutant reporter gene has 
resulted in a useful experimental tool which has been used in other applications in our 
laboratory, such as assaying and comparing the polymerase activity of different virus 
strains during the recent A/H1N1 2009 outbreak. These fluorescent mini-genome reporter 
plasmids could also be used to transiently transfect alternate cell lines, such as A549s, 
should a more robust screen involving multiple manipulations of the monolayer be 
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required. Whilst 293T cells are particularly sensitive to the addition of exogenous Trypsin, 
they were shown here to tolerate a concentration that was sufficiently high to propagate 
A/Victoria/3/75 infection. It is likely that other, Trypsin-independent viruses, such as the 
lab-adapted WSN strain, could be used to drive these plasmids with some success. 
Furthermore, we have shown how the system can be used in two stages in a manner that 
may help to elucidate mechanisms of action for novel compounds during a library screen. If 
cells containing reporter plasmids are incubated in the absence of Trypsin, then in the 
primary round of infection, compounds which interfere with viral entry, uncoating or 
polymerase activity could be detected. Supernatants from this initial screen could then be 
Trypsin-treated and transferred to a second set of freshly transfected cells, where drugs 
which affect virus assembly and release could be detected (Figure 3.9.). 
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Chapter 4: Assessing the spectrum of activity of a drug screen hit. 
 
4.1 Introduction 
 
Work described in Chapter 4 identified three hits from the iminosugar library provided by 
Summit  that inhibited replication of influenza A/Victoria virus.  Following the relay of initial 
results to Summit Plc, they informed us that two of the compounds were already known in 
the literature. Compound SMT14350 was Castanospermine, whereas SMT014453 was 
Celgosivir, a ‘prodrug of Castanospermine’. Due to concerns over whether these 
compounds would be reliably resupplied by Summit Plc, we chose to concentrate further 
experiments on Castanospermine, as the compound was readily available from a 
commercial source (Sigma). Castanospermine is a known inhibitor of glucosidase enzymes 
(Saul et al., 1983). Glucosidase type I and II enzymes play a role in the post-translational 
transport of glycoproteins and are responsible for trimming N-linked oligosaccharide side 
chains on the surface of glycoproteins in the ER. It is known that proper trimming of these 
N-linked oligosaccharides is important for successful glycoprotein maturation. For example, 
the intracellular chaperones calnexin and calreticulin interact with incompletely folded 
proteins and progresses the maturation process by allowing proteins to acquire proper 3D 
structure. These chaperones also protect nascent proteins from degradation (Hebert et al., 
1996). The manner in which newly synthesised glycoproteins are recognised by such 
chaperones is via their oligosaccharide side chains (Hebert et al., 1995), and thus by 
antagonising the production of this side-chain signal, these drugs may deny glycoproteins 
protection along the maturation pathway.  
A literature search for ‘Influenza *AND+ Castanospermine’ on PubMed returned 13 
publications, ranging in publication date from 1983-2000. In 1983, Pan and colleagues 
reported that haemagglutinin glycoproteins of an H1N1 virus, NWS, were susceptible to 
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treatment of MDCK cells with Castanospermine, as witnessed by the unprocessed glucose 
residues abundant on the glycoprotein in the presence of drug, but also that this 
observation did not correspond to a decrease in viral plaque titre (Pan et al., 1983). Most 
recently, Saito & Yamaguchi showed that the surface glycoproteins of influenza differed in 
their dependency on proper oligosaccharide trimming, and suggested that NA transport to 
the cell surface was inhibited by 50% in the presence of Castanospermine, whereas HA 
transport was not affected (Saito & Yamaguchi, 2000). This paper also highlighted a 
reduction in viral titres in the presence of Castanospermine, but it remained unclear 
whether the effect was viral subtype specific, a point that is particularly important to 
address given their choice to study such an uncommon H1N8 recombinant virus. 
Research described in this chapter aimed to test the susceptibility of different influenza 
viruses to this drug to assess its utility as a broad spectrum anti-influenza compound.  
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4.2. Results 
4.2.1. Assessing the cytotoxicity of Castanospermine. 
The iminosugars had been screened at 40µM in the initial screening procedure and had not 
shown any destruction of the MDCK monolayer at this concentration. An industrially 
favoured cytotoxicity assay was performed with the commercially available compound 
Castanospermine, to determine a) that the commercially sourced compound was also non-
toxic to cells and b) the highest concentration of drug that could be used for 
characterisation studies (Figure 4.1.). In the previous chapter, we showed that 
Castanospermine (SMT014350) at high concentrations did not affect host-cell polymerase 
activity and was thus less toxic than the hits from the Phytopure library (Figure 3.10). Now, 
we used a Methylene Blue cytotoxicity assay to determine the TD50 of Castanospermine. 
Following the cytotoxicity assay, all further experiments were carried out using a 
Castanospermine concentration of either 40µM or 100µM, as indicated in individual figure 
legends. 
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Figure 4. 1. Effect of Castanospermine concentration on MDCK cells survival 
 
Octuplet wells on triplicate plates of MDCK cells were incubated at 37°C in the presence of 
serially-diluted Castanospermine for three days. At 24, 48 and 72 hours cells were removed 
and subjected to methylene blue treatment. Briefly, supernatant was removed and cells 
incubated for two hours in methylene blue solution. Cells were then washed with PBS and 
subjected to 1% SDS treatment for one hour before being read for absorbance using a 
spectrophotometer at 660nm. A control group which remained untreated throughout was 
also assayed at each time point and represented 100% cell viability. Drug treated wells 
were averaged and are plotted as a percentage of the untreated group. Error bars 
correspond to the standard deviation between octuplet samples.   
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4.2.2. Assessing the effectiveness of Summit hits against A/Victoria/3/75 and 
B/Beijing/1/87 in a multicycle growth curve. 
The initial screen suggested that three test compounds were effective at protecting MDCK 
cells from A/Victoria/3/75. We next assessed the efficacy and spectrum of activity of all 
three iminosugars against  A/Victoria/3/75 or B/Beijing/1/87 viruses by assaying for viral 
titre over time (Figure 4.2.). The concentration of drug used in this experiment remained at 
40µM, but the challenge dose of virus was increased to an MOI of 1. The results in Figure 
4.2. show that all three iminosugar compounds were inhibitory against this challenge dose 
of A/Victoria/3/75. However it should be noted that this effect only reached statistical 
significance at early time points following infection. Compound SMT014275 was the most 
potent compound of the three against A/Victoria virus, maintaining significant potency 
until 24 hours post-infection. None of the drugs significantly inhibited the replication of the 
influenza B virus, thus this virus was insensitive to these three drugs. At this higher 
challenge dose it was concluded that although these three compounds inhibited the 
destruction of a cell monolayer from A/Victoria virus, overall their potency was low. 
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Figure 4. 2. The effect of iminosugar library compounds on the replication of A/Victoria 
and B/Beijing viruses. 
 
MDCK cells were infected at an MOI of 1.0 with either A/Victoria or B/Beijing viruses and 
incubated for one hour at 37°C or 33°C, respectively. Virus was removed and the cells acid-
washed briefly with PBS at pH 3.3, before SFDMEM containing 40µM of an individual 
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iminosugar compound and exogenous Trypsin was added. Samples were collected from the 
same well at corresponding time points, at which time the quantity of supernatant 
removed was replaced with an equivalent amount containing drug and Trypsin. Virus 
content of these samples was then enumerated by plaque assay on MDCK cells. The 
untreated wells were incubated with the same volume of overall DMSO as was present in 
the drug treated wells to control for any side effect of DMSO treatment. Data shown are 
the average of triplicate samples and the error bars correspond to the standard deviation 
between samples. A two-tailed, unpaired student’s t-test was used to assess for statistical 
significance with * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
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4.2.3. Effect of Castanospermine on a range of influenza A viruses. 
Following the observation in Figure 4.2. that Castanospermine was effective against an 
influenza A isolate, but ineffective against an influenza B isolate, we tested the effect of the 
drug against a wider spectrum of influenza A viruses, including the new pandemic H1N1 
influenza strain, first of all at a lower MOI of 0.001. As a measure of drug efficacy, we 
assayed the supernatants of infected cells for reproductive virus with a conventional 
plaque assay, and also measured the neuraminidase activity of released virus with a 
MuNANA assay. The MuNANA assay is a sensitive measurement which assays the efficiency 
of influenza neuraminidase at cleaving a small sialic-acid-like substrate into a fluorescent 
product. We began by ensuring that virus NA enzyme activity itself was not directly 
inhibited by Castanospermine treatment. When each virus was incubated in the presence 
of Castanospermine for one hour, each virus type retained the ability to cleave the 
MuNANA substrate, indicating that there was no direct inhibitory effect of the drug on NA 
activity (Figure 4.3). This is in contrast to the observation that NA activity was substantially 
reduced in the presence of oseltamivir. Interestingly, the NA activity of B/Beijing was less 
affected by oseltamivir than the influenza A viruses.  
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Figure 4. 3. Effect of Castanospermine and Oseltamivir on NA activity as measured by 
MuNANA substrate catabolisation.  
 
Using black 96 well plates, to triplicate wells were added 50µl of virus and 50µl of 
Castanospermine or Oseltamivir at a concentration of 100 or 1µM respectively. The plate 
was incubated at 37 C for 1 hour before MuNANA substrate was added and the plate 
incubated at 37 C for a further hour. Fluorescence intensity was measured. Wells which 
possessed MuNANA substrate and buffer alone were read as background values and the 
average of these wells was subtracted from all other wells. The average of triplicate 
samples is shown here with error bars representing the standard deviation between 
samples.  
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We then inoculated MDCK cells with the same range of influenza A viruses at an MOI of 
0.001. A lower MOI was chosen in order to detect differences resulting from drug 
treatment following the initial revelation that Castanospermine only inhibited replication 
early during infection (when fewer virions were present) as seen in figure 4.2. Following an 
overnight infection in the presence of Castanospermine, virus supernatant was removed 
and subjected to plaque assay (a) to determine viral titre, and MuNANA assay (b) to 
determine viral neuraminidase activity as a second measure of released virus. The viruses 
chosen for this study are shown in Table 4.1. 
 
Virus Comments 
B/Beijing/1/87 A representative influenza B isolate. 
  
A/Victoria/3/75 A representative influenza A H3N2 human virus with 
filamentous morphology (Elleman & Barclay, 2004). 
  
A/England/195/09 A representative pandemic influenza A H1N1 isolate also shown 
to have filamentous morphology (Itoh et al., 2009). 
  
A/PR8 A laboratory adapted influenza A H1N1 virus with spherical 
morphology 
  
A/PR8 & Victoria NA A 7:1 recombinant virus generated by reverse genetics in this 
study, containing all internal segments of PR8  
and the N2 NA gene of Victoria. 
  
A/PR8 & Victoria 
HA+NA 
A 6:2 recombinant virus generated in this study by reverse 
genetics containing all internal segments of PR8 and the H3 HA 
and N2 NA of Victoria. 
  
RD3 A 6:2 recombinant virus described by (Whiteley et al., 2007) 
generated by reverse genetics containing all internal segments 
of PR8 and the H7 (modified) HA and N1 NA of 
A/Chicken/Italy/4789/99 
  
Table 4. 1 List of viruses screened against Castanospermine. 
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Our panel of viruses included B/Beijing and A/Victoria as resistant and sensitive viral 
isolates respectively. We included A/England/195/09 as the pandemic isolate strain to ask 
whether Castanospermine was effective against a currently circulating influenza virus. 
Because we suspected that surface glycoproteins would be important determinants of 
susceptibility, we included A/PR8 virus and a number of recombinant viruses that were 
rescued specifically for this project and contained the surface proteins of other isolates 
built upon a PR8 backbone. A/PR8 and A/Victoria viruses are associated with different 
budding strategies that results in different virion morphologies, with PR8 forming 
conventional spherical virions, whereas Victoria virus forms longer, filamentous particles 
which may be more or less affected by glycosylation interference. Finally, we used a 
reverse genetics virus containing the internal proteins of PR8 with the H7N1 surface 
glycoproteins of A/Chicken/Italy/4789/99 originally generated by (Whiteley et al., 2007). 
This virus displays surface antigens of an avian isolate with pandemic potential and, if 
affected, could potentially validate the use of this drug as a future pandemic stockpiling 
solution.   
The recombinant viruses PR8 + Vic NA and PR8 + Vic HA and NA  were generated as part of 
this project by reverse genetics. Individual plasmids containing all eight segments of the 
desired recombinant virus were transfected into 293T cells under the expression of a 
polymerase I promoter. Four plasmids containing the individual polymerase genes of 
influenza, plus NP were concurrently transfected under the expression of a polymerase II 
promoter. These four plasmids are transcribed by host-cell polymerases and form a vRNP 
complex, the minimum proteins required for influenza virus segment replication and 
translation. The further eight plasmids are then transcribed by the vRNP complex and bud 
as whole viruses. Each of the recombinant viruses rescued successfully, though the PR8 
virus containing the surface HA and NA of Victoria replicated to a 100-fold lower titre in 
MDCK cells, suggesting a natural attenuation in the fitness of this isolate. 
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Figure 4. 4. Schematic of influenza virus rescue. 
293T cells were transfected simultaneously with 12 plasmids. Four plasmids, under a host-
cell polymerase recognised Pol.II promoter are transcribed by the host cell and assemble 
into the viral polymerase machinery (NP, PB1, PB2 and PA). The reconstituted viral 
polymerase then recognises the remaining 8 plasmids, under a Pol.I promoter, and 
transcribes the viral proteins encoded within. These proteins then assemble into new 
virions and are released as progeny virions. As viral release from 293T cells is inefficient, 
293T cells are co-cultured with MDCK cells to boost viral titre of reconstituted viruses. 
MDCK cells are infected as usual by novel virus and replication occurs more efficiently in 
the more-permissive cell line. 
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We observed that all influenza A subtypes subjected to drug treatment starting with a low 
initial MOI of 0.001 underwent a reduction in viral titre when virus was grown in the 
presence of Castanospermine, whereas the influenza B isolate remained impervious to  
drug treatment, even at this low initial MOI. Generally, the reduction of viral titre 
corresponded with a reduction in fluorescence generated by the cleavage of MuNANA, 
though the MuNANA assay generated more statistically significant data.   
A/Victoria was particularly susceptible to Castanospermine treatment, as was pandemic 
A/England/195/09 virus (Figure 4.5 a)) and for both of these viruses both assays reached 
statistical significance. However for the other 4 viruses tested the results were less 
dramatic and did not uniformly reach statistical significance.  
For example, although the NA content of released virus after PR8 infection in presence of 
drug was reduced, this did not have a statistically significant effect on the viral titre.  This 
may suggest that the PR8 virus can tolerate a certain amount of reduction in NA expression 
on the cell surface or on virus particles with little compromise to infectivity. Indeed, when 
the NA gene from the highly susceptible Victoria strain was transferred to PR8, the effect of 
drug on virus infectivity became significant.  
However neither of the recombinant viruses in which paired HA and NA were present on 
the PR8 body, PR8 + Vic HA and NA nor RD3 virus, showed statistical significance in the 
effect of drug on either NA activity of released particles nor infectivity. It is possible that 
with further repeats of this assay, statistical significance of drug inhibition on all four PR8 
based viruses could be established but time did not permit this.  
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Figure 4. 5. The effect of Castanospermine on viral titre and neuraminidase activity of a 
panel of influenza viruses. 
(Figure legend overleaf) 
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MDCK cells were infected at an MOI of 0.001 and allowed to replicate for 24 hours in the 
presence of 100µM Castanospermine, or drug vehicle. Following 24 hours infection, 
supernatants were removed and subjected to plaque assay to determine viral titre (a), or 
MuNANA assay (b) to analyse for NA activity.  Data shown is the average of triplicate wells 
and error bars correspond to the standard deviation between these samples. A two-tailed 
unpaired student’s t-test was used to calculate statistical significance between untreated 
and treated control groups with * = p < 0.05, ** = p < 0.01, *** = p < 0.001 and NS = Not 
significant 
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At higher viral challenge of MOI = 1 the Influenza B isolate remained uninhibited by 
Castanospermine as expected (Figure 4.6a). Furthermore, the effects of drug against 
influenza A isolates was no longer significantly inhibited by the action of Castanospermine 
at this concentration. Only A/Victoria virus suffered a reduction in viral titres. Conversely, 
NA activity of all isolates was significantly reduced by Castanospermine treatment (Figure 
4.6b.). This suggests that although viral titres are generally unaffected, the amount of NA 
on the surface of those virions that are present is decreased. It is possible that this is due to 
improperly formed or fewer functional NA tetramers appearing on the surface of the 
virions which bud from the cell.  
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Figure 4. 6. The effect of Castanospermine on viral titre and neuraminidase activity of 
wild type viruses inoculated at a high MOI. 
 
MDCK cells were infected at an MOI of 1.0 and allowed to replicate for 24 hours in the 
presence of 100µM Castanospermine, or drug vehicle. Following 24 hours infection, 
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supernatants were removed and subjected to plaque assay to determine viral titre (a), or 
MuNANA assay (b) to analyse for NA activity as above.  Data shown is the average of 
triplicate wells and error bars correspond to the standard deviation between these 
samples. A two-tailed unpaired student’s t-test was used to calculate statistical significance 
between untreated and treated control groups with * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, NS = Not significant 
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4.2.4. Defining the basis of susceptibility to Castanospermine 
Building on the observation that A/England/195/2009 virus was uninhibited at higher MOIs 
of virus, but suffered from a reduction in its ability to process the MuNANA substrate, we 
hypothesised that inhibition of neuraminidase transport to the surface of the cell was likely 
a general effect of the drug on influenza, but that some virus were tolerant of such an 
inhibition. To test whether Castanospermine directly affected the total number of NA 
molecules that reached the surface of the cell, we used a FLAG-tagged neuraminidase 
construct and transfected it into 293T cells. Three hours post-transfection, the medium was 
removed and replaced with medium containing either 100µM of drug, or the equivalent 
DMSO containing control. Gene expression was then allowed to proceed overnight before 
cells were immunostained and analysed by FACS (Table 4.2.). Our results show that the 
quantity of FLAG-tagged NA particles which reach the cell surface (non-permeablised wells) 
was not affected by the presence of Castanospermine. Furthermore, when comparing 
permeablised and non-permeablised cells for fluorescence, we saw no difference between 
drug treated and untreated cell populations, suggesting that the concentration of FLAG-
containing NA proteins was not significantly altered in the presence or absence of drug 
either intra-cellularly or on the cell surface.  
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Table 4. 2. Percentage of drug treated cells positive for FLAG-tagged NA in permeablised 
and non-permeablised cell populations as compared to an untreated control. 
 
Triplicate wells of 293T cells were transfected with a plasmid containing the FLAG-tagged 
neuraminidase protein of A/England/195/2009 under the expression of a polymerase II 
promoter. Three hours post-transfection, medium was removed and replaced with drug- or 
vehicle-containing 2% DMEM, and cells were incubated overnight at 37°C. The following 
day, triplicate wells were detached from the plate, pooled and fixed using 2% 
paraformaldehyde. One group underwent permeablisation with saponin, and then both 
groups were stained with a primary mouse αFLAG antibody, and secondary Goat αMouse 
FITC antibody. Cells were then subjected to FACS analysis. Control wells containing 
untransfected cells, and transfected cells subjected to only secondary antibody treatment 
were used to subtract background readings from the final analysis.  
 
 
 
 
 
 
 
 
 
 
 Permeablised  Non-Permeablised  
A/England/195/2009  97.9 % 98.7 % 
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4.2.3. Sequence analysis of influenza surface glycoproteins 
With the knowledge that SMT014350 was the glycosidase inhibiting drug, 
Castanospermine, we then sought to identify a genetic basis for the susceptibility or 
resistance of  influenza A or B viruses respectively to inhibition by the drug. Based on 
previous publications, it was assumed that the surface glycoproteins were the drug targets. 
Early research into Castanospermine observed effects on the HA protein of NWS virus, with 
drug treatment preventing haemagglutinin from associating with host-cell proteins, 
resulting in premature folding and oligomerisation which led to overall less efficient 
maturation (Hebert et al., 1996). However, work by Saito & Yamaguchi suggested that the 
NA protein was more susceptible to Castanospermine inhibition, using a reassortant H1N8 
virus (Saito & Yamaguchi, 2000).  We  performed a bioinformatic analysis to see whether 
the glycoproteins of the susceptible influenza A virus strains differed in the number of 
potential glycosylation sites from those of the relatively resistant influenza B virus strain 
used here (Table 4.3.). N-linked-glycans are attached to glycoproteins at specific amino acid 
residues which contain the consecutive code Asn-X-Ser (NxS) or Asn-X-Thr (NxT), with X 
forming any amino-acid other than proline. These glycosylation sites are known as sequons, 
and serve to highlight locations on the protein which can potentially undergo N-linked-
glycan attachment. Generally speaking, the more sequons contained in a protein, the more 
highly glycosylated the protein. We noted from our genetic analysis that the Victoria HA 
and NA proteins contained more consensus glycosylation sites than the HA and NA of PR8 
or of influenza B Beijing, both of which appeared relatively resistant to the drug. 
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 NxS  NxT  TOTAL  
A/Victoria HA  2  7  9  
A/Victoria NA  3  6  9  
 
PR8 HA  4  3  7  
PR8 NA  2  3  5  
 
B/Beijing/1/87 HA  1  5  6  
B/Beijing/1/87 NA  2  2  4  
 
A/England/195/2009 HA  3  5  8  
A/England/195/2009 NA  3  3  6 
 
A/Chicken/Italy/13474/99 HA  0  6  6 
A/Chicken/Italy/13474/99 NA 3 1 4 
    
Table 4. 3. Number of potential glycosylation sites in the glycoproteins of our test viruses 
 
As a final validation of the reporter cell line, developed in the previous chapter, we sought 
to show whether the spectrum of influenza A viruses tested above by traditional means 
would be inhibited by Castanospermine in our mCherry Red/358-GFP expression model of 
virus replication. The previous chapter characterised A/Victoria alone as the sole driver of 
GFP expression, but once attempts were made to use other viral isolates under the same 
initial MOI infection conditions, it was observed very low GFP expression across the range, 
except for A/Victoria virus (data not shown.) To overcome this, cells were infected with an 
initial MOI of 2.5 instead of 0.1 used previously and left to replicate in the presence of low 
concentrations of Trypsin (0.3µg/ml). Given that the viral promoter associated with these 
reporter plasmids is influenza A-specific, Influenza B was excluded from this assay. 
When using this high MOI, it was questionable whether we would see any sufficient 
knockdown given the generally low potency of Castanospermine observed in figure 4.2 and 
also given that a drug that inhibited glycosylation of nascent surface glycoproteins should 
only show inhibitory activity on viral titres accumulated over multiple cycles of infection. 
However, as the data presented in Figure 4.6. shows, all influenza viruses, with the 
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exception of RD3, were inhibited in their ability to drive GFP expression. However, only for 
A/Victoria and A/PR8 containing Victoria HA or HA and NA, did these results reach 
statistical significance (Figure 4.7.). The overarching pattern of the results in this chapter 
suggests that A/Victoria is much more sensitive to the presence of Castanospermine than 
A/PR8, and indeed when a recombinant PR8 virus is supplemented with the viral surface 
proteins of Victoria, it becomes more susceptible to inhibition by the drug. It is possible 
that this is due A/Victoria surface glycoproteins being more highly glycosylated and thus 
more likely to be caught in an aberrant cell pathway if proper glycoprotein processing and 
transport is inhibited by the drug.  
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Figure 4. 7. Ability of a panel of Influenza A viruses to drive expression of GFP under 
control of a viral promoter.  
 
Black 96-well plates with translucent bottoms were seeded with 293T cells, and transfected 
with mCherry Red and 358-GFP plasmids overnight. Medium was then removed and viruses 
inoculated at an MOI of 2.5 for one hour. Medium was then replaced with SF DMEM (not 
containing phenol red) containing either 100µM of drug, or the drug vehicle, and 0.3µg/ml 
Trypsin. Cells were incubated at 37°C/5% CO2 for three days before red and green signal 
was read. Data presented  shows the average of quadruplicate wells, where the GFP signal 
has been normalised to Cherry Red signal. Data is expressed as the average percentage of 
untreated wells. Background wells were set up and values obtained from these wells were 
subtracted from the green and red values. A one-tailed, unpaired student’s t-test was 
undertaken to assess statistical significance with * = p < 0.05 and ** = p < 0.01. Where not 
stars are present, differences were not statistically significant. 
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4.3. Discussion 
This chapter began with the knowledge that three compounds from the Summit iminosugar 
library protected MDCK cells from cytopathic destruction by A/Victoria virus. Attempts 
were made to elucidate whether the protective effects of these three compounds 
extended to an influenza B virus, though it was found that none of the drugs inhibited 
multicycle replication of this virus. Once these findings were relayed to Summit Plc., it was 
revealed that two of the drugs had known biological and antiviral activity already. 
Compound SMT14350 was Castanospermine, whereas SMT014453, which shared the same 
molecular weight, was a derivative form of Castanospermine, Celgosivir. Of these two 
drugs, Castanospermine could be purchased commercially and thus formed the basis of 
future experiments which sought to further address the affectivity of the drug against a 
range of influenza A viruses. In choosing Castanospermine, the most potent drug of the 
initial three hits, SMT014453 (Figure 4.2.) was lost from further characterisation studies. 
However, Summit Plc were not forthcoming with the molecular classification of this drug, 
nor did they make available future stocks for further academic study. 
Castanospermine (Figure 4.8.) is naturally found in chestnut trees (Castanospermum 
australae) and can be easily purified and isolated in large quantities. The drug acts as an 
inhibitor of the α-glucosidase I enzyme in the ER and has been shown to interfere with 
replication of an array of viruses in vitro, including HIV-1 (Montefiori et al., 1988) and 
Dengue (Courageot et al., 2000), whereas Castanospermine derivatives such as Celgosivir 
have shown activity against the surrogate HCV model, BVDV (Whitby et al., 2004). 
Castanospermine has also shown in vivo activity against HSV (Bridges et al., 1995), Dengue 
(Whitby et al., 2005) and MLV (Ruprecht et al., 1989). Moreover, Castanospermine has 
been utilised in combination with other established therapies with some success. 
Furthermore, other iminosugars which inhibit α-glucosidase enzymes, such as 
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Deoxynojirimycin (DNJ) have shown potency against a similar wide range of viruses. When 
added in combination with interferon and ribavirin, DNJ showed potent activity against 
BVDV in MDBK cells and resulted in the permanent eradication of virus from the system, as 
opposed to ribavirin and interferon administered as a dual therapy (Woodhouse et al., 
2008). When used in combination with amantadine, DNJ also achieved a reduction in viral 
titres of the BVDV infection model (Steinmann et al., 2007). Taken together it would appear 
that inhibition of the enzymes affiliated with N-linked glycosylation could form the basis of 
broad-spectrum antiviral therapy. 
 
 
Figure 4. 8. Structure of Castanospermine (Image: creative commons) 
 
It was observed immediately that an Influenza B isolate appeared less susceptible to the 
effects of Castanospermine treatment than did an Influenza A isolate. The finding that 
similar viruses adopt selective sensitivity to the drug has been shown by Whitby and 
colleagues, who credit the drug for inhibiting four different dengue virus serotypes, 
whereas the other flavivirus species Yellow Fever Virus and West Nile virus were partially 
and completely immune to the effects of the drug respectively (Whitby et al., 2005). It was 
then observed that the more numerous glycosylation sites on the surface glycoproteins of 
A/Victoria virus may account for the apparent increased sensitivity of the virus to 
Castanospermine, and the relative paucity of sequons for B/Beijing, may explains its 
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resistance. However, it is not a given that all sequons are glycosylated during protein 
processing nor that the effect of inhibiting one sequons is equal to the effect of inhibiting 
another. For example, although the surface glycoproteins of RD3 virus shared equivalent 
numbers of potential glycosylation sites to B/Beijing, mean viral titres for this virus were 
reduced in cell culture. We performed the bioinformatic analysis of surface glycoproteins 
after we had chosen the viral strains to examine, to observe whether resistance and 
susceptibility mapped to the number of sequons associated with each glycoprotein. 
However, it remains to be seen whether drug susceptibility could actually be ‘predicted’ on 
the basis of the number of glycosylation sites contained within a protein. Future work with 
this experiment could incorporate viruses which contain more heavily and more sparsely 
glycosylated glycoproteins at the surface to see if there is a true map between sequons and 
susceptibility.  
It has been reported in the literature that some cell lines encode for an intracellular 
enzyme capable of cleaving sugar-side chains that would otherwise remain uncleaved by 
Castanospermine inhibition. That is to say, viral glycoproteins could undergo proper 
glucose residue trimming thanks to the auxiliary enzyme endomannosidase, which can 
perform an identical job to glucosidase I, but is not inhibited by Castanospermine 
(Karaivanova et al., 1998). Although MDCK cells are thought to express this enzyme, we 
saw clearly that some viral strains retained susceptibility to this drug. However, one may 
speculate that the folding and transport of Influenza A and B viruses occur in different 
manners, and indeed it may be possible that Influenza B glycoproteins spend a greater 
amount of time in the Golgi and thus has a greater chance to interact with this ‘rescuing’ 
endomannosidase.  
The drug was only significantly effective at low doses of challenge virus, but did inhibit the 
replication of the pandemic A/England/195/09 isolate. Although transport of the viral NA 
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protein to the cell surface was not directly affected by Castanospermine treatment, the 
function of this protein in egressed virions was. This may suggest that some viruses are less 
concerned with the concentration of functional NA in their virion than others, or that the 
drug affects the budding or morphology of the virus particle irrespective of the actual 
amount of NA at the cell surface, perhaps by affecting HA transport instead. This 
observation could be relevant when assessing virus susceptibility to oseltamivir. The 
traditional NA mutation which confers resistance to oseltamivir, H275Y, is known to result 
in a natural attenuation of some influenza viruses, presumably due to a loss of NA 
functionality (Ives et al., 2002). If viruses exist which can tolerate attenuations in overall NA 
activity that do not adversely affect overall virus titre, then one may speculate that these 
viruses may be primed to include mutations such as H275Y in their neuraminidase proteins 
without significant detriment to overall fitness. 
Future work should seek to elucidate whether other influenza B isolates are also resistant 
to the effects of Castanospermine. Furthermore, it has not been possible to map drug 
sensitivity to a particular glycoprotein. It would be prudent to repeat the FACS analysis to 
observe the difference in HA transport to the surface under the presence of 
Castanospermine, and indeed to perform the analysis on cells undergoing whole virus 
infection as opposed to transiently transfected proteins. Suitable reagents for this were not 
available at the time of study. It was decided to look at viruses with different budding 
morphologies to assess whether the shape of the final virion would be more or less 
susceptible to Castanospermine treatment, however our virus panel contained different 
numbers of glycosylation sites between the proteins. To attempt to map drug sensitivity to 
morphology, we should analyse matched virus pairs that have identical numbers of 
sequons in their surface glycoproteins, but which still bud with distinctly different 
morphologies. Such viruses have been described in (Elleman & Barclay, 2004). Although 
overall the observed potency of Castanospermine was seen to be low in this experiment, 
- 161 - 
 
the observed broad-spectrum activity of the drug against a range of other viruses, and the 
fact that the drug target it a host-cell process suggests it would be worthy to conduct 
follow up experiments. The structure of Castanospermine also allows for significant 
chemical modification which could generate derivatives that possess greater active site 
selectivity, which may result in more potent antiviral activity (Aguilar-Moncayo et al., 
2009). 
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Chapter 5. Assessing the effects of the neuraminidase inhibitor resistance mutation 
H275Y on the neuraminidase protein of pandemic influenza H1N1 2009  
 
5.1. Introduction 
March 2009 saw the emergence of a novel strain of influenza with the ability to transmit 
readily between humans. This isolate was rapidly identified as an A/H1N1 virus and was 
comprised of a combination of gene segments previously undescribed in both humans and 
swine and included a neuraminidase gene derived from a Eurasian lineage swine virus that 
itself had crossed from birds in Europe into pigs in the late 1970s (Garten et al., 2009). The 
novel influenza virus went on to cause the first influenza pandemic in over 40 years (Fraser 
et al., 2009). Two therapies are currently licensed to treat influenza infections: the 
adamantane drugs (amantadine and rimantadine) and the neuraminidase inhibitors 
(oseltamivir and zanamivir). Over recent years, anticipation of an impending pandemic has 
prompted many countries to stockpile antiviral drugs as part of preparedness plans 
intended to minimise the impact of a pandemic influenza outbreak (Meijer et al., 2007). 
The neuraminidase inhibitor drug, oseltamivir, has been the focus of stockpiling strategies 
due to its convenient oral formulation, superior bioavailability and suitability for use 
amongst paediatric and elderly populations. Pandemic influenza A/H1N1 2009 virus 
crossed into humans carrying a well characterised amantadine-resistance mutation, S31N, 
within the M2 ion channel protein, rendering the adamantane class of antiviral drug 
ineffective against the virus. Thankfully, initial isolates were susceptible to neuraminidase 
inhibitors, including the heavily stockpiled oseltamivir and consequently this drug was used 
extensively in the treatment and prophylaxis of pandemic influenza (Centre for Disease 
Control and Prevention (CDC), 2009). Oseltamivir resistance has emerged infrequently in 
pandemic A/H1N1 2009 influenza viruses (Baz et al., 2009; Chen et al., 2009). In contrast, 
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seasonal H1N1 influenza viruses from the 2007/2008 season onwards were predominantly 
resistant to oseltamivir with resistance conferred by the H275Y mutation in the viral 
neuraminidase (Meijer et al., 2009). 
Traditionally, the H275Y mutation was associated with a compromise in viral fitness 
amongst H1N1 isolates (Ives et al., 2002). However, isolates from the 2007/2008 season 
with this mutation suffered no attenuation (Baz et al., 2010). It is likely that certain other 
sequence variations, such as the D344N change found within the NA gene of oseltamivir-
resistant viruses from the 2007/8 season, counteract the decrease in enzyme function that 
H275Y confers (Collins et al., 2009; Rameix-Welti et al., 2008). Residue 344 is a tyrosine in 
most avian influenza NA genes but mutated to aspartic acid in the N1 and N2 NAs of the 
1918 and 1957 pandemic viruses during their circulation in humans.  A mutation to 
asparagine occurred in circulating human H1N1 viruses prior to the 2007 season and led to 
increased NA activity. The NA enzyme of the novel swine origin 2009 H1N1 pandemic virus 
is derived from the avian virus-like Eurasian lineage H1N1 swine virus, and harboured 
asparagine at residue 344 at the time it crossed into humans, suggesting it may tolerate 
mutations such as H275Y that would concomitantly decrease NA activity and confer 
oseltamivir resistance.  
Given the importance of the neuraminidase inhibiting drugs to pandemic preparation, their 
effectiveness is routinely monitored in vitro in many countries across the globe. Generally, 
influenza isolates are assayed for sensitivity to neuraminidase enzyme inhibition by NAIs 
using a ‘MuNANA’ assay, in which the ability of NA to cleave a monomeric, sialic-acid like 
substrate into fluorescent product is measured. The use of this fluorometric assay has led 
to the identification of several resistance mutations in the neuraminidase enzyme, as 
scored by an increase in the IC50 of the NAI. Many of these are recorded by the 
Neuraminidase Inhibitor Susceptibility Network (NISN, 2010). However, this assay gives no 
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inclination as to whether a virus has the potential to adopt a resistance mutation, nor does 
it analyse the effects of a resistance mutation on viral growth kinetics. In this chapter the 
effect in vitro of the H275Y mutation in the NA of a prototypic A/H1N1 2009 isolate was 
assessed. 
5.2. Results 
5.2.1. Generating the H275Y mutation in the neuraminidase protein of a pandemic isolate 
The representative pandemic isolate used in this study was A/England/195/2009, one of 
the first fully sequenced new variant (nv) A/H1N1 2009 influenza isolates in the UK. The 
eight segments of A/England/195/2009 were synthesised individually and cloned into a 
custom vector that flanked them with a pPol.I (virally-driven) promoter and a ribozyme, by 
GeneArt AG, in order to constitute a reverse genetics system for the virus. The plasmids for 
each segment were designed by Dr. Lorian Hartgroves (Imperial College London). The 
H275Y mutation required a single nucleotide change in the neuraminidase protein, which 
was then introduced using site-directed mutagenesis. Two viruses containing all seven 
‘backbone’ segments of a laboratory-adapted influenza strain A/Puerto Rico/8/34 (PR8), 
and one of either the wild type neuraminidase gene of A/England/195/09, or the NA gene 
which contained H275Y were rescued for the first set of experiments described here. The 
decision to rescue a pair of isogenic viruses using an established PR8 body was made in 
order to circumvent stringent containment protocols which were in place during the initial 
stages of the pandemic that required wild type virus to be handled in CL3 facilities. It also 
gave the opportunity to study a completely uncharacterised protein in the well 
characterised PR8 system that would likely guarantee successful rescue and replication in 
cell culture. Both viruses were successfully rescued using previously described methods 
(Figure 4.4, (Elleman & Barclay, 2004)) and after a single passage, replicated to identical 
titres (Figure 5.1a.). These viruses were then assayed using a multi-cycle growth curve to 
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look for differences in viral growth kinetics. Both the wild type neuraminidase- and mutant 
neuraminidase- containing viruses displayed identical growth kinetics over 72 hours (Figure 
5.1b.). From these early assays it was concluded that the presence of a H or Y at position 
275 had no effect on the overall fitness of virus with pandemic origin NA gene in vitro. 
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Figure 5. 1. Initial titre and growth kinetics of rescued recombinant viruses. 
 
Two isogenic viruses, differing only at position 275 in the neuraminidase, were rescued 
using conventional techniques and assayed for differences in viral replication. a) Both 
viruses rescued successfully and when passaged, replicated to equivalent titres. b) The 
viruses were then assayed on MDCKs using a multi-cycle growth curve at a starting MOI of 
0.1, and displayed identical growth characteristics to one another. Data shown is the mean 
of triplicate samples, with error bars corresponding to the standard deviation of the mean. 
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5.2.2. Assessing the effect of H275Y on NAI tolerance and the sialidase activity of 
A/England/195/09 neuraminidase. 
The sialidase enzyme properties of both wild type and the mutant H275Y NA were assessed 
using two separate techniques. Firstly, a fluorescent substrate, 2’-(4-methylumbelliferyl)-α-
D-N-acetylneuraminic acid (MuNANA), was used as previously described (Potier et al., 
1979) to assess the ability of the neuraminidase proteins to catabolise a small monomeric 
substrate, and to consequently calculate the enzyme kinetics and sensitivity to NAI drugs of 
the two neuraminidase proteins. Then, to assess the ability of the NA enzymes to 
desialylate more complex, multivalent substrates, a chicken erythrocyte elution assay was 
established, whereby neuraminidase is required to cleave sialic acid from the abundantly 
sialylated cell surface of red blood cells. Using the MuNANA substrate, there was an 
approximate 300-fold increase in oseltamivir IC50 values caused by the presence of Y275 
(Table 5.1.). This mutation did not confer resistance against zanamivir. There was a 25% 
decrease in the binding affinity of the enzyme for its substrate resulting from the resistance 
mutation, as indicated by the difference in Km values. These results show that the H275Y 
mutation was able to confer resistance to oseltamivir in pandemic influenza isolates, and 
that the presence of Y275 slightly impeded the affinity of neuraminidase for its substrate. 
Also included in the MuNANA experiment was the human isolate of pandemic H1N1 virus, 
A/England/195/09, which presented comparable Km and IC50 values to the rgPR8 + E195 
virus. Both of these viruses contained the same NA gene which suggests that the PR8 
reverse genetics backbone did not alter the neuraminidase activity in this assay. This 
MuNANA assay was carried out by Shah Miah at the Health Protection Agency in Colindale.   
Next, equivalent titres of both viruses were titrated in a haemagglutination assay. Both 
viruses induced ‘haemagglutination’ (held erythrocytes in suspension) chicken red blood 
cells to a 1/128 dilution (Figure 5.2.). The plate was then incubated at 37°C, causing wells 
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containing higher titres of virus in which haemagglutination had previously been observed, 
to display ‘haemagglutination reversal’ (erythrocytes sediment out of solution). This is 
accounted for by the irreversible digestion of the sialic acid receptor from the erythrocyte 
surface by active NA enzyme. The ability of the wild type A/H1N1 2009 NA to elute virus 
from red blood cells was approximately 4-fold greater than that of the H275Y isogenic 
mutant (Table 5.1.). This suggests that neuraminidase activity in the oseltamivir resistant 
virus is compromised when compared to the wild type neuraminidase. 
Table 5. 1 The susceptibility of pandemic A/H1N1 2009 NA to antiviral drugs and activity 
against small and large substrates. 
Reverse genetics viruses containing the NA from representative pandemic influenza H1N1 
virus, A/England/195/2009, were assessed for their ability to catabolise mono- and 
multivalent substrates. The 2’-(4-methylumbelliferyl)-α-D-N-acetylneuraminic acid 
(MuNANA) substrate was used to determine IC50 values against two neuraminidase 
inhibitors and assess enzyme Km values.  The red cell elution method is described below. 
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Figure 5. 2. Haemagglutination and ‘reverse’ haemagglutination ability of PR8-based 
viruses. 
 
 The haemagglutination activity of rgPR8+E195NA and rgPR8+E195NAH275Y viruses were 
tested along with A/PR/8/34 virus as a control. All three viruses agglutinated chicken red 
blood cells to a titre of 1/128 units when left at 4oC for one hour (top panel). The plate was 
then moved to 37oC in order to increase neuraminidase activity. After one hour, 
agglutination had been eliminated by England 195NA as witness by the regression of 
agglutination from the left hand side of the plate to the right. England 195NAH275Y did not 
regress across the plate as far as wild type A/England/195 NA.  
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Next, the effect of H275Y on oseltamivir tolerance in a cell infection assay, was assessed. 
The IC50 values of NAIs calculated in the MuNANA assay do not translate to effective doses 
in an in vitro infection due to the more complex interplay between neuraminidase 
molecules and their substrates. The concentration of oseltamivir present in the overlay 
medium of plaque assays involving these two viruses was titrated to assess how much 
oseltamivir was required to abrogate viral infection. The results show that 100nM 
concentrations of oseltamivir were sufficient to eradicate viral replication of the virus 
containing drug-sensitive neuraminidase (Figure 5.3.). Drug-resistant variants were able to 
tolerate oseltamivir concentrations far beyond this, and finally succumbed to drug only 
when 100µM concentrations were used. The plaque morphology of each virus was also 
compared and even under a low dose (10nM) of oseltamivir was not noticeably different. 
Plaques of drug sensitive virus were totally abrogated at 100nM concentrations of 
oseltamivir in the overlay. The finding that pandemic neuraminidases containing H275Y can 
tolerate up to 1000-fold higher concentrations of drug in vitro is likely to have major clinical 
repercussions. The concentration of oseltamivir reached in circulation in patients 
undergoing treatment is estimated to be as low as 5µM (Fuke et al., 2008), suggesting 
treatment of a resistant isolate with standard clinical dosing regimens will likely result in 
drug failure. 
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Figure 5. 3. The effect of oseltamivir on plaque formation in vitro. 
 
Plaque assays were performed on MDCK cells using rgPR8+E195NA and rgPR8+E195NAH275Y 
viruses in the presence of increasing concentrations of oseltamivir. MDCK cells were 
infected with concentrations of virus that were known to generate ~50 plaques in a 6 well 
plate and left for 3 days before being stained with crystal violet. Plaques were then 
counted and photographed. The histogram data represent the mean of three triplicate 
samples with the error bars corresponding to standard deviation between samples. 
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5.2.3. Assessing the effect of H275Y-containing neuraminidase in a recombinant 
pandemic strain. 
Following the preliminary experiments conducted using a virus with a PR8 backbone, we 
moved to ascertain the effect of drug-sensitive and drug-resistant neuraminidases in the 
context of its other properly matched pandemic segments. When assessing the role of 
neuraminidase, it is important to account for the effects of the other surface glycoprotein, 
haemagglutinin, considering both proteins perform opposing jobs. The fact that HA is a 
virus receptor binder and NA is a receptor destroyer often results in evolutionary changes 
in these genes to accommodate reciprocal changes in the other (Kaverin et al., 1998; 
Wagner et al., 2002)). If pandemic 2009 N1 neuraminidase was weakened by the presence 
of H275Y, this weakness may be exacerbated when paired with a haemagglutinin protein 
whose activity is only usually tolerated by the whole virus due to a compensating highly 
active NA protein. 
Using reverse genetics, two isogenic viruses were rescued comprising all eight segments of 
the A/England/195/09 pandemic isolate, differing only at position 275 in the NA. Both 
viruses successfully rescued and replicated to equivalent titres, as seen previously with our 
7 + 1 recombinant viruses. The growth characteristics of these isogenic viruses in MDCK cell 
was not significantly different in either cell type at any time point, indicating that the small 
compromises in enzyme activity observed in Table 5.1. were not sufficient to result in 
significantly lower titres, even in the context of the entire pandemic virus genome (Figure 
5.4. a)). These viruses were then assayed in their ability to infect and spread in highly 
differentiated Human Airway Epithelial  (HAE) cells. The HAE cells represent a more difficult 
environment for viral replication than the laboratory standard MDCK cells due to the 
presence of stratified specialised cells (e.g. ciliated and non-ciliated cells) and due to the 
presence of mucus which is routinely secreted by goblet cells present in the 3D culture. 
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These cells are also maintained at an air-liquid interface, which provides further 
impediments to viral dissemination. Initially, cells were inoculated onto HAE cells or MDCK 
cells as control at low multiplicities and their growth kinetics compared side-by-side (Figure 
5.3.) Although the mutant virus (dashed line) appeared to replicate less efficiently, 
particularly in HAE cultures, these differenced were not statistically relevant. 
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Figure 5. 4. Growth of drug-sensitive and drug-resistant pandemic influenza in MDCK and 
HAE cells.  
 
Recombinant A/England/195/2009 viruses containing wild type or mutated H275Y NA 
segments were inoculated onto cells. a) Viruses were inoculated in triplicate onto 6-well 
plates of MDCK cells at an MOI of 0.01. Samples of supernatant were collected at various 
time points and then subjected to plaque assay on new MDCK cells to assess viral titre. b) 
Viruses were inoculated in triplicate onto the apical surface of HAE cells suspended on 
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transwell inserts on a 24-well plate for one hour at an MOI of 0.01 before being removed 
and washed once with PBS. Cells were left at an air/liquid interface for the remainder of 
the experiment and virus released from the apical surface at various time points was 
collected by adding ‘virus diluent’ (0.35% BSA, 1% Penicillin/Streptomycin in PBS) to the 
cells for 5 minutes. These virus harvests were then used in a plaque assay on fresh MDCK 
cells as above. Each of these figures is representative of data obtained in triplicate on 2 
separate occasions. 
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5.2.4. Co-infections of drug-sensitive and drug-resistant isolates 
Both viruses were then used to co-infect either MDCK or HAE cells at low MOIs and with 
the two viruses at defined ratios. Following a 72 hour infection, virus released was 
collected, the RNA extracted, and then used to produce cDNA of the neuraminidase 
segment which was sequenced. Analysis of the sequence chromatograms showed that in 
MDCK cells, there was no growth advantage for virus with either H or Y at residue 275. The 
output sequence exactly reflected the input ratio of the two viruses (Figure 5.5. a and b). In 
contrast, after 72 hours propagation in HAE cells where mucus could accumulate, the wild 
type oseltamivir-sensitive virus with 275H NA accumulated to a higher degree than did the 
drug resistant variant (Figure 5.5 c). 
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Figure 5. 5. Sequencing chromatogram of co-infection experiment 
MDCK or HAE cells were infected at a total MOI of 0.01 with defined mix (50:50) or (80:20) 
of the isogenic A/England/195/2009 viruses with either 275H or 275Y in NA. After 72 hours 
virus released from the cells was collected, the RNA extracted and the NA gene amplified 
by RT-PCR. PCR products were then sequenced. The sequence chromatogram shows the 
region spanning codon 275  in which C nucleotide results in the wild type 275H amino acid 
and T nucleotide results in the drug resistant 275Y genotype. 
a) Virus released from MDCK cells infected with a 50:50 mix of 275H and 275Y virus.  
b) Virus released from MDCK cells infected with an 80:20 mix of 275Y and 275H virus. 
c) Virus released from HAE cells infected with a 50:50 mix of 275H and 275Y virus. 
 
This experiment was conducted in triplicate and all three triplicates were sequenced 
individually. The results shown are single wells chosen arbitrarily (the middle well from 
each triplicate was used) from each condition and is representative of all three wells. The 
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input virus was also sequenced from the 50:50 and 80:20 ratios and produced identical 
chromatograms to rows a) and b) in this figure (data not shown). 
Next, an attempt was made to quantify the observed differences in these chromatograms 
by using a plaque assay to determine the ratio of drug resistant and drug sensitive viruses 
in the supernatants of co-infected wells. The supernatants from each condition were 
diluted equally to a set concentration and a plaque assay was performed in the presence 
and absence of oseltamivir. The concentration of oseltamivir used was known to inhibit all 
plaque formation from wild type drug-sensitive virus. From Table  5.2. we can assume that 
influenza viruses with the H275Y mutation are able to form plaques in the presence of this 
concentration of oseltamivir, but overall they form fewer plaques when subjected to 10µM 
drug treatment – in this case, 7 in the presence of oseltamivir, 12 in the absence. Thus 
where we would expect to see 100% drug resistant plaques present in the drug treated 
wells, we only see 55% of those plaques under 10µM oseltamivir selection. The key 
comparison in this table is between the 50:50 mixtures of viruses in MDCK and HAE cells. 
What we can see from the results is that even though this assay has under-scored the 
number of drug-resistant virus plaques, there is still a substantial difference between the 
supernatants derived from MDCKs compared to those derived from HAE cells. The number 
of drug resistant virus plaques obtained from the co-infection experiment on HAE wells was 
~50% less than those counted from the same co-infection performed in MDCK cells (13 
plaques from the HAE Vs 27 plaques from MDCK cells). Thus, this analysis suggested an 
enrichment of wild type virus after replication in HAE, as implied by the sequencing 
chromatogram above, but it was still difficult to enumerate the amount of different NAs 
from the co-infections. 
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Virus - Oseltamivir + Oseltamivir (10µM) % Resistant plaques 
A/England/195/09 22 0 0 
A/England/195/09 H275Y 12 7 55 
50:50 MDCK 43 12 27 
80:20 MDCK 27 16 57 
50:50 HAE 14 2 13 
Table 5. 2. Number of drug-sensitive and drug-resistant plaque forming units in the 
supernatant of co-infected cells.  
 
The cell supernatants from 5.2.4. were diluted 100,000-fold and a plaque assay was carried 
out in triplicate wells in the presence or absence of 10µM oseltamivir. Plaques were then 
enumerated 3 days post-infection and the average number of plaques is shown in the 
table. 
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To elucidate the total quantity of H275 or Y275 genomes present in the released virus from 
co-infected wells of MDCK and HAE cells more reliably, a pyrosequencing analysis of the 
supernatants was performed. Briefly, total RNA was extracted from the supernatants and 
subjected to the pyrosequencing methodology as described in (Lackenby et al., 2008a). This 
assay directly quantifies the total number of neuraminidase strands containing either the 
drug-sensitive nucleotide C (shown as reverse compliment – G in Figure 5.6.) or the drug-
resistant nucleotide T (shown as reverse compliment – A) in the NA protein. The 
percentage readouts of triplicate wells are given in Table 5.3. and a representative readout 
from this assay is shown in Figure 5.6. This data matches that obtained from the 
chromatograms presented in Figure 5.5 and highlights that whereas growth of drug-
resistant and drug-sensitive virus in MDCK cells resulted in an even distribution of both 
neuraminidase genotypes, as seen by the 50.3:49.7 overall percentages of each, the 
replication of drug-resistant virus in the more clinically relevant HAE cell line was impaired, 
as shown by the 59:41% advantage conferred by H275.  
 
 
 
 
 
 
 
 
 
- 181 - 
 
MDCK HAE 
50:50 H:Y 80:20 Y:H 50:50 H:Y 
G A G A G A 
49.4 50.6 22.1 77.9 60.2 39.8 
49.9 50.1 21 79 51.4 48.6 
51.5 48.5 21.2 78.8 65.5 34.5 
50.3 49.7 21.4 78.6 59.0 41.0 
Table 5. 3. Pyrosequencing results of co-infected supernatants. 
 
The individual results of triplicate samples are shown. The bottom row denotes the average 
of the triplicates. 
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a) 50:50 H:Y in MDCK  
b) 80:20 Y:H in MDCK  
c) 50:50 H:Y in HAE     
Figure 5. 6. Pyrosequencing chromatogram results of co-infection supernatants 
 
Each figure is representative of a single pyrosequencing run conducted on the co-infected 
supernatants of a) 50:50 H:Y in MDCK cells, b) 80:20 Y:H in MDCK cells, c) 50:50 H:Y in HAE 
cells. The highlighted yellow area shows the mixture and quantity of both drug-resistant (A) 
and drug-sensitive  (G) nucleotide at this position. Note: The nucleotides shown here are 
the reverse complement of those shown in Figure 5.5. The pyrosequencing step for this 
assay was performed by Shah Miah at the HPA. 
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5.3. Discussion 
The biological consequences of the H275Y mutation in the NA gene of A/H1N1 2009 
influenza virus, that confers resistance to oseltamivir, are important to know because the 
drug is the first line treatment for patients who present with pandemic influenza infection. 
Drug resistance was already observed in infected individuals in the community and in the 
clinic during the first and second waves of the swine flu pandemic (Baz et al., 2009; CDC, 
2009; Chen et al., 2009) although it did not spread widely. Whether oseltamivir-resistant 
nvH1N1 viruses might disseminate in subsequent waves through the community is key to 
future public health planning.  
The NA gene of the new pandemic H1N1 virus was acquired from Eurasian swine influenza 
H1N1 virus, a lineage of virus that crossed from avian species into swine in the late 1970s, 
and retains some characteristics of avian virus NAs. For example, like many avian virus NA 
enzymes, A/H1N1 2009 NA is inherently more active than NAs of recently circulating 
human influenza viruses, for which elution of virus from red blood cells is rarely observed 
(for example, comparing PR8 wild type virus to both PR8 viruses containing pandemic NA in 
Figure 5.2., lower panel). In this background, the small compromise in enzyme affinity for 
sialic acid substrate (observed by a 1.3 fold increase in the neuraminidase Km value) and 
the decrease in cell surface expression that result from the H275Y mutation (Bloom et al., 
2010), had no effect on virus growth in MDCK cell culture.  On the other hand, in vivo NA 
must cleave complex substrates to mediate virus release from an infected airway cell and 
gain access through a complex layer of mucins to the new target cell. Subtle decreases in 
NA activity or cell surface expression may have more profound consequences in the airway 
than in monoculture. To probe this, we tested the NA activity of the mutated virus in two 
other assays that presented large sialated substrates. We detected a 4-fold compromise in 
the ability of the virus with H275Y mutation to mediate desialylation of chicken 
erythrocytes, although the biological significance of this assay is not entirely clear. In 
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differentiated cultures of human airway cells, the mutant virus showed a small, 
reproducible, but statistically insignificant decrease in infectious titre released at later time 
points of the multicycle infection. Importantly, in competition assays in HAE cultures, but 
not in MDCK monolayers, the wild type virus outcompeted growth of the drug resistant 
strain suggesting that in the absence of drug, the 275Y motif carries a fitness cost in the 
environment of the human airway.  
In both recent seasonal H1N1 strains and in H5N1 highly pathogenic viruses, mutations that 
increase the NA activity, protein stability or cell surface transport likely compensate for the 
effects of the mutation at 275 that would otherwise decrease the function of the enzyme. 
Examples of such mutations are D344N, (Rameix-Welti et al., 2008), and V235M and/or 
R223Q (Bloom et al., 2010). Neither of the latter two mutations currently exist in the 
neuraminidase protein of A/H1N1 2009 isolates, but  further circulation of the novel H1N1 
virus in humans may select for these or other NA or HA mutations that better prime the 
virus to accommodate or even select for the H275Y mutation.  
 
For contemporary A/H1N1 2009 viruses, the cost or advantage of drug resistance is so 
subtle that different groups have come to different conclusions about its relevance. In a 
hospital setting there have been reports that suggest patient-to-patient transmission of 
drug-resistant virus has occurred amongst immunocompromised individuals (Moore et al., 
2010). Hamelin and colleagues have recently shown that oseltamivir-resistant A/H1N1 
2009 virus was as equally virulent as its wild-type counterpart in mice and ferrets and did 
transmit to co-housed animals (Hamelin et al., 2010). Likewise, Seibert and colleagues 
showed that in  two different viral genetic backgrounds the H275Y mutant was as virulent 
and as transmissible as the wild type virus in both ferrets and guinea pigs which are an 
alternative animal model for influenza transmission (Seibert et al., 2010). Similarly Kiso and 
- 185 - 
 
co-workers found that two sets of oseltamivir resistant pH1N1 viruses were equally virulent 
in mice and ferrets as their wild type counterparts and transmitted equally well between 
ferrets even via the droplet route using a competitive assay whereby the animals were co-
infected with a 50:50 ratio of the two viruses (Kiso et al., 2010b). However, careful analysis 
of the data from Kiso shows that there was a two-day delay in transmission of the resistant 
virus, O180r, compared to its matched sensitive partner, suggesting some compromise that 
may translate into a substantial advantage to wild type virus spread in the community. In 
addition, Duan et al. found that their strain of drug resistant virus did not transmit between 
ferrets by the respiratory droplet route and that in co-infected animals, the wild type virus 
outgrew the resistant mutant and was uniquely transmitted to contact animals (Duan et al., 
2010). The difference in results and interpretation of data between these groups highlights 
that within this very active field of experimental research, environmental conditions and 
both host and strain specific effects may influence the outcome of experiments where 
fitness costs are minimal. Factors such as the distance between exposed animals, the 
relative humidity and temperature within the facility (Lowen & Palese, 2009) and the 
genetic background of the virus may all vary. Indeed table 5.3 shows the genetic 
differences between some of the strains used in these studies. Sequence information on 
other strains was not available for analysis. Although it is difficult to discern from table 5.3. 
a particular amino acid that may affect the results, the comparison does serve to show that 
there are many differences in the viral genetic background of the strains used that could 
affect the results. The discrepant conclusions from the plethora of recent papers on this 
subject also suggest that animal models, even the ferret ‘golden standard’, that may be 
optimized to detect transmission of influenza virus, may not be ideal as currently devised to 
discern subtle differences between strains. It may be that in future adaptations of these 
assays, competition assays involving mixed viruses, lower inoculum doses, larger distances 
between cages and testing for chains of transmission will help refine the ferret model, to 
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that it may recapitulate the field situation more accurately. On the other hand we have 
presented here a simple in vitro system that is at least based on human airway cells rather 
than animal cells, and is amenable to a higher throughput and increased number of 
replicated if developed in the future. Finally the data in these papers is derived from very 
few animals, sometimes as few as 2 per group and may not adequately reflect the 
possibility that in the community small fitness costs may preclude dominance of a virus 
variant. Anecdotal evidence from clinical or epidemiological studies in humans shows that, 
in most instances, contemporary drug-resistant variants of A/H1N1 2009 were replaced by 
drug-sensitive variants when the selective pressure of oseltamivir was removed, suggesting 
that wild-type isolates are fitter in vivo in man (Campanini et al., 2010). Likewise, under 
competitive conditions incorporating long incubations, during which mucus accumulated in 
the HAE culture system, we found that the wild type virus out-competed the drug resistant 
virus, in the absence of drug selection pressure. Interestingly, several recent papers have 
also favoured the use of competitive assays to discern viral fitness advantage between two 
strains of influenza virus in animal models (Duan et al., 2010; Hurt et al., 2010).The HAE 
culture system offers an alternative biologically relevant model as a useful adjunct to 
animal studies that may adequately reflect the environment in which virus replicates in 
healthy humans. Information from a variety of model systems should be combined to guide 
the appropriate use of oseltamivir. Such knowledge clearly needs to be revised specifically 
for each novel influenza virus that emerges either as a seasonal strain by drift or as a 
pandemic viruses by antigenic shift.   
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Table 5. 4. Sequence analysis of viruses used by recent publications to date that assess 
drug-resistant pandemic influenza transmission. 
(Table legend overleaf) 
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Sequence variation between drug resistant viruses used in some of the publications 
documenting pandemic influenza drug resistance to date:  A/Quebec/141447/2009 
(Hamelin et al., 2010), a resistant mutant that did transmit to co-housed animals, though 
droplet transmission was not tested, A/Denmark/528/2009 (Duan et al., 2010), a resistant 
mutant which showed compromised transmission, A/Osaka/180/2009 (Kiso et al., 2010b), a 
resistant mutant which did transmit by respiratory droplet but showed a 2 day delay in 
sentinels becoming virus positive and  A/England/195/2009 (this study), a resistant mutant 
which showed a compromise in fitness in competition studied performed on human airway 
epithelial cells. 
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6. General Discussion 
 
6.1. Overview of work presented 
The work presented in this thesis has dealt largely with two aspects of antiviral 
chemotherapy of influenza infections. Firstly, we highlighted the limitations and difficulties 
associated with traditional drug screening technologies and indeed the further elucidation 
of antiviral compounds which present from screening hits. Secondly, we have challenged 
the validity of relying on oseltamivir as the sole stockpiled drug in pandemic planning 
agendas by asking what consequences a common drug-resistance mutation would exact on 
the pandemic influenza virus. 
 
Several antiviral compounds were discovered using a rudimentary drug screening 
technique which assayed cell monolayer protection as a successful indication of antiviral 
activity. Following the discovery that seven Phytopure compounds showed activity, 
substantial time was invested at the beginning of the project in attempting to identify their 
mechanisms of action. Buoyed by the knowledge that these hits did not destroy monolayer 
integrity alone, and displayed negative toxicity according to a commercial cytotoxicity 
assay, we proceeded with antiviral studies designed to specify the antiviral mechanism of 
action of these compounds. Ultimately, it was observed that antiviral activity was 
attributable to wholesale inhibition of gene expression in the host cell, a distinctly 
undesirable trait for a potential therapeutic drug intended for treating the majority of 
influenza infections that are usually mild and self-limiting. We successfully attempted to 
overcome the limitations associated with our primitive screening technique by generating a 
novel screening tool, which has the potential of industrial scale-up for high throughput 
screening, and possesses the capability of identifying compounds which exhibit inhibitory 
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toxicity towards host-cell polymerases. Whilst in the future it would be prudent to subject 
novel screening hits to a battery of different cytotoxicity assays before embarking on 
further characterisation studies, it was heartening to discover that our cell screening 
technique identified immediately the cytotoxicity associated with our most potent 
Phytopure library hit. 
 
The year 2009 provided a unique opportunity for influenza virologists to experience 
firsthand the outbreak and consequences of an influenza pandemic. As was widely 
expected, the principal prophylactic measure of seasonal vaccination did not protect 
against this new virus and whilst work commenced in generating a new specific vaccine 
which would protect against pandemic H1N1 influenza, the antiviral drug oseltamivir was 
relied upon extensively as the only widely available preventative and treatment measure, 
(reviewed in (Hayden, 2009)). Prior to the pandemic outbreak, H1N1 viruses from the 
2007/2008 season extensively acquired resistance to oseltamivir, with 90-100% of isolates 
containing the molecular resistance signature mutation H275Y by the beginning of the 
2008/2009 season (Correia et al., 2010; Meijer et al., 2009). Although the novel pandemic 
influenza strain was also of H1N1 phenotype, this virus did not harbour H275Y, or any other 
oseltamivir resistance mutation and remained fully susceptible to the drug (Centre for 
Disease Control and Prevention (CDC), 2009). We identified that a representative pandemic 
isolate could replicate with the H275Y mutation engineered into its neuraminidase protein 
without significant detriment to its overall viral fitness. However, we also observed minor 
impediments in neuraminidase activity, and in the ability of drug-resistant virus to compete 
with drug-sensitive virus, in a biologically relevant cell line.  
It is highly likely that antiviral drugs will continue to form an important arm of our influenza 
defences long into the future. Although vaccine technologies continue to evolve (reviewed 
- 191 - 
 
in (Horimoto & Kawaoka, 2006; 2009)), humanity’s biggest successes through vaccination 
have been against viruses which have a narrow host-range, such as Polio and Smallpox. The 
fact that human co-exist so closely with the natural avian reservoir for influenza, and that 
influenza viruses are largely asymptomatic in avian populations, means influenza viruses 
will be very difficult to eradicate through vaccination alone. To this end, the screening of 
compound libraries for novel antivirals is a worthy endeavour. In this project we developed 
a novel screening tool which allows for simultaneous antiviral and toxicity readouts would 
be beneficial to future high-throughput screens. As previously discussed, reporter cell lines 
have proved instrumental in identifying novel antiviral compounds from high throughput 
screens (3.3.). To build on this available technology, it is conceivable that the dual 
fluorescent read-out system engineered in this project could be invaluable for screening 
combinations of novel or established compounds, to observe whether a particular 
compound mix is synergistic, or even toxic to host cells. 
Furthermore, work presented in the introduction of this project detailed potentially new 
chemotherapeutics against influenza, with novel mechanisms of action. However, certain 
candidates, such as the pentraxin and collectin-like molecules (1.3.2.1.) had not been 
tested in higher cell-based or animal models. A likely cause for this is that certain research 
groups do not have access to specialist animal housing facilities, nor the budgets or 
experienced personnel to cover the expense of maintaining and handling animals. Given 
that the licensing of new drugs requires several rounds of animal-testing before a approval 
for human consumption is attained, these compounds may never progress out of the in 
vitro experimental stage. To this end, use of the human airway epithelial cell line could 
prove useful for providing supplementary data on novel compounds, isolated from 
rudimentary high-throughput screens, and aid in assessing the potential of these molecules 
to be taken forward for in vivo experimentation. These cells do not require specialist 
facilities and are substantially cheaper than acquiring animals for experimentation. They 
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provide an opportunity to study the effects of lead compounds on human innate cytokine 
responses, as well as demonstrate the toxicity and efficacy profile of novel molecules on 
human tissue.  
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Addendum: The effect of pandemic influenza on antiviral drug use. 
The revelation that pandemic H1N1 influenza was susceptible to oseltamivir was fortuitous 
for public health policy and meant that the stockpiled supply of drug could be used 
following the outbreak. It is estimated that enough drug had been stockpiled to supply 25% 
of the UK’s population with a five day treatment course and following the outbreak of the 
pandemic, the National Pandemic Flu Service (NPFS) was given executive control to 
distribute the drug. This was the first time that prescription drugs had been handed out en 
masse without the need for patients to consult a doctor, and in the aftermath of the 
pandemic, questions have been raised regarding the effectiveness of the NPFS. Estimates 
suggest that 1.1 million doses of oseltamivir were dispensed under the scheme (NHS Direct, 
2010), roughly 7% of the total stockpile, yet whether these doses actually went to sick 
patients, or were procured to generate a personal stockpile (as often happens when the 
media interest in influenza is heightened (Gasink et al., 2009)), is unknown. The rationale of 
the NPFS was to protect NHS hospitals and GPs from an influx of non-emergency patients 
during the outbreak, yet the course of disease of the pandemic itself was overall very mild. 
The formation of a rapid drug-dispensation service ensured that drugs were readily 
available for patients to initiate treatment within the 48 hours of symptom onset that is 
recommended for successful therapy. Furthermore, the service will have technically 
reduced the number of virus-shedding individuals from leaving their houses, providing a 
possible physical barrier to pandemic spread. However, it is a scheme which was obviously 
designed with a far more virulent pandemic influenza virus in mind, and one might 
question why the service was activated, and indeed ran for as long as it did once the 
severity of the pandemic had become clear. The NPFS was activated on the 23rd of July, 
2009, following epidemiological data that was published suggesting 100,000 new swine flu 
cases had been reported in the week prior resulting in 26 deaths, 17 of which occurring in 
patients suffering from severe underlying illness (Siva, 2009). Although the mortality rate of 
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the virus was thus low, public interest in the service was so intense that the website 
crashed within four minutes of activation and traffic was recorded at an equivalent of 9.2 
million hits per hour. Britain’s Chief Medical Officer, Liam Donaldson’s press statement, 
that was (mis)interpreted as a claim that the pandemic could result in 20,000-65,000 
deaths over the winter months, several days before the launch of the website, assumedly 
aided in generating such hysteria over the launch. With such claims it is likely that the 
‘worried well’ as well as the genuinely ill would all attempt to sequester oseltamivir ‘just in 
case’.  
 
Detractors of the scheme will also claim that patients suffering from more severe 
afflictions, who present with flu-like symptoms, may go untreated or even be allocated 
oseltamivir for an unrelated disease (Newton et al., 2010). Furthermore, whilst the 
emergence of resistance to oseltamivir in the 2007/2008 season did not correlate with 
heightened drug use (Lackenby et al., 2008b), it is likely that the unregulated use of 
amantadine by poultry farmers in South-East Asia contributed to the proliferation of drug 
resistance against this M2 inhibitors amongst influenza viruses, which has been generally 
maintained in the circulating virus population since (Deyde et al., 2007). One may speculate 
that a system designed to alleviate the burden on health-care professionals could have 
conversely over-burdened them should the virus have acquired resistance to our only 
stockpiled antiviral drug. It is arguable that the risk of generating widespread drug-
resistance of a pandemic influenza strain to oseltamivir, coupled with the likely myriad of 
previously unnoticed side-effects which patients would be subjected to (Strong et al., 
2010), did not outweigh the positives of treating so many uncomplicated cases of a mild 
illness.  
 
- 195 - 
 
To better inform public healthcare officials as to the likelihood of a virus acquiring drug-
resistance, we propose the use of human airway epithelial cells could provide a more 
reliable experimental tool than standard cell culturing techniques, and a cheaper and more 
rapidly available alternative to animal experimentation in assessing the replication kinetics 
and drug sensitivity of influenza viruses. We were able to observe a replication 
disadvantage in the resistant isolate when drug-resistant and -sensitive viruses were 
infected onto HAE cells and the resulting viral RNA output analysed by pyrosequencing. 
Furthermore, by generating a reverse genetics system for the pandemic influenza virus, we 
have a powerful tool which may be used to introduce any mutation into the genome of the 
virus and study its effects on whole virus behaviour. This could be particularly useful for 
ensuring that our representative virus remains representative, as the circulating pandemic 
will continue to adapt in humans and will require periodic updating. Table 5.4. lists 
numerous changes which have already emerged in circulating pandemic viruses during the 
course of a single year. A focused use of the reverse genetics pandemic virus system would 
be to introduce specific mutations, which confer known effects  in other subtypes, into the 
pandemic virus to study their effects. Of particular interest to this study would be the 
introduction of mutations into the NA gene which have been suggested to result in 
enhanced transport of NA molecules to the cell surface in vitro (Bloom et al., 2010). It 
would be interesting to observe whether such mutations enhanced the replication kinetics 
of our drug-resistant isolate in HAE cells. Furthermore, a mutation which has often been 
seen emerging in tandem with H275Y in drug resistant pandemic isolates is I223V, which 
may be implicated in one of the rare incidences of human-to-human transmission of 
oseltamivir resistant pandemic influenza (Deyde et al., 2010). The effects of this mutation 
on viral fitness in HAE cells would be interesting to observe in future experiments. In order 
to validate that this HAE competition system can indeed detect virus mutants that will 
predominate in the community, similar assays to those described in chapter 5 could be set 
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up using a pair of viruses from the 2007/2008 winter season, during which the H275Y 
resistant mutant eventually dominated. It has already been shown that using animal 
experiments, the advantage conferred by this mutation within the seasonal H1N1 influenza 
viruses could be detected (Baz et al., 2010). 
 
Whilst the debate as to how best to use a substantial stockpile of antiviral drugs is 
essential, it is also a luxury that many third-world countries do not have. In 2005, Roche 
donated 3 million doses of oseltamivir to the WHO for use as an emergency response 
stockpile, and then further donated two million treatment courses for use in developing 
countries.  The Tamiflu Reserves Programme (TRP) was also initiated by Roche as an 
insurance policy that the poorest countries in the world were guaranteed oseltamivir 
supplies at a reduced cost following the outbreak of a pandemic (Reddy, 2010). Whilst this 
is a promising start, the sheer quantity of drug set aside for developing countries is not 
enough, particularly when acknowledging that very few poor countries have routine 
influenza vaccinations to supplement wholesale population protection against the virus. 
Furthermore, should a pandemic virus emerge with oseltamivir resistance, there would be 
no such support for developing nations. The need for an abundant antiviral is illustrated by 
these points. Antiviral research often focuses on the discovery of novel, organic or 
synthetic compounds which can be used to inhibit influenza. However, an alternative 
approach may be to focus on generic agents which are already readily available throughout 
the world. David Fedson is a champion of such research and argues that even if all vaccine 
technologies were focused on generating as much novel vaccine as possible over a six 
month period, they would only manage to produce 1.5 billion doses. This knowledge, 
combined with the lack of meaningful third-world antiviral stockpiles would mean that 
‘88% of the world’s population’ could be left without any therapeutic intervention against 
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influenza at all (Fedson, 2008; 2009a; b). This could have particularly devastating 
consequences if the pandemic virus was highly virulent in man. This project sought to 
identify novel inhibitors of influenza from scratch, but ultimately resulted in highlighting 
the antiviral effect of a known compound. Castanospermine is naturally found in chestnuts 
of C. australe, and can be readily extracted in large quantities, and synthetically altered into 
other potent antiviral forms. The observation that this compound holds broad spectrum 
activity against many other viruses, as well as influenza A viruses, and inhibits viral 
replication by targeting a host-cell mechanism, are all highly desirable traits for an antiviral 
drug that might be stockpiled by governments to protect communities against a range of 
emerging viruses. We showed that Castanospermine had a direct inhibitory effect on the 
viral titres of several influenza A viruses. It may be prudent to assess the activity of this 
drug on HAE cells as a more faithful representation of how the virus replicate in the 
presence of the drug in vivo, and perform in vivo studies if the in vitro work so justifies. 
 
A further debate should be initiated over who genuinely needs antiviral therapy during 
seasonal and mild pandemic influenza virus outbreaks. There is no doubt that patients with 
underlying health problems or in ‘at-risk’ groups, such as pregnant women, the very young 
or the clinically obese,  will be more susceptible to serious complications derived from 
influenza infections, and this was particularly evident during the pandemic outbreak 
(Jamieson et al., 2009; Miller et al., 2010; Nguyen-Van-Tam et al., 2010; Webb et al., 2009). 
Estimates suggest that around 70% of individuals who died from severe complications 
following pandemic influenza infection presented with underlying health problems 
(Donaldson et al., 2009; Louie et al., 2009), suggesting that healthy individuals generally 
fared better with the disease. It would therefore be prudent to ensure that in future, only 
the severely ill and at-risk groups receive oseltamivir treatment, rather than every patient 
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who presents with flu-like symptoms. This would ensure that less of the drug stockpile is 
committed to non-emergencies.  
 
Interestingly, although immunosurpressed patients are the most needing of antiviral 
therapy, they are also the group most likely to generate resistance to drugs due to the 
prolonged shedding of virus in their system (WHO, 2009). The implications of this are 
extremely significant given the importance of effective viral control in these patients.  
Whilst other individual therapeutic agents such as inhaled or intravenous zanamivir could 
be a substituted therapy, it would make more intuitive sense to initiate a combination of 
treatment regimens which could inhibit viral replication on multiple fronts. Recent in vitro 
data has emerged which suggests a triple combination therapy containing amantadine, 
ribavirin and oseltamivir is synergistic in treating pandemic A/H1N1 2009 infection, and 
that surprisingly, the amantadine component of the regimen contributes to the overall 
efficacy despite the virus being resistant to this drug (Nguyen et al., 2010). This result is 
extremely interesting and given the abundance of these drugs, and the relatively well 
understood toxicities of each compound, it would be prudent to quickly conduct a human 
clinical trial with the regimen. Other combinations of antiviral drugs have also been 
described in the literature (Kim et al., 2010; Zheng et al., 2008). Whilst there would be a 
significant increase in costs associated with stockpiling multiple compounds for a future 
influenza pandemic, perhaps only frontline hospitals would require the combination of 
drugs, rather than 25% of the country’s population, particularly if future influenza 
pandemics are as mild as the 2009 outbreak. What is certain is that it is unacceptable 
practice in the modern era to repeatedly use a single drug class against an infectious 
disease until the target organism develops resistance. 
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Perhaps one final interesting point to consider with regard to antivirals is the idea that the 
WHO are about to administer a seasonal vaccine containing the 2009 A/H1N1 virus in place 
of previous seasonal H1N1 viruses as the representative H1N1 strain. Historically, we have 
seen that pandemic events replace circulating strains with the prevailing new isolate 
(Ferguson et al., 2003), and recent surveillance would suggest that the same thing is 
happening this year, as old seasonal H1N1 isolates have not been identified. However, it is 
worth bearing in mind that the previous seasonal H1N1 viruses are all resistant to 
oseltamivir and are routinely handled in most influenza laboratories. One may speculate 
that if these viruses emerged again and no effective drug is widely available, nor the 
population sufficiently vaccinated, then a potentially severe influenza season could ensue.  
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